日本臨牀　76/増刊4　パーキンソン病（第2版）

出版社： 日本臨牀社
発行日： 2018-05-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： パーキンソン病（第2版）―基礎・臨床研究のアップデート
電子書籍版： 2018-05-31 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

19,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

19,800 円(税込)

購入する

目次

  • 特集　パーキンソン病（第2版）―基礎・臨床研究のアップデート

    序文

    I．総　論
    　１．パーキンソン病の歴史的な流れ
    　２．パーキンソン病の疾患概念と分類
    　３．わが国におけるパーキンソン病の疫学研究
    　４．わが国におけるパーキンソン病病態研究の歩みと世界への貢献

    II．病　因
    　１．原因・関連遺伝子
    　２．環境因子
    　３．その他の因子

    III． 病理・病態
    　１．神経病理学的検討
    　２．神経生理−基底核生理

    IV．検査・診断
    　１．診断基準
    　２． 臨床症状
    　３．臨床症状定量ツール (MDS-UPDRS)
    　４．一般検査-電気生理学的検査、血液・尿・髄液検査
    　５．自律神経障害とその機能検査法
    　６. 神経心理的検査
    　７. 画像検査
    　８. パーキンソン病における消化管粘膜生検および皮膚生検
    　９. 診断バイオマーカー
    　10．関連疾患

    V．治　療
    　１．新しい診療ガイドライン
    　２．早期パーキンソン病治療
    　３．進行期パーキンソン病治療
    　４．非薬物治療 三原
    　５．主な治療薬の種類と特徴
    　６．治療薬の併用療法
    　７．パーキンソン病における新規治療法の開発状況
    　８．機器装着治療
    　９．再生療法
    　10．遺伝子治療
    　11．リハビリテーション

    VI．治療上の問題点と対策
    　１．運動症状
    　２．非運動症状
    　３．その他

    VII．QOL
    　１．ADL(activity of daily living)
    　２．在宅医療
    　３．人間らしく生きる日常のための考察
    　４．日本パーキンソン病コングレス（JPC）
    　５．患者の高齢化に対する長期治療計画

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.7 掲載の参考文献
1) Human Mortality Database, University of California, Berkley (USA) and Max Planck Institute for Demographic Research (Germany). 〔Available at http://www.mortality.org〕 (Gratton L, Scott A : The 100-Year Life, Bloomsbury Information, 2016 [邦訳] : LIFE SHIFT-, 東洋経済新報社, 2016.)
 
2) Parkinson J : An Essay on the Shaking Palsy, Whittingham & Rowland, London, 1817.
 
3) Hunter J : Hunterian Reminiscences (ed. by Parkinson JWK), p198-201, Sherwood, Gilbert and piper, London, 1833.
 
4) Fereshtehnejad SM, et al : Clinical criteria for subtyping Parkinson's disease : biomarkers and longitudinal progression. Brain 140 : 1959-1976, 2017.
PubMed
5) Fujimaki M, et al : Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology 90 : e404-e411, 2018.
PubMed

I 総論

P.16 掲載の参考文献
1) Carlsson A, et al : 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180 : 1200, 1957.
PubMed
2) Bertler A, Rosengren E : Occurrence and distribution of dopamine in brain and other tissues. Experientia 15 : 10-11, 1959.
PubMed
3) 「パーキンソン病治療ガイドライン」作成小委員会 (編) : 日本神経学会治療ガイドライン パーキンソン病治療ガイドライン 2002, 2002.
 
4) 「パーキンソン病治療ガイドライン」作成小委員会 (編) : パーキンソン病治療ガイドライン 2011 (日本神経学会監修), 医学書院, 2011.
 
5) Fahn S, et al : Levodopa and the progression of Parkinson's disease. N Engl J Med 351 : 2498-2508, 2004.
PubMed
6) Parkinson Study Group : A controlled trial of rasagiline in early Parkinson disease : the TEMPO Study. Arch Neurol 59 : 1937-1943, 2002.
 
7) Cenci MA : Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30 : 236-243, 2007.
 
8) Chase TN, et al : Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 39 : 7-10 ; discussion 19, 1989.
 
9) Stocchi F, et al : Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease : the STRIDE-PD study. Ann Neurol 68 : 18-27, 2010.
PubMed
10) Nutt JG : Continuous dopaminergic stimulation : Is it the answer to the motor complications of Levodopa? Mov Disord 22 : 1-9, 2007.
 
11) Braak H, et al : Idiopathic Parkinson's disease : possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) 110 : 517-536, 2003.
PubMed
12) Alexander GE, Crutcher MD : Functional architecture of basal ganglia circuits : neural substrates of parallel processing. Trends Neurosci 13 : 266-271, 1990.
PubMed
13) Bergman H, et al : Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249 : 1436-1438, 1990.
PubMed
14) Katayama Y, et al : Double blinded evaluation of the effects of pallidal and subthalamic nucleus stimulation on daytime activity in advanced Parkinson's disease. Parkinsonism Relat Disord 7 : 35-40, 2000.
PubMed
15) Antonini A, Toeosa E : A pomorphine and levodopa infusion therapies for advanced Parkinson's disease : selection criteria and patient management. Expert Rev Neurother 9 : 859-867, 2009.
 
P.21 掲載の参考文献
1) Parkinson J : An Essay on the Shaking Palsy, Sherwood, London, 1817.
 
2) 柳沢信夫 : パーキンソン病の診断. パーキンソン病-診断と治療- (柳澤信夫編), 53-64, 金原出版, 2000.
 
3) Gibb WR, Lees AJ : The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 : 745-752, 1988.
 
4) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197-211, 2003.
PubMed
5) Langston JW : The Parkinson's complex : parkinsonism is just the tip of the iceberg. Ann Neurol 59 : 591-596, 2006.
PubMed
6) Postuma RB, et al : MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30 : 1591-1601, 2015.
PubMed
7) Berg D, et al : MDS research criteria for prodromal Parkinson's disease. Mov Disord 30 : 1600-1611, 2015.
PubMed
8) Iranzo A, et al : Neurodegenerative disease status and post-mortem pathology in idiopathic rapideye-movement sleep behaviour disorder : an observational cohort study. Lancet Neurol 12 : 443-453, 2013.
 
9) Obeso JA, et al : Past, present, and future of Parkinson's disease : Aspecial essay on the 200th Anniversary of the Shaking Palsy. Mov Disord 32 : 1264-1310, 2017.
 
10) 村田美穂 : パーキンソン病の診断基準・病型分類・重症度. 内科 95 : 1532-1536, 2005.
 
11) Nutt JG : Motor subtype in Parkinson's disease : Different disorders or different stages of disease? Mov Disord 31 : 957-961, 2016.
 
12) Mitsui J, et al : Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 66 : 571-576, 2009.
PubMed
13) Baba T, et al : Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease : a 3 year longitudinal study. Brain 135 : 161-169, 2012.
PubMed
14) Fereshtehnejad SM, et al : Clinical criteria for subtyping Parkinson's disease : biomarkers and longitudinal progression. Brain 140 : 1959-1976, 2017.
PubMed
15) Espay AJ, et al : Biomarker-driven phenotyping in Parkinson's disease : Atranslational missing link in disease-modifying clinical trials. Mov Disord 32 : 319-324, 2017.
 
P.28 掲載の参考文献
1) 古和久典, ほか : パーキンソン病医学・医療の最前線. 第1部 : 基礎編 1. パーキンソン病の疫学と一生. Progress in Medicine 32 : 1154-1160, 2012.
 
2) 木村英紀, 加藤丈夫 : パーキンソン病の疫学. 綜合臨牀 59 : 2371-2376, 2010.
Medical*Online
3) 谷口彰, ほか : 厚生労働省特定疾患治療研究事業臨床調査個人票の集計結果からみたパーキンソン病患者の現状. 臨床神経学 48 : 106-113, 2008.
 
4) Wirdefeldt K, et al : Epidemiology of Parkinson's disease : a review of the evidence. Eur J Epidemiol 26 (Suppl 1) : Sl-586, 2011.
 
5) Muangpaisan W, et al : Systematic review of the prevalence and incidence of Parkinson's disease in Asia. J Epidemiol 19 : 281-293, 2009.
 
6) Moriwaka F, et al : Prevalence of Parkinson's disease in Hokkaido, the northernmost island of Japan. Intern Med 35 : 276-279, 1996.
PubMed
7) 伊藤和則, ほか : 北海道 (岩見沢市) におけるParkinson病の疫学調査. 神経内科 57 : 492-497, 2002.
 
8) Kimura H, et al : Female preponderance of Parkinson's disease in Japan. Neuroepidemiology 21 : 292-296, 2002.
PubMed
9) Yamawaki M, et al : Changes in prevalence and incidence of Parkinson's disease in Japan during a quarter of a century. Neuroepidemiology 32 : 263-269, 2009.
PubMed
10) Okada K, et al : Prevalence of Parkinson's disease in Izumo City, Japan. Gerontology 36 : 340-344, 1990.
PubMed
11) Morioka S, et al : Incidence of Parkinson disease in Wakayama, Japan. J Epidemiol 12 : 403-407, 2002.
PubMed
12) 中川正法, 有里敬代 : 鹿児島県におけるParkinson病の疫学調査-1980年調査との比較検討-. 神経内科 57 : 471-474, 2002.
 
13) Nakashita S, et al : Clinical assessment and prevalence of parkinsonism in Japanese elderly people. Acta Neurol Scand 133 : 373-379, 2016.
PubMed
14) Uemura Y, et al : Mild parkinsonian signs in a community-dwelling elderly population sample in Japan. J Neurol Sci 304 : 61-66, 2011.
 
15) Wada-lsoe K, et al : Longitudinal course of mild parkinsonian signs in elderly people : A populationbased study in Japan. J Neurol Sci 362 : 7-13, 2016.
 
P.35 掲載の参考文献
1) Sano I, et al : Distribution of catechol compounds in human brain. Biochim Biophys Acta 32 : 586-587, 1959.
PubMed
2) 佐野勇 : 錐体外路系の生化学. 神経研究の進歩 5 : 42-48, 1960.
 
3) Nagatsu T, et al : Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 239 : 2910-2917, 1964.
PubMed
4) Ichinose H, et al : Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 8 : 236-242, 1994.
PubMed
5) Narabayashi H, et al : Procaine-Oil Blocking of the Globus Pallidus for the treatment of rigidity and tremor of parkinsonism (Preliminary Report). Proc Jpn Acad 29 : 134-137, 1953.
 
6) Nambu A, et al : Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res 43 : 111-117, 2002.
PubMed
7) 小阪憲司 : "Lewy小体病" の臨床神経病理学的研究. 精神神経学雑誌 82 : 292-311, 1980.
 
8) Fujiwara H, et al : alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4 : 160-164, 2002.
 
9) Hakusui S, et al : A radiological analysis of heart sympathetic functions with meta- [123I] iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 49 : 81-84, 1994.
PubMed
10) Orimo S, et al : Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 57 : 1140-1141, 2001.
PubMed
11) Kitada T, et al : Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 : 605-608, 1998.
 
12) Matsuda N, et al : PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 189 : 211-221, 2010.
PubMed
13) Funayama M, et al : A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51 : 296-301, 2002.
PubMed
14) Funayama M, et al : CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease : a genome-wide linkage and sequencing study. Lancet Neurol 14 : 274-282, 2015.
PubMed
15) Satake W, et al : Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41 : 1303-1307, 2009.
PubMed

II 病因

P.43 掲載の参考文献
1) Polymeropoulos MH, et al : Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 : 2045-2047, 1997.
PubMed
2) Singleton AB, et al : alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 : 841, 2003.
PubMed
3) Ibanez P, et al : Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364 : 1169-1171, 2004.
PubMed
4) Chartier-Harlin MC, et al : Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 : 1167-1169, 2004.
PubMed
5) Satake W, et al : Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41 : 1303-1307, 2009.
PubMed
6) Simon-Sanchez J, et al : Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41 : 1308-1312, 2009.
PubMed
7) Sailer A, et al : A genome-wide association study in multiple system atrophy. Neurology 87 : 1591-1598, 2016.
PubMed
8) Rodriguez JA, et al : Structure of the toxic core of α-synuclein from invisible crystals. Nature 525 : 486-490, 2015.
 
9) Giasson BI, et al : Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 : 985-989, 2000.
PubMed
10) Braak H, et al : Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318 : 121-134, 2004.
PubMed
11) Luk KC, et al : Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 209 : 975-986, 2012.
 
12) ClinicalTrials. gov Identifier : NCT01568099.
 
13) ClinicalTrials. gov Identifier : NCT03100149.
PubMed
P.49 掲載の参考文献
1) Kitada T, et al : Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 : 605-608, 1998.
 
2) Park J, et al : Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441 : 1157-1161, 2006.
PubMed
3) Narendra D, et al : Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183 : 795-803, 2008.
PubMed
4) Narendra DP, et al : PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 8 : e1000298, 2010.
PubMed
5) Matsuda N, et al : PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 189 : 211-221, 2010.
PubMed
6) Shiba-Fukushima K, et al : PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy. Sci Rep 2 : 1002, 2012.
PubMed
7) Koyano F, et al : Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 510 : 162-166, 2014.
PubMed
8) Shiba-Fukushima K, et al : Phosphorylation of mitochondrial polyubiquitin by PINK1 promotes Parkin mitochondrial tethering. PLoS Genet 10 : e1004861, 2014.
PubMed
9) Ordureau A, et al : Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARK1N translocation and ubiquitin chain synthesis. Mol Cell 56 : 360-375, 2014.
PubMed
10) Harper JW, et al : Building and decoding ubiquitin chains for mitophagy. Nat Rev Mol Cell Biol 19 : 93-108, 2018.
 
11) Shiba-Fukushima K, et al : Evidence that phosphorylated ubiquitin signaling is involved in the etiology of Parkinson's disease. Hum Mol Genet 26 : 3172-3185, 2017.
PubMed
12) Pickrell AM, et al : Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress. Neuron 87 : 371-381, 2015.
PubMed
13) Wang X, et al : PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147 : 893-906, 2011.
PubMed
14) Liu S, et al : Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet 8 : e1002537, 2012.
PubMed
15) Wauer T, et al : Mechanism of phospho-ubiquitin-induced PARK1N activation. Nature 524 : 370-374, 2015.
PubMed
P.55 掲載の参考文献
1) Leroy E, et al : The ubiquitin pathway in Parkinson's disease. Nature 395 : 451-452, 1998.
PubMed
2) Bishop P, et al : Ubiquitin C-terminal hydrolase L1 (UCH-L1) : structure, distribution and roles in brain function and dysfunction. Biochem J 473 : 2453-2462, 2016.
PubMed
3) Saigoh K, et al : Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 23 : 47-51, 1999.
PubMed
4) Bilguvar K, et al : Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration. Proc Natl Acad Sci USA 110 : 3489-3494, 2013.
PubMed
5) Rydning SL, et al : Novel UCHL1 mutations reveal new insights into ubiquitin processing. Hum Mol Genet 26 : 1031-1040, 2017.
PubMed
6) Wang KK, et al : Ubiquitin C-terminal hydrolase-L1 (UCH-L1) as a therapeutic and diagnostic target in neurodegeneration, neurotrauma and neuro-injuries. Expert Opin Ther Targets 21 : 627-638, 2017.
PubMed
7) Kabuta T, et al : Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1. Hum Mol Genet 17 : 1482-1496, 2008.
PubMed
8) Nishikawa K, et al : Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun 304 : 176-183, 2003.
PubMed
9) Osaka H, et al : Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 12 : 1945-1958, 2003.
PubMed
10) Sakurai M, et al : Reduction in memory in passive avoidance learning, exploratory behaviour and synaptic plasticity in mice with a spontaneous deletion in the ubiquitin C-terminal hydrolase L1 gene. Eur J Neurosci 27 : 691-701, 2008.
PubMed
11) Kabuta T, Wada K, : Insights into links between familial and sporadic Parkinson's disease : physical relationship between UCH-L1 variants and chaperone-mediated autophagy. Autophagy 4 : 827-829, 2008.
PubMed
12) Kabuta T, et al : Ubiquitin C-terminal hydrolase Ll (UCH-L1) acts as a novel potentiator of cyclindependent kinases to enhance cell proliferation independently of its hydrolase activity. J Biol Chem 288 : 12615-12626, 2013.
 
13) Setsuie R, et al : Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's diseaseassociated UCH-L1 I93M mutant. Neurochem Int 50 : 119-129, 2007.
PubMed
14) Ragland M, et al : Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) Sl8Y variant and Parkinson's Disease : a HuGE review and meta-analysis. Am J Epidemiol 170 : 1344-1357, 2009.
PubMed
15) Xilouri M, et al : Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system. Hum Mol Genet 21 : 874-889, 2012.
PubMed
16) Nagamine S, et al : Deficiency of ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) leads to vulnerability to lipid peroxidation. Neurochem Int 57 : 102-110, 2010.
PubMed
17) Chu KY, et al : Ubiquitin C-terminal hydrolase L1 is required for pancreatic beta cell survival and function in lipotoxic conditions. Diabetologia 55 : 128-140, 2012.
PubMed
18) Konya C, et al : Parkinson's disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1. Neurochem Int 59 : 251-258, 2011.
 
P.59 掲載の参考文献
1) Valente EM, et al : Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 : 1158-1160, 2004.
PubMed
2) Cardona F, et al : Phylogenetic and in silico structural analysis of the Parkinson disease-related kinase PINK1. Hum Mutat 32 : 369-378, 2011.
PubMed
3) Truban D, et al : PINK1, Parkin, and Mitochondrial Quality Control : What can we Learn about Parkinson's Disease Pathobiology? JParkinsons Dis 7 : 13-29, 2017.
PubMed
4) Schneider SA, Kiein C : PINK1 Type of Young-Onset Parkinson Disease. GeneReviews [Internet] : Initial Posting ; March 16, 2010 : Last Update ; September 18, 2014.
 
5) Samaranch L, et al : PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 133 : 1128-1142, 2010.
PubMed
6) Takanashi M, et al : Absence of Lewy pathology associated with PINK1 homozygous mutation. Neurology 86 : 2212-2213, 2016.
PubMed
7) Greene AW, et al : Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. EMBO Rep 13 : 378-385, 2012.
PubMed
8) Yamano K, Youle RJ : PINK1 is degraded through the N-end rule pathway. Autophagy 9 : 1758-1769, 2013.
 
9) Okatsu K, et al : PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. Nat Commun 3 : 1016, 2012.
PubMed
10) Koyano F, et al : Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 510 : 162-166, 2014.
PubMed
11) Narendra D, et al : Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183 : 795-803, 2008.
PubMed
12) Woodroof HI, et al : Discovery of catalytically active orthologues of the Parkinson's disease kinase PINK1 : analysis of substrate specificity and impact of mutations. Open Biol 1 : 110012, 2011.
PubMed
13) Schubert AF, et al : Structure of PINK1 in complex with its substrate ubiquitin. Nature 552 : 51-56, 2017.
PubMed
14) Puschmann A, et al : Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. Brain 140 : 98-117, 2017.
 
15) Matheoud D, et al : Parkinson's Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation. Cell 166 : 314-327, 2016,
PubMed
P.63 掲載の参考文献
1) Nagakubo D, et al : DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 231 : 509-513, 1997.
PubMed
2) Cao J, et al : DJ-1 as a human oncogene and potential therapeutic target. Biochem Pharmacol 93 : 241-250, 2015.
PubMed
3) Bonifati V, et al : Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 : 256-259, 2003.
 
4) Bandyopadhyay S, Cookson MR : Evolutionary and functional relationships within the DJ1 superfamily. BMC Evol Biol 4 : 6, 2004.
PubMed
5) Chen S, et al : The Parkinson's disease-associated protein DJ-1 plays a positive nonmitochondrial role in endocytosis in Dictyostelium cells. Dis Model Mech 10 : 1261-1271, 2017.
 
6) Ariga H, et al : Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev 2013 : 683920, 2013.
PubMed
7) Kahle PJ, et al : DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med 47 : 1354-1361, 2009.
PubMed
8) Wang Z, et al : DJ-1 modulates the expression of Cu/Zn-superoxide dismutase-l through the Erk1/2-Elk1 pathway in neuroprotection. Ann Neurol 70 : 591-599, 2011.
 
9) Xu XM, et al : The Arabidopsis DJ-1a protein confers stress protection through cytosolic SOD activation. J Cell Sci 123 : 1644-1651, 2010.
PubMed
10) Kim YC, et al : Oxidation of DJ-1-dependent cell transformation through direct binding of DJ-1 to PTEN. Int J Oncol 35 : 1331-1341, 2009.
PubMed
11) Zhou W, et al : DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 280 : 43150-43158, 2005.
PubMed
12) Biosa A, et al : Recent findings on the physiological function of DJ-1 : Beyond Parkinson's disease. Neurobio Dis 108 : 65-72, 2017.
 
13) Shendelman S, et al : DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2 : e362, 2004.
PubMed
14) Piston D, et al : DJ-1 is a redox sensitive adapter protein for high molecular weight complexes involved in regulation of catecholamine homeostasis. Hum Mol Genet 26 : 4028-4041, 2017.
PubMed
15) Kahle PJ, et al : DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med 47 : 1354-1361, 2009.
PubMed
16) http://omim.org/entry/602533#0006
 
17) Moore DJ, et al : A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J Neurochem 87 : 1558-1567, 2003.
PubMed
18) Fu K, et al : Familial Parkinson's Disease-Associated L166P Mutant DJ-1 is Cleaved by Mitochondrial Serine Protease Omi/HtrA2. Neurosci Bull 33 : 685-694, 2017.
PubMed
19) Maita C, et al : Monolner DJ-1 and its N-terminal sequence are necessary for mitochondrial localization of DJ-1 mutants. PLoS ONE 8 : e54087, 2013.
PubMed
20) Tang B, et al : Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet 15 : 1816-1825, 2006.
PubMed
21) McCoy MK, et al : DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. Autophagy 7 : 531-532, 2011.
PubMed
22) Wang H, et al : Involvement of DJ-1 in ischemic preconditioning-induced delayed cardioprotection in vivo. Mol Med Rep 15 : 995-1001, 2017.
PubMed
23) Han B, et al : DJ-1 as a potential biomarker for the early diagnosis in lung cancer patients. Tumour Biol 39 : 1010428317714625, 2017.
PubMed
24) Waragai M, et al : Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett 425 : 18-22, 2007.
PubMed
25) Maita C, et al : Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett 431 : 86-89, 2008.
PubMed
26) An C, et al : Expression of the DJ-1 protein in the serum of Chinese patients with Parkinson's disease. Neurosci Lett 665 : 236-239, 2018.
 
27) Ho DH, et al : Increased DJ-1 in urine exosome of Korean males with Parkinson's disease. Biomed Res Int 2014 : 704678, 2014.
PubMed
28) Chen Y, et al : MicroRNA-4639 Is a Regulator of DJ-1 Expression and a Potential Early Diagnostic Marker for Parkinson's Disease. Front Aging Neurosci 9 : 232, 2017.
 
P.71 掲載の参考文献
1) Lin MK, Farrer MJ : Genetics and genomics of Parkinson's disease. Genome Med 6 : 48, 2014.
PubMed
2) Funayama M, et al : A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1, Ann Neurol 51 : 296-301, 2002.
PubMed
3) Zimprich A, et al : Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 : 601-607, 2004.
PubMed
4) Paisan-Ruiz C, et al : Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 : 595-600, 2004.
PubMed
5) Funayama M, et al : An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57 : 918-921, 2005.
PubMed
6) Meylan E, Tschopp J : The RIP kinases : crucial integrators of cellular stress. Trends Biochem Sci 30 : 151-159, 2005.
PubMed
7) Trinh J, et al : DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism : a genome-wide linkage and association study. Lancet Neurol 15 : 1248-1256, 2016.
PubMed
8) Hasegawa K, et al : Familial parkinsonism : study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 15 : 300-306, 2009.
PubMed
9) Ohta E, et al : LRRK2 directly phosphorylates Akt1 as a possible physiological substrate : impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett 585 : 2165-2170, 2011.
PubMed
10) Lobbestael E, et al : Phosphorylation of LRRK2 : from kinase to substrate. Biochem Soc Trans 40 : 1102-1110, 2012.
PubMed
11) MacLeod DA, et al : RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77 : 425-439, 2013.
PubMed
12) Seol W : Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease. BMB Rep 43 : 233-244, 2010.
PubMed
13) Greggio E, Cookson MR : Leucine-rich repeat kinase 2 mutations and Parkinson's disease : three questions. ASN Neuro 1 : 2009. pii : e00002. doi : 10.1042/AN20090007.
 
14) Ohta E, et al : I (2020) T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule. Biochem Biophys Res Commun 390 : 710-715, 2009.
 
15) Ohta E, et al : Dominant-negative effects of LRRK2 heterodimers : apossible mechanism of neurodegeneration in Parkinson's disease caused by LRRK2 I2020T mutation. Biochem Biophys Res Commun 430 : 560-566, 2013.
 
16) Greene ID, et al : Evidence that the LRRK2 ROC domain Parkinson's disease-associated mutants A1442P and R1441C exhibit increased intracellular degradation. J Neurosci Res 92 : 506-516, 2014.
PubMed
17) Rudenko IN, et al : The G2385R risk factor for Parkinson's disease enhances CHIP-dependent intracellular degradation of LRRK2. Biochem J 474 : 1547-1558, 2017.
PubMed
18) Sloan M, et al : Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models. Biochem Soc Trans 40 : 1080-1085, 2012.
PubMed
19) Tong Y, et al : Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA 107 : 9879-9884, 2010.
PubMed
20) Ohta E, et al : Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis. Biochem Biophys Res Commun 391 : 242-247, 2010.
PubMed
21) Li Y, et al : Mutant LRRK2 (R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12 : 826-828, 2009.
PubMed
22) Maekawa T, et al : The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities. Mol Neurodegener 7 : 15, 2012.
PubMed
23) Gillardon F : Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration? J Neurochem 110 : 1514-1522, 2009.
PubMed
24) Adeosun SO, et al : Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice. Neurobiol Learn Mem 142 : 182-189, 2017.
PubMed
25) Kubo M, et al : LRRK2 is expressed in B-2 but not in B-1 B cells, and downregulated by cellular activation. J Neuroimmunol 229 : 123-128, 2010.
 
26) Dzamko N, et al : The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS ONE 7 : e39132, 2012.
PubMed
27) Gillardon F, et al : Parkinson's disease-linked leucine-rich repeat kinase 2 (R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208 : 41-48, 2012.
PubMed
28) Liu Z, et al : The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 12 : 1063-1070, 2011.
PubMed
29) Kubo M, et al : Leucine-rich repeat kinase 2 is a regulator of B cell function, affecting homeostasis, BCR signaling, IgA production, and TI antigen responses. J Neuroimmunol 292 : 1-8, 2016.
PubMed
30) Cooper O, et al : Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 4 : 141ra90, 2012.
PubMed
31) Nguyen HN, et al : LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8 : 267-280, 2011.
PubMed
32) Sanchez-Danes A, et al : Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med 4 : 380-395, 2012.
PubMed
33) Liu GH, et al : Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491 : 603-607, 2012.
PubMed
34) Reinhardt P, et al : Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 12 : 354-367, 2013.
PubMed
35) Sanders LH, et al : LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients : reversal by gene correction. Neurobiol Dis 62 : 381-386, 2014.
PubMed
36) Lopez de Maturana R, et al : Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons. J Neuroinflammation 13 : 295, 2016.
 
37) Ohta E, et al : I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway. Hum Mol Genet 24 : 4879-4900, 2015.
 
P.78 掲載の参考文献
1) Davison C : Pallido-pyramidal disease. J Neuropathol Exp Neurol 13 : 50-59, 1954.
PubMed
2) Najim al-Din AS, et al : Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia : Kufor-Rakeb syndrome. Acta Neurol Scand 89 : 347-352, 1994.
PubMed
3) Ramirez A, et al : Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38 : 1184-1191, 2006.
PubMed
4) Ning YP, et al : PARK9-linked parkinsonism in eastern Asia : mutation detection in ATP13A2 and clinical phenotype. Neurology 70 : 1491-1493, 2008.
PubMed
5) Di Fonzo A, et al : ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68 : 1557-1562, 2007,
 
6) Bras J, et al : Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum Mol Genet 21 : 2646-2650, 2012.
PubMed
7) Schneider SA, et al : ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 25 : 979-984, 2010.
PubMed
8) Estrada-Cuzcano A, et al : Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78). Brain 140 : 287-305, 2017.
PubMed
9) Usenovic M, et al : Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity. J Neurosci 32 : 4240-4246, 2012.
 
10) Tsunemi T, Krainc D : Znz+dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum Mol Genet 23 : 2791-2801, 2014.
 
11) Satake W, et al : Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41 : 1303-1307, 2009.
PubMed
12) Schultheis PJ, et al : Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits. Hum Mol Genet 22 : 2067-2082, 2013.
 
13) Sato S, et al : Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atpl3a2-Deficient Mice. Am J Pathol 186 : 3074-3082, 2016.
PubMed
14) Tsunemi T, et al : ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein. J Neurosci 34 : 15281-15287, 2014.
 
15) Colombo M, et al : Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30 : 255-289, 2014.
PubMed
16) Steinbichler TB, et al : The role of exosomes in cancer mnetastasis. Semin Cancer Biol 44 : 170-180, 2017.
 
17) Fruhbeis C, et al : Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyteneuron communication. PLoS Biol 11 : e1001604, 2013.
PubMed
18) Falguieres T, et al : In vitro budding of intralumenal vesicles into late endosomes is regulated by Alix and Tsg101. Mol Biol Cell 19 : 4942-4955, 2008.
 
19) Luk KC, et al : Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 : 949-953, 2012.
 
P.85 掲載の参考文献
1) Morgan NV, et al : PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 38 : 752-754, 2006.
PubMed
2) Yamamoto T, et al : Novel PLA2G6 mutations associated with an exonic deletion due to non-allelic homologous recombination in a patient with infantile neuroaxonal dystrophy. Hum Genome Var 2 : 15048, 2015.
 
3) Riku Y, et al : Extensive aggregation of α-synuclein and tau in juvenile-onset neuroaxonal dystrophy : an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site. Acta Neuropathol Commun 1 : 12, 2013.
 
4) Miki Y, et al : Neuropathology of PARK14 is identical to idiopathic Parkinson's disease. Mov Disord 32 : 799-800, 2017.
PubMed
5) 隅寿恵, ほか : PLA2G6 (PARK14) 遺伝子欠損に伴う軸索変性の病態. 医学のあゆみ (第1土曜特集号), 247 (10) : 1061-1068, 2013.
 
6) Yoshino H, et al : Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 75 : 1356-1361, 2010.
PubMed
7) Burke JE, Dennis EA : Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 50 (Suppl) : S237-242, 2009.
PubMed
8) Shinzawa K, et al : Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice : a model of human neurodegenerative disease. J Neurosci 28 : 2212-2220, 2008.
 
9) Kinghorn KJ, et al : Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain 138 : 1801-1816, 2015.
PubMed
10) Wada H, et al : Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla296. Am J Pathol 175 : 2257-2263, 2009.
 
11) Zhou Q, et al : Impairment of PARK14-dependent Ca (2+) signalling is a novel determinant of Parkinson's disease. Nat Commun 7 : 10332, 2016.
PubMed
12) Beck G, et al : Neuroaxonal dystrophy in calcium-independent phospholipase A2β deficiency results from insufficient remodeling and degeneration of mitochondrial and presynaptic membranes. J Neurosci 31 : 11411-11420, 2011.
 
13) Chiu CC, et al : PARK14 PLA2G6 mutants are defective in preventing rotenone-induced mitochondrial dysfunction, ROS generation and activation of mitochondrial apoptotic pathway. Oncotarget 8 : 79046-79060, 2017.
PubMed
14) Bendor JT, et al : The function of α-synuclein. Neuron 79 : 1044-1066, 2013.
 
15) Sumi-Akamaru H, et al : High expression of α-synuclein in damaged mitochondria with PLA2G6 dysfunction. Acta Neuropathol Commun 4 : 27, 2016.
 
P.90 掲載の参考文献
1) Vilarino-Guell C, et al : VPS35 mutations in Parkinson disease. Am J Hum Genet 89 : 162-167, 2011.
PubMed
2) Chen YF, et al : Identification of VPS35 p.D620N mutation-related Parkinson's disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation : acase report and literature review. BMC Neurol 17 : 191, 2017.
 
3) 栗崎博司, ほか : 臨床医のための神経病理PARK17. Clinical Neuroscience 32 : 850-851, 2014.
 
4) Rovelet-Lecrux A, et al : De novo deleterious genetic variations target a biological network centered on Aβ peptide in early-onset Alzheimer disease. Mol Psychiatry 20 : 1046-1056, 2015.
 
5) Small SA, Petsko GA : Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat Rev Neurosci 16 : 126-132, 2015.
PubMed
6) Miura E, et al : VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease. Neurobiol Dis 71 : 1-13, 2014.
 
7) Zavodszky E, et al : Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy. Nat Commun 5 : 3828, 2014.
PubMed
8) Tang FL, et al : VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease. J Neurosci 35 : 10613-10628, 2015.
 
9) Munsie LN, et al : Retromer-dependent neurotransrnitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N. Hum Mol Genet 24 : 1691-1703, 2015.
PubMed
10) Wang C, et al : VPS35 regulates cell surface recycling and signaling of dopamine receptor D1. Neurobiol Aging 46 : 22-3L 2016.
PubMed
11) Tang FL, et al : VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by Impairing Mitochondrial Fusion and Function. Cell Rep 12 : 1631-1643, 2015.
 
12) Wang W, et al : Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat Med 22 : 54-63, 2016.
PubMed
13) MacLeod DA, et al : RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77 : 425-439, 2013.
PubMed
14) Inoshita T, et al : Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila. Hum Mol Genet 26 : 2933-2948, 2017.
PubMed
15) Malik BR, et al : VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin. Hum Mol Genet 24 : 6106-6117, 2015.
PubMed
P.95 掲載の参考文献
1) Funayama M, et al : CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease : a genome-wide linkage and sequencing study. Lancet Neurol 14 : 274-282, 2015.
PubMed
2) Li NN, et al : Genetic analysis of CHCHD2 gene in Chinese Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 171 : 1148-1152, 2016.
PubMed
3) Ikeda A, et al : A novel mutation of CHCHD2 p. R8H in a sporadic case of Parkinson's disease. Parkinsonism Relat Disord 34 : 66-68, 2017.
 
4) Jansen IE, et al : CHCHD2 and Parkinson's disease. Lancet Neurol 14 : 678-679, 2015.
PubMed
5) Koschmidder E, et al : A nonsense mutation in CHCHD2 in a patient with Parkinson disease. Neurology 86 : 577-579, 2016.
 
6) Shi CH, et al : CHCHD2 gene mutations in familial and sporadic Parkinson's disease. Neurobiol Aging 38 : 217. e9-217. el3, 2016.
 
7) Yang X, et al : Mutational scanning of the CHCHD2 gene in Han Chinese patients with Parkinson's disease and meta-analysis of the literature. Parkinsonism Relat Disord 29 : 42-46, 2016.
 
8) Gao C, et al : Mutation analysis of CHCHD2 gene in Chinese Han farnilial essential tremor patients and familial Parkinson's disease patients. Neurobiol Aging 49 : 218. e9-218. e11, 2017.
 
9) Baughman JM, et al : A computational screen for regulators of oxidative phosphorylation implicates SLIRP in mitochondrial RNA homeostasis. PLoS Genet 5 : elOOOSgO, 2009.
PubMed
10) Zhu L, et al : The mitochondrial protein CHCHD2 primes the differentiation potential of human induced pluripotent stem cells to neuroectodermal lineages. J Cell Biol 215 : 187-202, 2016.
PubMed
11) Liu Y, et al : CHCHD2 inhibits apoptosis by interacting with Bcl-x L to regulate Bax activation. Cell Death Differ 22 : 1035-1046, 2015.
PubMed
12) Liu Y, Zhang Y : CHCHD2 connects mitochondrial metabolism to apoptosis. Mol Cell Oncol 2 : e1004964, 2015.
PubMed
13) Meng H, et al : Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Nat Commun 8 : 15500, 2017.
PubMed
14) Oka T, et al : Identification of a novel protein MICSI that is involved in maintenance of mitochondrial morphology and apoptotic release of cytochrome c. Mol Biol Cell 19 : 2597-2608, 2008.
 
15) Feyeux M, et al : Early transcriptional changes linked to naturally occurring Huntington's disease mutations in neural derivatives of human embryonic stem cells. Hum Mol Genet 21 : 3883-3895, 2012.
PubMed
16) Song R, et al : Cyclic adenosine monophosphate response element-binding protein transcriptionally regulates CHCHD2 associated with the molecular pathogenesis of hepatocellular carcinoma. Mol Med Rep 11 : 4053-4062, 2015.
PubMed
P.101 掲載の参考文献
1) Gibb WR, Lees AJ : The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 : 745-752, 1988.
 
2) Spillantini MG, et al : Alpha-synuclein in Lewy bodies. Nature 388 : 839-840, 1997.
PubMed
3) Deng H, et al : The genetics of Parkinson disease. Ageing Res Rev 42 : 72-85, 2018.
PubMed
4) Nishioka K, et al : Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 59 : 298-309, 2006.
PubMed
5) Nishioka K, et al : Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord 24 : 1811-1819, 2009.
PubMed
6) Paisan-Ruiz C, et al : Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 : 595-600, 2004.
PubMed
7) Zimprich A, et al : Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 : 601-607, 2004.
PubMed
8) Kitada T, et al : Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene. Mamm Genome 11 : 417-421, 2000.
 
9) Valente EM, et al : Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, 0n hurnan chromosome 1p35-p36. Am J Hum Genet 68 : 895-900, 2001.
 
10) Lesage S, et al : Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. Am J Hum Genet 98 : 500-513, 2016.
PubMed
11) Velayos-Baeza A, et al : Analysis of the human VPS13 gene family. Genomics 84 : 536-549, 2004.
PubMed
12) McKeith IG, et al : Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortiurn. Neurology 65 : 1863-1872, 2005.
PubMed
13) Schormair B, et al : Diagnostic exome sequencing in early-onset Parkinson's disease confirms VPS13C as a rare cause of autosomal-recessive Parkinson's disease. Clin Genet 93 : 603-612, 2018.
PubMed
14) Safaralizadeh T, et al : SIPA1L2, MIR4697, GCH1 and VPS13C loci and risk of Parkinson's diseases in Iranian population : A case-control study. J Neurol Sci 369 : 1-4, 2016.
PubMed
15) Ramirez A, et al : Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38 : 1184-1191, 2006.
PubMed
16) Paisan-Ruiz C, et al : Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 65 : 19-23, 2009.
 
17) Conedera S, et al : FBXO7 mutations in Parkinson's disease and multiple system atrophy. Neurobiol Aging 40 : 192. e1-192. e5, 2016.
 
18) Rampoldi L, et al : A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet 28 : 119-120, 2001.
PubMed
19) Kolehmainen J, et al : Cohen syndrome is caused by mutations in a novel gene, COH1, encoding a transmembrane protein with a presumed role in vesicle-mediated sorting and intracellular protein transport. Am J Hum Genet 72 : 1359-1369, 2003.
 
20) Julie G, et al : Recessive mutations in VPS13D cause childhood-onset movement disorder. Ann Neurol. 2018 Mar 8. doi : 10.1002/ana.25204. [Epub ahead of print]
 
21) Myers MD, Payne GS : Vps13 and Cdc31/centrin : Puzzling partners in membrane traffic. J Cell Biol 216 : 299-301, 2017.
PubMed
22) Bankaitis VA, et al : Isolation of yeast mutants defective in protein targeting to the vacuole. Proc Natl Acad Sci USA 83 : 9075-9079, 1986.
 
23) Enyenihi AH, Saunders WS : Large-scale functional genomic analysis of sporulation and meiosis in Saccharomyces cerevisiae. Genetics 163 : 47-54, 2003.
PubMed
24) Braschi E, et al : Vps35 mediates vesicle transport between the mitochondria and peroxisomes. Curr Biol 20 : 1310-1315, 2010.
PubMed
25) Park JS, et al : Yeast Vps13 promotes mitochondrial function and is localized at membrane contact sites. Mol Biol Cell 27 : 2435-2449, 2016.
PubMed
26) Pickrell AM, Youle RJ : The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron 85 : 257-273, 2015,
PubMed
27) Matsuda N, et al : PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 189 : 211-221, 2010.
PubMed
P.106 掲載の参考文献
1) Baizabal-Carvallo JF, Jankovic J : Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol 12 : 175-185, 2016.
PubMed
2) Ogaki K, et al : Visual grasping in frontotemporal dementia and parkinsonism linked to chromosome 17 (microtubule-associated with protein tau) : a comparison of N-lsopropyl-p- [ (123) I] -iodoamphetamine brain perfusion single photon emission computed tomography analysis with progressive supranuclear palsy. Mov Disord 26 : 561-563, 2011.
 
3) Ogaki K, et al : Analyses of the MAPT, PGRN, and Cgorf72 mutations in Japanese patients with FTLD, PSP, and CBS. Parkinsonism Relat Disord 19 : 15-20, 2013.
 
4) Spector AR, et al : Anatomy of disturbed sleep in pallido-ponto-nigral degeneration. Ann Neurol 69 : 1014-1025, 2011.
PubMed
5) Iovino M, et al : Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations. Brain 138 : 3345-3359, 2015.
PubMed
6) Simon-Sanchez J, et al : Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41 : 1308-1312, 2009.
PubMed
7) Pittman AM, et al : Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet 42 : 837-846, 2005.
PubMed
8) Pascale E, et al : Genetic Architecture of MAPT Gene Region in Parkinson Disease Subtypes. Front Cell Neurosci 10 : 96, 2016.
PubMed
9) Coupland KG, et al : DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro. Mov Disord 29 : 1606-1614, 2014.
PubMed
10) Winder-Rhodes SE, et al : Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals. Neurobiol Aging 36 : 1519-1528, 2015.
PubMed
11) Morley JF, et al : Genetic in fluences on cognitive decline in Parkinson's disease. Mov Disord 27 : 512-518, 2012.
 
12) Mata IF, et al : APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 71 : 1405-1412, 2014.
PubMed
13) Paul KC, et al : ApoE, MAPT and COMT and Parkinson's disease susceptibility and cognitive symptom progression. J Parkinsons Dis 6 : 349-359, 2016.
PubMed
14) Robakis D, et al : The effect of MAPT haplotype on neocortical Lewy body pathology in Parkinson disease. J Neural Transm (Vienna) 123 : 583-588, 2016.
PubMed
15) Valenca GT, et al : The role of MAPT haplotype H2 and isoform 1N/4R in parkinsonism of older adults. PLoS One 11 (7) : e01574252, 2016.
PubMed
P.111 掲載の参考文献
1) Perry TL, et al : Hereditary mental depression and Parkinsonism with taurine deficiency. Arch Neurol 32 : 108-113, 1975.
PubMed
2) 小野麻衣子, 樋口真人 : 微小管機能とタウ. 日本臨牀 69 (増刊号 : 認知症学 (上)) : 64-68, 2011.
 
3) Herbert AL, et al : Dynein/dynactin is necessary for anterograde transport of Mbp mRNA in oligodendrocytes and for myelination in vivo. Proc Natl Acad Sci USA 114 : E9153-E9162, 2017.
PubMed
4) 永田博司 : 軸索輸送と神経疾患. 最新医学 48 : 1303-1305, 1993.
Medical*Online
5) Farrer MJ, et al : DCTN1 mutations in Perry syndrome. Nat Genet 41 : 163-165, 2009.
PubMed
6) Wider C, et al : Elucidating the genetics and pathology of Perry syndrome. J Neurol Sci 289 : 149-154, 2010.
PubMed
7) Araki E, et al : A novel DCTN1 mutation with late-onset parkinsonism and frontotemporal atrophy. Mov Disord 29 : 1201-1204, 2014.
PubMed
8) Gustavsson EK, et al : DCTN1 p.K56R in progressive supranuclear palsy. Parkinsonism Relat Disord 28 : 56-61, 2016.
PubMed
9) Vilarino-Guell C, et al : Characterization of DCTN1 genetic variability in neurodegeneration. Neurology 72 : 2024-2028, 2009.
PubMed
10) Mishima T, et al : Establishing diagnostic criteria for Perry syndrome. J Neurol Neurosurg Psychiatry, 2017. [doi : 10.1136/jnnp-2017-316864]
 
11) Wider C, et al : Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord 15 : 281-286, 2009.
PubMed
12) Hosaka Y, et al : Reduced TDP-43 Expression Improves Neuronal Activities in a Drosophila Model of Perry Syndrome. EBioMedicine 21 : 218-227, 2017.
 
13) Puls I, et al : Mutant dynactin in motor neuron disease. Nat Genet 33 : 455-456, 2003.
PubMed
P.115 掲載の参考文献
1) Gwinn-Hardy K, et al : Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 55 : 800-805, 2000.
PubMed
2) Kim JM, et al : Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. Arch Neurol 64 : 1510-1518, 2007.
PubMed
3) Elden AC, et al : Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466 : 1069-1075, 2010.
PubMed
4) Wang L, et al : Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Neurology 85 : 1283-1292, 2015.
PubMed
5) Sobczak K, Krzyzosiak WJ : CAG repeats containing CAA interruptions form branched hairpin structures in spinocerebellar ataxia type 2 transcripts. J Biol Chem 280 : 3898-3910, 2005.
PubMed
6) Kim YE, et al : SCA2 family presenting as typical Parkinson's disease : 34 year follow up. Parkinsonism Relat Disord 40 : 69-72, 2017.
PubMed
7) Varrone A, et al : Reduced striatal [123I] FP-CIT binding in SCA2 patients without parkinsonism. Ann Neurol 55 : 426-430, 2004.
PubMed
8) Miyaue N, et al : DAT SPECT may have diagnostic value in prodromal SCA2 patients with parkinsonism. Parkinsonism Relat Disord 44 : 137-141, 2017.
PubMed
9) Takao M, et al : Spinocerebellar ataxia type 2 is associated with Parkinsonism and Lewy body pathology. BMJ Case Rep 2011, 2011.
PubMed
10) Schols L, et al : No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra. Brain 138 : 3316-3326, 2015.
PubMed
11) Auburger G, et al : Efficient Prevention of Neurodegenerative Diseases by Depletion of Starvation Response Factor Ataxin-2. Trends Neurosci 40 : 507-516, 2017.
PubMed
12) Yokoshi M, et al : Direct binding of Ataxin-2 to distinct elements in 3' UTRs promotes mRNA stability and protein expression. Mol Cell 55 : 186-198, 2014.
PubMed
13) Wang X, Chen XJ : A cytosolic network suppressing mitochondria-mediated proteostatic stress and cell death. Nature 524 : 481-484, 2015.
 
14) Lastres-Becker I, et al : Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K/mTOR and is induced by starvation. Biochim Biophys Acta 1862 : 1558-1569, 2016.
PubMed
15) Sen NE, et al : Search for SCA2 blood RNA biomarkers highlights Ataxin-2 as strong modifier of the mitochondrial factor PINK1 levels. Neurobiol Dis 96 : 115-126, 2016.
PubMed
16) Becker LA, et al : Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544 : 367-371, 2017.
PubMed
17) Scoles DR, et al : Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature 544 : 362-366, 2017.
PubMed
P.120 掲載の参考文献
1) Goker-Alpan O, et al : Parkinsonism among Gaucher disease carriers. J Med Genet 41 : 937-940, 2004.
PubMed
2) Aharon-Peretz J, et al : Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 351 : 1972-1977, 2004.
PubMed
3) Sidransky E, et al : Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361 : 1651-1661, 2009.
PubMed
4) Mitsui J, et al : Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 66 : 571-576, 2009.
PubMed
5) Li Y, et al : Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease. Neurobiol Aging 35 : 935. e3-8, 2014.
 
6) Anheim M, et al : Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 78 : 417-420, 2012.
PubMed
7) Rana HQ, et al : Age-specific Parkinson disease risk in GBA mutation carriers : information for genetic counseling. Genet Med 15 : 146-149, 2013.
PubMed
8) Cilia R, et al : Survival and dementia in GBA-associated Parkinson's disease : The mutation matters. Ann Neurol 80 : 662-673, 2016.
PubMed
9) Liu G, et al : Prediction of cognition in Parkinson's disease with a clinical-genetic score : a longitudinal analysis of nine cohorts. Lancet Neurol 16 : 620-629, 2017.
 
10) Nalls MA, et al : A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 70 : 727-735, 2013.
PubMed
11) Mitsui J, et al : Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol 2 : 417-426, 2015.
PubMed
12) Srulijes K, et al : No association of GBA mutations and multiple system atrophy. Eur J Neurol 20 : e61-62, 2013.
PubMed
13) Parnetti L, et al : Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients. Mov Disord 32 : 1423-1431, 2017.
 
14) Alcalay RN. et al : Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 138 : 2648-2658, 2015.
PubMed
15) Xu YH, et al : Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab 102 : 436-447, 2011.
 
16) Sardi SP, et al : CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci USA 108 : 12101-12106, 2011.
 
17) Mazzulli JR, et al : Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146 : 37-52, 2011.
 
18) Sardi SP, et al : Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc Natl Acad Sci USA 114 : 2699-2704, 2017.
PubMed
19) Maegawa GH, et al : Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 284 : 23502-23516, 2009.
PubMed
20) Narita A, et al : Ambroxol chaperone therapy for neuronopathic Gaucher disease : A pilot study. Ann Clin Transl Neurol 3 : 200-215, 2016.
PubMed
P.126 掲載の参考文献
1) Sudhaman S, et al : Evidence of mutations in RIC3 acetylcholine receptor chaperone as a novel cause of autosomal-dominant Parkinson's disease with non-motor phenotypes. J Med Genet 53 : 559-566, 2016.
PubMed
2) He D, et al : Genetic analysis of the RIC3 gene in Han Chinese patients with Parkinson's disease. Neurosci Lett 653 : 351-354, 2017.
 
3) Ross JP, et al : RIC3 variants are not associated with Parkinson's disease in French-Canadians and French. Neurobiol Aging 53 : 194.e9-194.e11, 2017.
PubMed
4) Alexander JK, et al : Ric-3 promotes alpha7 nicotinic receptor assembly and trafficking through the ER subcompartment of dendrites. J Neurosci 30 : 10112-10126, 2010.
PubMed
5) Vilariio-Guell C, et al : DNAJC13 mutations in Parkinson disease. Hum Mol Genet 23 : 1794-1801, 2014.
 
6) Lorenzo-Betancor O, et al : DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. Eur J Neurol 22 : 1323-1325, 2015.
PubMed
7) Deng HX, et al : Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet 48 : 733-739, 2016.
PubMed
8) Appel-Cresswell S, et al : Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism. Mov Disord 29 : 1684-1687, 2014.
PubMed
9) Deng HX, et al : Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet 48 : 733-739, 2016.
PubMed
10) Giri A, et al : Lack of evidence for a role of genetic variation in TMEM230 in the risk for Parkinson's disease in the Caucasian population. Neurobiol Aging 50 : 167.e11-167.e13, 2017.
 
11) Yan W, et al : TMEM230 mutation analysis in Parkinson's disease in a Chinese population. Neurobiol Aging 49 : 219.e1-21.e3, 2017.
 
12) Chartier-Harlin MC, et al : Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 89 : 398-406, 2011.
PubMed
13) Deng H, et al : The EIF4GI gene and Parkinson's disease. Acta Neurol Scand 132 : 73-78, 2015.
 
14) Nishioka K, et al : EIF4G1 gene mutations are not a common cause of Parkinson's disease in the Japanese population. Parkinsonism Relat Disord 20 : 659-661, 2014.
 
15) Nichols N, et al : EIF4G1 mutations do not cause Parkinson's disease. Neurobiol Aging 36 : 2444. e1-4, 2015.
PubMed
P.132 掲載の参考文献
1) Ogaki K, Ross OA : Chromosome 22q11.2 deletion may contain a locus for recessive early-onset Parkinson's disease. Parkinsonism Relat Disord 20 : 945-946, 2014.
PubMed
2) Krahn LE, et al : Childhood-onset schizophrenia associated with parkinsonism in a patient with a microdeletion of chromosome 22. Mayo Clin Proc 73 : 956-959, 1998.
 
3) Zaleski C, et al : The co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome. Am J Med Genet A 149A : 525-528, 2009.
PubMed
4) Booij J, et al : Co-occurrence of early-onset Parkinson disease and 22q11.2 deletion syndrome : Potential role for dopamine transporter imaging. Am J Med Genet A 152A : 2937-2938, 2010.
PubMed
5) Butcher NJ, et al : Association between early-onset Parkinson disease and 22q11.2 deletion syndrome : identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol 70 : 1359-1366, 2013.
PubMed
6) Mok KY, et al : Deletions at 22q11.2 in idiopathic Parkinson's disease : a combined analysis of genomewide association data. Lancet Neurol 15 : 585-596, 2016.
PubMed
7) Oki M, et al : Early-onset Parkinson's Disease Associated with Chromosome 22q11.2 Deletion Syndrome. Intern Med 55 : 303-305, 2016.
PubMed
8) Dufournet B, et al : Parkinson's disease associated with 22q11.2 deletion : Clinical characteristics and response to treatment. Rev Neurol (Paris) 173 : 406-410, 2017.
PubMed
9) Butcher NJ, et al : Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease. PLoS ONE 12 : e0173944, 2017.
PubMed
10) Quadri M, et al : Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum Mutat 34 : 1208-1215, 2013.
PubMed
11) Krebs CE, et al : The Sacl domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. Hum Mutat 34 : 1200-1207, 2013.
 
12) Olgiati S, et al : PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new ltalian family. Neurogenetics 15 : 183-188, 2014.
 
13) Kirola L, et al : Identification of a novel homozygous mutation Arg459Pro in SYNJ1 gene of an Indian family with autosomal recessive juvenile Parkinsonism. Parkinsonism Relat Disord 31 : 124-128, 2016.
PubMed
14) Rauschendorf MA, et al : Novel compound heterozygous synaptojanin-1 mutation causes l-doparesponsive dystonia-parkinsonism syndrome. Mov Disord 32 : 478-480, 2017.
 
15) Taghavi S, et al : A Clinical and Molecular Genetic Study of 50 Families with Autosomal Recessive Parkinsonism Revealed Known and Novel Gene Mutations. Mol Neurobiol 55 : 3477-3489, 2018.
 
16) Picillo M, et al : Clinical progression of SYNJ1-related early onset atypical parkinsonism : 3-year follow up of the original Italian family. J Neurol 261 : 823-824, 2014.
PubMed
17) De Rosa A, et al : Non-motor symptoms and cardiac innervation in SYNJ1-related parkinsonism. Parkinsonism Relat Disord 23 : 102-105, 2016.
PubMed
18) Dyment DA, et al : Homozygous nonsense mutation in SYNJ1 associated with intractable epilepsy and tau pathology. Neurobiol Aging 36 : 1222. e1-5, 2015.
 
19) Puschmann A : New Genes Causing Hereditary Parkinson's Diseaseor Parkinsonism. Curr Neurol Neurosci Rep 17 : 66, 2017.
 
20) Cremona O, et al : Essential role of phosphoinositide metabolism in synaptic vesicle recycling. Cell 99 : 179-188, 1999.
PubMed
21) Wilson GR, et al : Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology. Am J Hum Genet 95 : 729-735, 2014.
 
22) Laxova R, et al : An X-linked recessive basal ganglia disorder with mental retardation. Am J Med Genet 21 : 681-689, 1985.
 
23) Gregg RG, et al : Waisman syndrome, a human X-linked recessive basal ganglia disorder with mental retardation : localization to Xq27.3-qter. Genomics 9 : 701-706, 1991.
PubMed
24) Giannandrea M, et al : Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly. Am J Hum Genet 86 : 185-195, 2010.
PubMed
25) El-Hattab AW, et al : Int22h-1/int22h-2-mediated Xq28 rearrangements : intellectual disability associated with duplications and in utero male lethality with deletions. J Med Genet 48 : 840-850, 2011.
PubMed
26) Vanmarsenille L, et al : Increased dosage of RAB39B affects neuronal development and could explain the cognitive impairment in male patients with distal Xq28 copy number gains. Hum Mutat 35 : 377-383, 2014.
PubMed
27) Mata IF, et al : The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. Mol Neurodegener 10 : 50, 2015.
PubMed
28) Lesage S, et al : Loss-of-function mutations in RAB39B are associated with typical early-onset Parkinson disease. Neurol Genet 1 : e9, 2015.
PubMed
29) Shi CH, et al : A novel RAB39B gene mutation in X-linked juvenile parkinsonism with basal ganglia calcification. Mov Disord 31 : 1905-1909, 2016.
 
30) Edvardson S, et al : A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrinuncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS ONE 7 : e36458, 2012.
PubMed
31) Koroglu C, et al : DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat Disord 19 : 320-324, 2013.
 
32) Elsayed LE, et al : A Novel Nonsense Mutation in DNAJC6 Expands the Phenotype of Autosomal-Recessive Juvenile-Onset Parkinson's Disease. Ann Neurol 79 : 335-337, 2016.
PubMed
33) Olgiati S, et al : DNAJC6 Mutations Associated With Early-Onset Parkinson's Disease. Ann Neurol 79 : 244-256, 2016.
PubMed
34) Olgiati S, et al : Reply. Ann Neurol 79 : 337-338, 2016.
PubMed
35) Hasegawa T, et al : DnaJ/Hsp40 Family and Parkinson's Disease. Front Neurosci 11 : 743, 2017.
PubMed
36) Cardona F, Perez-Tur J : Other Proteins Involved in Parkinson's Disease and Related Disorders. Curr Protein Pept Sci 18 : 765-778, 2017.
PubMed
37) Yim YI, et al : Endocytosis and clathrin-uncoating defects at synapses of auxilin knockout mice. Proc Natl Acad Sci USA 107 : 4412-4417, 2010.
PubMed
38) Sudhaman S, et al : Discovery of a frameshift mutation in podocalyxin-like (PODXL) gene, coding for a neural adhesion molecule, as causal for autosomal-recessive juvenile Parkinsonism. J Med Genet 53 : 450-456, 2016.
PubMed
39) Jaberi E, et al : Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction. Mov Disord 31 : 1004-1011, 2016.
PubMed
40) Khodadadi H, et al : PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism. Mov Disord 32 : 287-291, 2017.
PubMed
P.138 掲載の参考文献
1) Mencacci NE, et al : Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain 137 : 2480-2492, 2014.
PubMed
2) Wijemanne S, Jankovic J : Dopa-responsive dystonia-clinical and genetic heterogeneity. Nat Rev Neurol 11 : 414-424, 2015.
PubMed
3) Tadic V, et al : Dopa-responsive dystonia revisited : diagnostic delay, residual signs, and nonmotor signs. Arch Neurol 69 : 1558-1562, 2012.
PubMed
4) Hagenah J, et al : High mutation rate in dopa-responsive dystonia : detection with comprehensive GCH1 screening. Neurology 64 : 908-911, 2005.
 
5) Lewthwaite AJ, et al : Novel GCH1 variant in Dopa-responsive dystonia and Parkinson's disease. Parkinsonism Relat Disord 21 : 394-397, 2015.
PubMed
6) Hjermind LE, et al : Dopa-responsive dystonia and early-onset Parkinson's disease in a patient with GTP cyclohydrolase I deficiency? Mov Disord 21 : 679-682, 2006.
 
7) Wider C, et al : Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1 : redefining DYT14 as DYT5. Neurology 70 : 1377-1383, 2008.
PubMed
8) Eggers C, et al : Are Dopa-responsive dystonia and Parkinson's disease related disorders? A case report. Parkinsonism Relat Disord 18 : 666-668, 2012.
PubMed
9) Irie S, et al : A case of parkinsonism and dopa-induced severe dyskinesia associated with novel mutation in the GTP cyclohydrolase I gene. Parkinsonism Relat Disord 17 : 769-770, 2011.
PubMed
10) Momma K, et al : A new mutation in the GCH1 gene presents as early-onset Parkinsonism. Parkinsonism Relat Disord 15 : 160-161, 2009.
PubMed
11) Kikuchi A, et al : Arg (184) His mutant GTP cyclohydrolase I, causing recessive hyperphenylalaninemia, is responsible for dopa-responsive dystonia with parkinsonism : a casereport Mov Disord 19 : 590-593, 2003.
 
12) Webb J, Willette AA : Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity. Neurobiol Aging 50 : 39-46, 2017.
PubMed
13) Safaralizadeh T, et al : SIPA1L2, MIR4697, GCH1 and VPS13C loci and risk of Parkinson's diseases in Iranian population : A case-control study. J Neurol Sci 369 : 1-4, 2016.
PubMed
14) Chen CM, et al : Association of GCH1 and MIR4697, but not SIPA1L2 and VPS13C polymorphisms, with Parkinson's disease in Taiwan. Neurobiol Aging 39 : 221. e1-5, 2016.
PubMed
P.145 掲載の参考文献
1) Volta M, et al : Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease. Lancet Neurol 14 : 1054-1064, 2015.
PubMed
2) Sveinbjornsdottir S, et al : Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 343 : 1765-1770, 2000.
PubMed
3) Wellcome Trust Case Control Consortium : Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 : 661-678, 2007.
 
4) Satake W, et al : Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41 : 1303-1307, 2009.
PubMed
5) Nalls MA, et al : Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46 : 989-993, 2014.
PubMed
6) Chang D, et al : A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet 49 : 1511-1516, 2017.
 
7) Mizuta I, et al : YY1 binds to α-synuclein 3'-flanking region SNP and stimulates antisense noncoding RNA expression. J Hum Genet 58 : 711-719, 2013.
 
8) Soldner F, et al : Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression. Nature 533 : 95-99, 2016.
 
9) MacLeod DA, et al : RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77 : 425-439, 2013.
PubMed
10) Vilarino-Guell C, et al : VPS35 mutations in Parkinson disease. Am J Hum Genet 89 : 162-167, 2011.
PubMed
11) Yamamoto-Katayama S, et al : Crystallographic studies on human BST-1/CD157 with ADP-ribosyl cyclase and NAD glycohydrolase activities. J Mol Biol 316 : 711-723, 2002.
PubMed
12) Hamza TH, et al : Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 42 : 781-785, 2010.
PubMed
13) Sidransky E, et al : Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361 : 1651-1661, 2009.
PubMed
14) Mencacci NE, et al : Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain 137 : 2480-2492, 2014.
PubMed
15) Lek M, et al : Analysis of protein-coding genetic variation in 60,706 humans. Nature 536 : 285-291, 2016.
PubMed
P.148 掲載の参考文献
1) Polymeropoulos MH, et al : Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 : 2045-2047, 1997.
PubMed
2) Helley MP, et al : Mitochondria : A Common Target for Genetic Mutations and Environmental Toxicants in Parkinson's Disease. Front Genet 8 : 177, 2017.
PubMed
3) 竹島多賀夫, ほか : 環境因子 農薬, 殺虫剤. 日本臨牀 67 (増刊号 : パーキンソン病) : 91-95, 2009.
 
4) Brighina L, et al : Alpha-synuclein, pesticides, and Parkinson disease : a case-control study. Neurology 70 : 1461-1469, 2008,
PubMed
5) Hatcher JM, et al : Parkinson's disease and pesticides : a toxicological perspective. Trends Pharmacol Sci 29 : 322-329, 2008.
PubMed
6) Tanaka A, et al : Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. J Cell Biol 191 : 1367-1380, 2010.
 
7) Brooks AI, et al : Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 823 : 1-10, 1999.
PubMed
8) Manning-Bog AB, et al : Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 23 : 3095-3099, 2003.
PubMed
9) Thiruchelvam M, et al : The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb : implications for Parkinson's disease. J Neurosci 20 : 9207-9214, 2000.
PubMed
10) Schapira AH, et al : Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1 (8649) : 1269, 1989.
PubMed
11) Barsoum MJ, et al : Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J 25 : 3900-3911, 2006.
PubMed
12) Betarbet R, et al : Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 : 1301-1306, 2000.
 
13) Di Maio R, et al : α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Sci Transl Med 8 : 342ra78, 2016.
 
14) Bhatt MH, et al : Acute and reversible parkinsonism due to organophosphate pesticide intoxication : five cases. Neurology 52 : 1467-1471, 1999.
PubMed
15) Sanchez-Ramos J, et al : Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures. Exp Neurol 150 : 263-271, 1998.
PubMed
16) Fitzmaurice AG, et al : Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc Natl Acad Sci USA 110 : 636-641, 2013.
PubMed
17) Fitzmaurice AG, et al : Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease. Neurology 82 : 419-426, 2014.
PubMed
18) Richardson JR, et al : Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease. FASEB J 20 : 1695-1697, 2006.
 
19) Nasuti C, et al : Early life exposure to permethrin : a progressive animal model of Parkinson's disease. J Pharmacol Toxicol Methods 83 : 80-86, 2017.
PubMed
P.154 掲載の参考文献
1) Ogata A, et al : Japanese encephalitis virus neurotropism is dependent on the degree of neuronal maturity. J Virol 65 : 880-886, 1991.
PubMed
2) Ogata A, et al : A rat model of Parkinson's disease induced by Japanese encephalitis virus. J Neurovirol 3 : 141-147, 1997.
PubMed
3) Sejvar JJ, et al : Neurologic manifestations and outcome of West Nile virus infection. JAMA 290 : 511-515, 2003.
PubMed
4) Bopeththa BVKM, Ralapanawa U : Post encephalitic parkinsonism following dengue viral infection. BMC Res Notes 10 : 655, 2017.
PubMed
5) Jang H, et al : Viral parkinsonism. Biochim Biophys Acta 1792 : 714-721, 2009.
PubMed
6) Gamboa ET, et al : Influenza virus antigen in postencephalitic parkinsonism brain. Detection by immunofluorescence. Arch Neurol 31 : 228-232, 1974.
PubMed
7) Ogata A, et al : Identification of macrophage migration inhibitory factor mRNA expression in neural cells of the rat brain by in situ hybridization. Neurosci Lett 246 : 173-177, 1998.
PubMed
8) Suzuki T, et al : Japanese encephalitis virus up-regulates expression of macrophage migration inhibitory factor (MIF) mRNA in the mouse brain. Biochim Biophys Acta 1517 : 100-106, 2000.
PubMed
9) Ogata A, et al : Sustained release dosage of thyrotropin-releasing hormone improves experimental Japanese encephalitis virus-induced parkinsonism in rats. J Neurol Sci 159 : 135-139, 1998.
PubMed
10) Hamaue N, et al : Selegiline effects on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by Japanese encephalitis virus. Biogenic Amines 16 : 523-530, 2001.
 
11) Ogata A, et al : Isatin, an endogenous MAO inhibitor, improves bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by Japanese encephalitis virus. J Neurol Sci 206 : 79-83, 2003.
 
12) Hamaue N, et al : Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus. Brain Res 1309 : 110-115, 2010.
 
13) Pradhan S, et al : Parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis. Neurology 53 : 1781-1786, 1999.
PubMed
14) Ogata A, et al : Post-encephalitic parkinsonism : clinical features and experimental model. Biogenic Amines 18 : 339-347, 2004.
 
15) Duvoisin RC, et al : Encephalitis and parkinsonism. Arch Neurol 12 : 227-239, 1965.
PubMed
P.161 掲載の参考文献
1) Bedford L et al : Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 28 : 8189-8198, 2008.
PubMed
2) Bonifati V, et al : Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 : 256-259, 2003.
 
3) Kitada T, et al : Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 : 605-608, 1998.
 
4) Koyano F, et al : Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 510 : 162-166, 2014.
PubMed
5) Lee JY, et al : Human DJ-1 and its homologs are novel glyoxalases. Hum Mol Genet 21 : 3215-3225, 2012.
PubMed
6) Lowe J, et al : Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J Pathol 155 : 9-15, 1988.
PubMed
7) Matsuda N, et al : Parkinson's disease-related DJ-1 functions in thiol quality control against aldehyde attack in vitro. Sci Rep 7 : 12816, 2017.
PubMed
8) Matsuda N, et al : PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 189 : 211-221, 2010.
PubMed
9) McNaught KS, et al : Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56 : 149-162, 2004.
PubMed
10) Mizuno Y, et al : Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163 : 1450-1455, 1989.
PubMed
11) Nagakubo D, et al : DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 231 : 509-513, 1997.
PubMed
12) Narendra D, et al : Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183 : 795-803, 2008.
PubMed
13) Okatsu K, et al : Phosphorylated ubiquitin chain is the genuine Parkin receptor. J Cell Biol 209 : 111-128, 2015.
PubMed
14) Richarme G, et al : Guanine glycation repair by DJ-1/Park7 and its bacterial homologs. Science 357 : 208-211, 2017.
PubMed
15) Schapira AH : Mitochondrial dysfunction in Parkinson's disease. Cell Death Differ 14 : 1261-1266, 2007.
PubMed
16) Shimura H, et al : Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25 : 302-305, 2000.
PubMed
17) Subedi KP, et al : Hsp31 of Escherichia coli K-12 is glyoxalase III. Mol Microbiol 81 : 926-936, 2011.
PubMed
18) Takahashi-Niki K, et al : [Function of DJ-1 in mitochondria]. Yakugaku Zasshi 132 : 1105-1110, 2012.
PubMed
19) Yamano K, et al : The ubiquitin signal and autophagy : an orchestrated dance leading to mitochondrial degradation. EMBO Rep 17 : 300-316, 2016.
PubMed
P.165 掲載の参考文献
1) Watkins JC, Jane DE : The glutamate story. Br J pharmacology 147 (Suppl 1) : S100-108, 2006.
 
2) Olney JW : Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164 : 719-721, 1969.
PubMed
3) Hayashi T : Effects of sodium glutamate on the nervous system. Keio J Med 3 : 183-192, 1954.
 
4) Blandini F : An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Funct Neurol 25 : 65-71, 2010.
PubMed
5) Caudle WM, Zhang J : Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol 220 : 230-233, 2009.
PubMed
6) Dragicevic E, et al : Dopamine midbrain neurons in health and Parkinson's disease : emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels. Neuroscience 284 : 798-814, 2015.
PubMed
7) Ankarcrona M, et al : Glutamate-induced neuronal death : a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15 : 961-973, 1995.
PubMed
8) Sattler R, et al : Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. J Neurochem 71 : 2349-2364, 1998.
PubMed
9) Cui H, et al : PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci 27 : 9901-9915, 2007.
PubMed
10) Braak H, Del Tredici K : Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 25 : 19-23, 2004.
 
11) Novelli A, et al : Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 451 : 205-212, 1988.
 
12) Wu YN, Johnson SW : Rotenone reduces Mg2+ -dependent block of NMDA currents in substantia nigra dopamine neurons. Neurotoxicology 30 : 320-325, 2009.
PubMed
13) Izumi Y, et al : Vulnerability to glutamate toxicity of dopaminergic neurons is dependent on endogenous dopamine and MAPK activation. J Neurochem 110 : 745-755, 2009.
PubMed
14) Surmeier DJ, et al : The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid Redox Signal 14 : 1289-1301, 2011.
PubMed
15) Goldberg JA, et al : Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nat Neurosci 15 : 1414-1421, 2012.
PubMed
16) Surmeier DJ, et al : Physiological phenotype and vulnerability in Parkinson's disease. Cold Spring Harb Perspect Med 2 : a009290, 2012.
PubMed
17) Hurley MJ, et al : Parkinson's disease is associated with altered expression of CaVl channels and calcium-binding proteins. Brain 136 : 2077-2097, 2013.
 
18) Rcom-H'cheo-Gauthier AN, et al : Calcium : Alpha-synuclein interactions in alpha-synucleinopathies. Front Neurosci 10 : 570, 2016.
PubMed
19) Smith Y, et al : Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey. J Comp Neurol 364 : 231-253, 1996.
PubMed
20) Meredith GE, et al : Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol 219 : 334-340, 2009.
 
21) Wallace BA, et al : Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 130 : 2129-2145, 2007.
PubMed
22) Temel Y, et al : Protection of nigral cell death by bilateral subthalamic nucleus stimulation. Brain Res 1120 : 100-105, 2006.
PubMed
23) Luquin MR, et al : Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease? Exp Neurol 201 : 407-415, 2006.
PubMed
P.172 掲載の参考文献
1) Dexter D, et al : Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet 2 (8507) : 639-640, 1986.
PubMed
2) Yoritaka A, et al : Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93 : 2696-2701, 1996.
PubMed
3) Zhang S, et al : Intercelluar transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal. Neurobiol Aging 61 : 52-65, 2018.
 
4) Surmeier DJ, et al : Calcium and Parkinson's disease. Biochem Biophys Res Commun 483 : 1013-1019, 2017.
PubMed
5) Olanow CW : Levodopa : effect on cell death and the natural history of Parkinson's disease. Mov Disord 30 : 37-44, 2015.
PubMed
6) Halliday GM, et al : Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 128 : 2654-2664, 2005.
PubMed
7) Hattori N, et al : Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann Neurol 30 : 563-571, 1991.
PubMed
8) Angelova PR, et al : Lipid peroxidation is essential for α-synuclein-induced cell death. J Neurochem 133 : 582-589, 2015.
 
9) Bender A, et al : TOM40 mediates mitochondrial dysfunction induced by a-synuclein accumulation in Parkinson's disease. PLoS ONE 8 : e62277, 2013.
PubMed
10) Ciron C, et al : PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein. Acta Neuropathol Commun 3 : 16, 2015.
 
11) Imaizumi Y, et al : Mitochondrial dysfunction associated with increased oxidative stress and α- synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain 5 : 35, 2012.
 
12) Meng H, et al : Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Nat Commun. 8 : 15500, 2017.
PubMed
13) Hatano T, et al : Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. J Neurol Neurosurg Psychiatry 87 : 295-301, 2016.
PubMed
14) Ikawa M, et al : Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu] ATSM PET. Nucl Med Biol 38 : 945-951, 2011.
PubMed
15) Bieschke J, et al : EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 107 : 7710-7715, 2010.
PubMed
P.176 掲載の参考文献
1) Banati RB, et al : The peripheral benzodiazepine binding site in the brain in multiple sclerosis : quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123 (Pt 11) : 2321-2337, 2000.
 
2) Ouchi Y, et al : Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57 : 168-175, 2005.
PubMed
3) Saunders JA, et al : CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol 7 : 927-938, 2012.
PubMed
4) Bas J, et al : Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol 113 : 146-152, 2001.
PubMed
5) Baba Y, et al : Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 11 : 493-498, 2005.
PubMed
6) Stevens CH, et al : Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol 252 : 95-99, 2012.
 
7) Niwa F, et al : Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. Geriatr Gerontol Int 12 : 102-107, 2012.
PubMed
8) Double KL, et al : Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol 217 : 297-301, 2009.
PubMed
9) Yanamandra K, et al : α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS ONE 6 : e18513, 2011.
 
10) Zappia M, et al : Anti-GM1 ganglioside antibodies in Parkinson's disease. Acta Neurol Scand 106 : 54-57, 2002.
PubMed
11) De Virgilio A, et al : Parkinson's disease : Autoimmunity and neuroinflammation. Autoimmun Rev 15 : 1005-1011, 2016.
 
12) Sulzer D, et al : Tcells from patients with Parkinson's disease recognize α-synuclein peptides. Nature 546 : 656-661, 2017.
 
13) Nagatsu T, et al : Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl (60) 277-290, 2000.
PubMed
14) McGeer PL, et al : Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24 : 574-576, 1988,
PubMed
15) Brochard V, et al : Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119 : 182-192, 2009.
 
16) Sommer A, et al : Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model. J Neuroinflammation 13 : 174, 2016.
 
17) Reynolds AD, et al : Neuroprotective activities of CD4+ CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol 82 : 1083-1094, 2007.
 
18) Pierce S, Coetzee GA : Parkinson's disease-associated genetic variation is linked to quantitative expression of inflammatory genes. PLoS ONE 12 : e0175882, 2017.
PubMed
19) Nalls MA, et al : Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46 : 989-993, 2014.
PubMed
20) Gagliano SA, et al : Genomics implicates adaptive and innate immunity in Alzheimer's and Parkinson's diseases. Ann Clin Transl Neurol 3 : 924-933, 2016.
PubMed
P.183 掲載の参考文献
1) Maroteaux L, et al : Synuclein : aneuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8 : 2804-2815, 1988.
 
2) Burre J : The Synaptic Function of α-Synuclein. J parkinsons Dis 5 : 699-713, 2015.
 
3) Calo L, et al : Synaptic failure and α-synuclein. Mov Disord 31 : 169-177, 2016.
 
4) Petersen K, et al : Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex. Neuroscience 91 : 651-659, 1999.
PubMed
5) Murphy DD, et al : Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20 : 3214-3220, 2000.
PubMed
6) Kahle PJ, et al : Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 20 : 6365-6373, 2000.
 
7) Sugeno N, et al : α-Synuclein enhances histone H3 lysine-9 dimethylation and H3K9me2-dependent transcriptional responses. Sci Rep 6 : 36328, 2016.
 
8) Burr6 J, et al : α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci USA 111 : E4274-4283, 2014.
 
9) Chandra S, et al : Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123 : 383-396, 2005.
PubMed
10) Hasegawa T, et al : Membrane Trafficking Illuminates a Path to Parkinson's Disease. Tohoku J Exp Med 242 : 63-76, 2017.
PubMed
11) Butler B, et al : Dopamine Transporter Activity Is Modulated by α-Synuclein. J Biol Chem 290 : 29542-29554, 2015.
 
12) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197-211, 2003.
PubMed
13) Orimo S, et al : Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131 : 642-650, 2008.
PubMed
14) Nakata Y, et al : Accumulation of α-synuclein triggered by presynaptic dysfunction. J Neurosci 32 : 17186-17196, 2012.
 
15) Bellucci A, et al : The End Is the Beginning : Parkinson's Disease in the Light of Brain Imaging. Front Aging Neurosci 9 : 330, 2017.
PubMed
16) Lu T, et al : REST and stress resistance in ageing and Alzheimer's disease. Nature 507 : 448-454, 2014.
PubMed

III 病理・病態

P.191 掲載の参考文献
1) Dickson DW, et al : Neuropathological assessment of Parkinson's disease : refining the diagnostic criteria. Lancet Neurol 8 : 1150-1157, 2009.
PubMed
2) Spillantini MG, et al : Alpha-synuclein in Lewy bodies. Nature 388 : 839-840, 1997.
PubMed
3) McKeith IG, et al : Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium. Neurology 65 : 1863-1872, 2005.
PubMed
4) McKeith IG, et al : Diagnosis and management of dementia with Lewy bodies, fourth consensus report of the DLB consortium. Neurology 89 : 88-100, 2017.
PubMed
5) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197-211, 2003.
PubMed
6) Kosaka K, : Diffuse Lewy body disease in Japan. J Neurol 237 : 197-204, 1990.
PubMed
7) Masuda-Suzukake M, et al : Prion-like spreading of pathological α-synuclein in brain. Brain 136 : 1128-1138, 2013.
 
8) Hawkes CH, et al : Parkinson's disease : a dual-hit hypothesis. Neuropathol Appl Neurobiol 33 : 599-614, 2007.
PubMed
9) Beach TG, et al : Unified staging system for Lewy body disorders : correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117 : 613-634, 2009.
PubMed
10) Parkkinen L, et al : Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57 : 82-91, 2005.
 
11) Compta Y, et al : Lewy-and Alzheimer-type pathologies in Parkinson's disease dementia : which is more important? Brain 134 : 1493-1505, 2011.
PubMed
P.197 掲載の参考文献
1) Del Tredici K, Braak H : Review : Sporadic Parkinson's disease : development and distribution of α-synuclein pathology. Neuropathol Appl Neurobiol 42 : 33-50, 2016.
 
2) Beach TG, et al : Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119 : 689-702, 2010.
PubMed
3) Wakabayashi K, et al : Parkinson's disease : the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 76 : 217-221, 1988.
 
4) Wakabayashi K, et al : Parkinson's disease : an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 79 : 581-583, 1990.
PubMed
5) Singaram C, et al : Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 346 : 861-864. 1995.
PubMed
6) Orimo S, et al : Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131 : 642-650, 2008.
PubMed
7) Fumimura Y, et al : Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease. J Neuropathol Exp Neurol 66 : 354-362, 2007.
PubMed
8) Ikemura M, et al : Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67 : 945-953, 2008.
PubMed
9) Donadio V, et al : Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease. Ann Neurol 79 : 306-316, 2016.
 
10) Del Tredici K, Braak H : Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov Disord 27 : 597-607, 2012.
PubMed
11) Kalaitzakis ME, et al : The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease : a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol 34 : 284-295, 2008.
 
12) Adler CH, Beach TG : Neuropathological basis of nonmotor manifestations of Parkinson's disease. Mov Disord 31 : 1114-1119, 2016.
PubMed
13) Jellinger KA : Neuropathology of Nonmotor Symptoms of Parkinson's Disease. Int Rev Neurobiol 133 : 13-62, 2017.
PubMed
14) Dickson DW, et al : Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 15 (Suppl 3) : S1-S5, 2009.
 
15) Sumikura H, et al : Distribution of q-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons. Acta Neuropathol Commun 3 : 57, 2015.
 
P.203 掲載の参考文献
1) Jucker M, Walker LC : Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501 : 45-51, 2013.
PubMed
2) Luk KC, et al : Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci USA 106 : 20051-20056, 2009.
PubMed
3) Volpicelli-Daley LA, et al : Exogenotls α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72 : 57-71, 2011.
 
4) Bieri G, et al : Internalization, axonal transport and release of fibrillar forms of alpha-synuclein. Neurobiol Dis 109 (Pt B) : 219-225, 2018.
 
5) Flavin WP, et al : Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathol 134 : 629-653, 2017.
PubMed
6) Harms AS, et al : α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. Acta Neuropathol Commun 5 : 85, 2017.
 
7) Luk KC, et al : Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 209 : 975-986, 2012.
 
8) Luk KC, et al : Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 : 949-953, 2012.
 
9) Masuda-Suzukake M, et al : Prion-like spreading of pathological α-synuclein in brain. Brain 136 : 1128-1138, 2013.
 
10) Recasens A, et al : Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 75 : 351-362, 2014.
 
11) Shimozawa A, et al : Propagation of pathological α-synuclein in marmoset brain. Acta Neuropathol Commun 5 : 12, 2017.
 
12) Rey NL, et al : Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J Exp Med 213 : 1759-1778, 2016.
 
13) Holmqvist S, et al : Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 128 : 805-820, 2014.
 
14) Pan-Montojo F, et al : Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2 : 898, 2012.
PubMed
15) Ulusoy A, et al : Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med 5 : 1119-1127, 2013.
 
16) Sacino AN, et al : Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci USA 111 : 10732-10737, 2014.
 
17) Peelaerts W, Baekelandt V : α-Synuclein strains and the variable pathologies of synucleinopathies. J Neurochem 139 (Suppl 1) : 256-274, 2016.
 
P.210 掲載の参考文献
1) 織茂智之 : パーキンソン病および類縁疾患のMIBG心筋シンチグラフィー. 脳と神経 56 : 543-557, 2004.
 
2) Kawano H, et al : Histological study on the distribution of autonomic nerves in the human heart. Heart Vessels 18 : 32-39, 2003.
 
3) Orimo S, et al : Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 109 : 583-588, 2005.
PubMed
4) 織茂智之 : MIBG心筋シンチグラフィの現状. 神経内科 82 : 173-181, 2015.
 
5) Orimo S, et al : Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 17 : 24-30, 2007.
PubMed
6) Miki Y, et al : Incidental Lewy body disease restricted to the heart and stellate ganglia. Mov Disord 24 : 2299-2301, 2009.
 
7) Orimo S, et al : Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Mov Disord 20 : 1350-1353, 2005.
PubMed
8) Orimo S, et al : Cardiac sympathetic denervation in Parkinson's disease linked to SNCA duplication. Acta Neuropathol 116 : 575-577, 2008.
PubMed
9) Orimo S : Pathological Background of Reduced Cardiac MIBG Uptake. In Clinical Assessment of the Autonomic Nervous System (ed by Iwase S, et al), p291-311, Springer, Tokyo, 2017.
 
10) Tijero B, et al : Cardiac sympathetic denervation in symptomatic and asymptomatic carriers of the E46K mutation in theαsynuclein gerle. Parkinsonism Relat Disord 19 : 95-100, 2013.
 
11) Orimo S, et al : Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 113 : 81-86, 2007.
PubMed
12) Orimo S, et al : Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131 : 642-650, 2008.
PubMed
13) Orimo S, et al : Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson's disease. Neuropathol Appl Neurobiol 37 : 791-802, 2011.
PubMed
14) Takahashi M, et al : Quantitative correlation between cardiac MIBG uptake and remaining axons in the cardiac sympathetic nerve in Lewy body disease. J Neurol Neurosurg Psychiatry
PubMed
P.216 掲載の参考文献
1) Alexander GE, Crutcher MD : Functional architecture of basal ganglia circuits : neural substrates of parallel processing. Trends Neurosci 13 : 266-271, 1990.
PubMed
2) Gibb WR, Lees AJ : The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 : 745-752, 1988.
 
2) Alexander GE, et al : Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9 : 357-381, 1986.
PubMed
3) DeLong MR : Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13 : 281-285, 1990.
PubMed
3) Calne DB, et al : Criteria for diagnosing Parkinson's disease. Ann Neurol 32 (Suppl) : S125-127, 1992.
 
4) Gelb DJ, et al : Diagnostic criteria for Parkinson disease. Arch Neurol 56 : 33-39, 1999.
PubMed
4) Nambu A, et al : Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res 43 : 111-117, 2002.
PubMed
5) Nambu A, et al : Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J Neurophysiol 84 : 289-300, 2000.
PubMed
5) 厚生労働省 : 指定難病制度における各疾患診断基準. [http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000062437.html]
 
6) Brown P, et al : Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease. J Neurosci 21 : 1033-1038, 2001.
PubMed
6) Postuma RB, et al : MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30 : 1591-1601, 2015. <日本語訳 : Movement Disorders (日本語版) 4 : No. 52-3, 2016.>
PubMed
7) Berg D, et al : MDS research criteria for prodromal Parkinson's disease. Mov Disord 30 : 1600-1611, 2015.
PubMed
7) Marsden JF, et al : Subthalamic nucleus, sensorimotor cortex and muscle interrelationships in Parkinson's disease. Brain 124 : 378-388, 2001.
PubMed
8) Hughes AJ, et al : Accuracy of clinical diagnosis of idiopathic Parkinson's disease : a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 : 181-184, 1992.
 
9) Hughes AJ, et al : Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57 : 1497-1499, 2001.
PubMed
10) Berardelli A, et al : EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol 20 : 16-34, 2013.
PubMed
11) Berg D, et al : Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord 29 : 454-462, 2014.
PubMed
12) 日本神経学会 (監修) : パーキンソン病の診断. パーキンソン病診療ガイドライン 2018 (「パーキンソン病診療ガイドライン」作成委員会編), 医学書院, 2018 (印刷中).
 
13) Malek N, et al : Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases. Parkinsonism Relat Disord 40 : 40-46, 2017.
 
14) Fereshtehnejad SM, et al : Validation of the MDS research criteria for prodromal Parkinson's disease : Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. Mov Disord 32 : 865-873, 2017.
 
15) Pilotto A, et al : Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. Mov Disord 32 : 1025-1034, 2017.
PubMed

IV 検査・診断

P.225 掲載の参考文献
1) Rizzo G, et al : Accuracy of clinical diagnosis of Parkinson disease : A systematic review and meta-analysis. Neurology 86 : 566-576, 2016.
PubMed
P.230 掲載の参考文献
1) Barone P, et al : The PRIAMO study : A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24 : 1641-1649, 2009.
PubMed
2) Lim Sy, et al : Overview of the extranigral aspects of Parkinson disease. Arch Neurol 66 : 167-172, 2009.
PubMed
3) Berg D, et al : MDS research criteria for prodromal Parkinson's disease. Mov Disord 30 : 1600-1611, 2015.
PubMed
4) Del Tredici K, Braak H : Review : Sporadic Parkinson's disease : development and distribution of α-synuclein pathology. Neuropathol Appl Neurobiol 42 : 33-50, 2016.
 
5) Siderowf A, Lang AE : Premotor Parkinson's disease : concepts and definitions. Mov Disord 27 : 608-616, 2012.
PubMed
6) Sommer U, et al : Detection of presymptomatic Parkinson's disease : combining smell tests, transcranial sonography, and SPECT. Mov Disord 19 : 1196-1202, 2004.
 
7) Ross GW, et al : Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 63 : 167-173, 2008.
PubMed
8) Schenck CH, et al : Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46 : 388-393, 1996.
PubMed
9) Iranzo A, et al : Neurodegenerative disease status and post-mortem pathology in idiopathic rapideye-movement sleep behaviour disorder : an observational cohort study. Lancet Neurol 12 : 443-453, 2013.
 
10) Adams-Carr KL, et al : Constipation preceding Parkinson's disease : asystematic review and metaanalysis. J Neurol Neurosurg Psychiatry 87 : 710-716, 2016.
 
11) Abbott RD, et al : Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57 : 456-462, 2001.
PubMed
12) Schuurman AG, et al : Increased risk of Parkinson's disease after depression : aretrospective cohort study. Neurology 58 : 1501-1504, 2002.
 
13) Shiba M, et al : Anxiety disorders and depressive disorders preceding Parkinson's disease : a case-control study. Mov Disord 15 : 669-677, 2000.
PubMed
14) Maetzler W, Hausdorff JM : Motor signs in the prodromal phase of Parkinson's disease. Mov Disord 27 : 627-633, 2012.
PubMed
15) Adler CH, et al : Incidental Lewy body disease : clinical comparison to a control cohort. Mov Disord 25 : 642-646, 2010.
PubMed
P.237 掲載の参考文献
1) Martinez-Martin P, et al : The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 26 : 399-406, 2011.
PubMed
2) Jankovic J : Parkinson's disease : clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79 : 368-376, 2008.
PubMed
3) DeMaagd G, Philip A : Parkinson's Disease and Its Management : Part 1 : Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. P T 40 : 504-532, 2015.
PubMed
4) Poewe W, et al : Parkinson disease. Nat Rev Dis Primers 3 : 17013, 2017.
PubMed
5) Zhang ZX, et al : Prevalence of Parkinson's disease and related disorders in the elderly population of greater Beijing, China. Mov Disord 18 : 764-772, 2003.
PubMed
6) Kang GA, et al : Clinical characteristics in early Parkinson's disease in a central California populationbased study. Mov Disord 20 : 1133-ll42, 2005.
 
7) Jankovic J, et al : Variable expression of Parkinson's disease : a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40 : 1529-1534, 1990.
 
8) Luquin MR, et al : Consensus on the Definition of Advanced Parkinson's Disease : A Neurologists-Based Delphi Study (CEPA Study). Parkinsons Dis 2017 : 4047392, 2017.
PubMed
9) Sveinbjornsdottir S : The clinical symptoms of Parkinson's disease. J Neurochem 139 (Suppl 1) : 318-324, 2016.
 
10) Wood BH, et al : Incidence and prediction of falls in Parkinson's disease : a prospective multidiscipiinary study. J Neurol Neurosurg Psychiatry 72 : 721-725, 2002.
PubMed
11) Kalf JG, et al : Reproducibility and validity of patient-rated assessment of speech, swallowing, and saliva control in Parkinson's disease. Arch Phys Med Rehabil 92 : 1152-1158, 2011.
PubMed
12) Hely MA, et al : The Sydney multicenter study of Parkinson's disease : the inevitability of dementia at 20 years. Mov Disord 23 : 837-844, 2008.
PubMed
13) Poewe W : The natural history of Parkinson's disease. J Neurol 253 (Suppl 7) : VII2-6, 2006.
 
14) Jankovic J, Stacy M : Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 21 : 677-692, 2007.
PubMed
15) Louis ED, et al : Progression of parkinsonian signs in Parkinson disease. Arch Neurol 56 : 334-337, 1999.
PubMed
16) Pont-Sunyer C, et al : The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord 30 : 229-237, 2015.
PubMed
17) Zis P, et al : Non-motor symptoms burden in treated and untreated early Parkinson's disease patients : argument for non-motor subtypes. Eur J Neurol 22 : 1145-1150, 2015.
PubMed
18) Simuni T, et al : Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease : the PPMI cohort. J Neurol Neurosurg Psychiatry 89 : 78-88, 2018.
PubMed
19) Zis P, et al : Non-motor symptoms profile and burden in drug nalve versus long-term Parkinson's disease patients. J Parkinsons Dis 4 : 541-547, 2014.
 
20) Barone P, et al : The PRIAMO study : A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24 : 1641-1649, 2009.
PubMed
21) Coelho M, Ferreira JJ : Late-stage Parkinson disease. Nat Rev Neurol 8 : 435-442, 2012.
 
P.243 掲載の参考文献
1) Postuma RB, et al : MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30 : 1591-1601, 2015.
PubMed
2) Maeda T, et al : Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson's disease patients from 35 medical centers. Parkinsonism Relat Disord 38 : 54-60, 2017.
PubMed
3) Barone P, et al : The PRIAMO study : A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24 : 1641-1649, 2009.
PubMed
4) Berg D, et al : MDS research criteria for prodromal Parkinson's disease. Mov Disord 30 : 1600-1611, 2015.
PubMed
5) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197-211, 2003.
PubMed
6) Pont-Sunyer C, et al : The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord 30 : 229-237, 2015.
PubMed
7) Ross GW, et al : Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 63 : 167-173, 2008.
PubMed
8) Baba T, et al : Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease : a 3 year longitudinal study. Brain 135 : 161-169, 2012.
PubMed
9) Voon V, et al : Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 64 : 212-216, 2007.
PubMed
10) Hely MA, et al : The Sydney multicenter study of Parkinson's disease : the inevitability of dementia at 20 years. Mov Disord 23 : 837-844, 2008.
PubMed
11) Chou KL, et al : A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord 25 : 2501-2507, 2010.
PubMed
12) Dubois B, et al : Diagnostic procedures for Parkinson's disease dementia : recommendations from the movement disorder society task force. Mov Disord 22 : 2314-2324, 2007.
PubMed
13) Litvan I, et al : Diagnostic criteria for mild cognitive impairment in Parkinson's disease : Movement Disorder Society Task Force guidelines. Mov Disord 27 : 349-356, 2012.
PubMed
14) Schenck CH, et al : Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder : a 16-year update on apreviously reported series. Sleep Med 14 : 744-748, 2013.
 
15) Abbott RD, et al : Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57 : 456-462, 2001.
PubMed
P.250 掲載の参考文献
1) Leigh RJ, Zee DS (ed) : The Neurology of Eye movements, 4th ed, Oxford University Press, New York, 2006.
 
2) Hikosaka O, et al : Role of the basal ganglia in the control of purposive saccadic eye movements. Physiol Rev 80 : 953-978, 2000.
PubMed
3) 阿曽沼早苗, ほか : パーキンソン病の視機能についての検討. 眼科臨床紀要 8 : 81-87. 2015.
 
4) Chaudhuri KR, et al : International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease : the NMSQuest study. Mov Disord 21 : 916-923, 2006.
PubMed
5) Martinez-Martin P, et al : Prevalence of nonmotor symptoms in Parkinson's disease in an international setting ; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22 : 1623-1629, 2007.
 
6) Biousse V, et al : Ophthalmologic features of Parkinson's disease. Neurology 62 : 177-180, 2004.
PubMed
7) Lepore FE : Parkinson's disease and diplopia. Neuro-Ophthalmology 30 : 37-40, 2006.
 
8) Yarbus AL : Eye Movements and Vision, p29-43, Plenum Press, New York, 1967.
 
9) van der Geest JN, Frens MA : Recording eye movements with video-oculography and scleral search coils : a direct comparison of two methods. J Neurosci Methods 114 : 185-195, 2002.
PubMed
10) Terao Y, et al : New perspectives on the pathophysiology of Parkinson's disease as assessed by saccade performance : a clinical review. Clin Neurophysiol 124 : 1491-1506, 2013.
PubMed
11) Rascol O, et al : Abnormal ocular movements in Parkinson's disease. Evidence for involvement of dopaminergic systems. Brain 112 (Pt 5) : 1193-1214, 1989.
 
12) Vermersch AI, et al : Sequences of memory-guided saccades in Parkinson's disease. Ann Neurol 35 : 487-490, 1994.
PubMed
13) Yugeta A, et al : Effects of STN stimulation on the initiation and inhibition of saccade in Parkinson disease. Neurology 74 : 743-748, 2010.
PubMed
14) Matsumoto H, et al : Small saccades restrict visual scanning area in Parkinson's disease. Mov Disord 26 : 1619-1626, 2011.
PubMed
P.255 掲載の参考文献
1) 久野貞子 : パーキンソン病の臨床症候. パーキンソン病と運動異常, p293-306, 中山書店, 2013.
 
2) Hoehn MM, Yahr MP : Parkinsonism : onset, progression and mortality. Neurology 17 : 427-442, 1967.
 
3) 柳澤信夫 : パーキンソン病の長期治療. 日本内科学会雑誌 77 : 1378-1382, 1988.
 
4) Hughes AJ, et al : A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 50 : 140-148, 1993.
PubMed
5) 村田美穂 : 加齢に伴う運動障害とParkinson病. 日本内科学会雑誌 104 : 1572-1577, 2015.
 
6) Ling H, et al : Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. Brain 135 : 1141-1153, 2012.
PubMed
7) 水野美邦 : パーキンソン病の症候. パーキンソン病の診かた, 治療の進めかた, p8-24, 中外医学社, 2012.
 
8) Hemmi S, et al : Dramatic response of dropped head sign to treatment with steroid in Parkinson's disease : report of three cases. Intern Med 50 : 757-761, 2011.
PubMed
9) 藤本健一 : パーキンソン病治療薬による姿勢異常の全国疫学調査. 厚生労働科学研究費補助金神経変性疾患に関する調査研究班, 平成22年度報告書, p188-190, 2011.
 
10) Schulz-Schaeffer WJ, et al : Effect of neurostimulation on camptocormia in Parkinson's disease depends on symptom duration. Mov Disord 30 : 368-372, 2015.
PubMed
11) Ashour R, et al : Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol 4 : 423-431, 2005.
PubMed
12) Abdo WF, et al : Ten steps to identify atypical parkinsonism. J Neurol Neurosurg Psychiatry 77 : 1367-1369, 2006.
PubMed
13) Barthel C, et al : The laser shoes : A new ambulatory device to alleviate freezing of gait in Parkinson disease. Neurology 90 : e164-e171, 2018.
PubMed
14) Andrews CJ : Influence of dystonia on the response to long-term L-dopa therapy in Parkinson's disease. J Neurol Neurosurg Psychiatry 36 : 630-636, 1973.
 
15) Aerts MB, et al : The "bicycle sign" for atypical parkinsonism. Lancet 377 : 125-126, 2011.
PubMed
P.260 掲載の参考文献
1) Fahn S, Elton RL : Unified Parkinson's disease rating scale. In : Recent Developments in Parkinson's Disease, Vol 2 (ed by Fahn S, et al), p153-163, 293-304, Macnillan Healthcare Information, Florham Park, 1987.
 
2) Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease : The Unified Parkinson's Disease Rating Scale (UPDRS) : status and recommendations. Mov Disord 18 : 738-750, 2003.
PubMed
3) Goetz CG, et al : Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) : scale presentation and clinimetric testing results. Mov Disord 23 : 2129-2170, 2008.
PubMed
4) Kashihara K, et al : Official Japanese Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale : validation against the original English version. Mov Disord Clin Pract 1 : 200-212, 2014.
PubMed
5) Goetz CG, et al : Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale : (MDS-UPDRS). Mov Disord 25 : 1190-1194, 2010.
PubMed
6) Peto V, et al : The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 4 : 241-248, 1995.
 
7) 河本純子, ほか : 日本人におけるParkinson's Disease Questionnaire-39 (PDQ-39) の信頼性評価. 臨床神経 43 : 71-76, 2003.
 
8) Bloem BR, et al : Measurement instruments to assess posture, gait, and balance in Parkinson's disease : Critique and Recommendations. Mov Disord 31 : 1342-1355, 2016.
PubMed
9) Chaudhuri KR, et al : International multicenter pilot study of the first comprehensive self-completed nonmotor symptorns questionnaire for Parkinson's disease : the NMSQuest study. Mov Disord 21 : 916-923, 2006.
PubMed
P.264 掲載の参考文献
1) Jankovic J, et al : Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry 67 : 646-650, 1999.
PubMed
2) Neufeld MY, et al : EEG in demented and non-demented parkinsonian patients. Acta Neurol Scand 78 : 1-5, 1988.
PubMed
3) Bonanni L, et al : EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 131 : 690-705, 2008.
PubMed
4) 依藤史郎 : 脳磁図 (MEG) を用いたパーキンソン病の解析. 脳 217 : 253-256, 2004.
 
5) Schlesinger I, et al : Uric acid in Parkinson's disease. Mov Disord 23 : 1653-1657, 2008.
PubMed
6) Gao X, et al : Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology 86 : 520-526, 2016.
PubMed
7) Ogawa I, et al : The significance of oxidized DJ-1 protein (oxDJ-1) as a biomarker for Parkinson's disease. Brain Nerve 66 : 471-477, 2014.
PubMed
8) Lee PH, et al : The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm (Vienna) 113 : 1435-1439, 2006.
PubMed
9) Ishii R, et al : Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference. PLoS ONE 10 : e0123162, 2015.
 
10) Swanson CR, et al : Reply to letter : Plasma fasting cholesterol profiles and age at onset in Parkinson's disease. Mov Disord 30 : 1975-1976, 2015.
PubMed
11) Goldstein DS, et al : Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain 135 : 1900-1913, 2012.
PubMed
12) Zhou B, et al : The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α-Synuclein Levels in Parkinson's Disease : A Meta-Analysis. Parkinsons Dis 2015 : 567386, 2015.
 
13) Tokuda T, et al : Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75 : 1766-1772, 2010.
 
14) Majbour NK, et al : Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Mol Neurodegener 11 : 7, 2016.
PubMed
15) Mollenhauer B, et al : Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 22 : 200-208, 2006.
PubMed
P.270 掲載の参考文献
1) De Pablo-Fernandez E, et al : Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurol 74 : 970-976, 2017.
PubMed
2) Goldstein DS, et al : Survival in synucleinopathies : A prospective cohort study. Neurology 85 : 1554-1561, 2015.
PubMed
3) Goldstein DS : Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 16 : 46-54, 2006.
PubMed
4) Rascol O, et al : Falls in ambulatory non-demented patients with Parkinson's disease. J Neural Transm (Vienna) 122 : 1447-1455, 2015.
PubMed
5) Centi J, et al : Effects of orthostatic hypotension on cognition in Parkinson disease. Neurology 88 : 17-24, 2017.
PubMed
6) McDonald C, et al : Orthostatic hypotension and cognitive impairment in Parkinson's disease : Causation or association? Mov Disord 31 : 937-946, 2016.
PubMed
7) Seyer-Hansen K, : Postprandial hypotension. Br Med J 2 (6097) : 1262, 1977.
PubMed
8) Umehara T, et al : Postprandial hypotension in de novo Parkinson's disease : a comparison with orthostatic hypotension. Parkinsonism Relat Disord 20 : 573-577, 2014.
PubMed
9) 長谷川康博 : Parkinson病の食事性低血圧. 神経内科 66 : 38-45, 2007.
 
10) Chobanian AV, et al : Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 : 1206-1252, 2003.
PubMed
11) Umehara T, et al : Clinical characteristics of supine hypertension in de novo Parkinson disease. Clin Auton Res 26 : 15-21, 2016.
PubMed
12) Berganzo K, et al : Nocturnal hypertension and dysautonomia in patients with Parkinson's disease : are they related? J Neurol 260 : 1752-1756, 2013.
PubMed
13) Tanaka R, et al : Association between abnormal nocturnal blood pressure profile and dementia in Parkinson's disease. Parkinsonism Relat Disord 46 : 24-29, 2018.
PubMed
14) Gilman S, et al : Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 8 : 359-362, 1998.
PubMed
15) Zerbe RL, et al : Vasopressin response to orthostatic hypotension. Etiologic and clinical implications. Am J Med 74 : 265-271, 1983.
PubMed
16) Manabe Y, et al : Systemic blood pressure profile correlates with cardiac 123I-MIBG uptake in patients with Parkinson's disease. J Neurol Sci 307 : 153-156, 2011.
PubMed
17) Oka H, et al : Reduced cardiac 123I-MIBG uptake reflects cardiac sympathetic dysfunction in de novo Parkinson's disease. J Neural Transm (Vienna) 118 : 1323-1327, 2011.
PubMed
18) Oka H, et al : Cardiovascular dysautonomia in de novo Parkinson's disease without orthostatic hypotension. Eur J Neurol 18 : 286-292, 2011.
PubMed
19) Oka H, et al : Olfactory dysfunction and cardiovascular dysautonomia in Parkinson's disease. J Neurol 257 : 969-976, 2010.
PubMed
20) Orimo S, et al : (123) I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies. Ageing Res Rev 30 : 122-133, 2016.
 
21) Nakamura T, et al : Dobutamine stress test unmasks cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci 263 : 133-138, 2007.
PubMed
P.276 掲載の参考文献
1) 榊原隆次 : 多系統萎縮症 vs パーキンソン病 自律神経症候から見た鑑別法 消化管障害 (解説). 自律神経 53 : 218-221, 2016.
 
2) 榊原隆次, ほか : 消化管自律神経機能検査レビュー. 自律神経機能検査 (第5版) (日本自律神経学会編), p342-344, 文光堂, 2015.
 
3) Recasens A, Dehay B : Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat 8 : 159 2014. (doi : 10.3389/fnana. 2014. 00159)
 
4) Tateno H, et al : Metaiodobenzylguanidine myocardial scintigraphy identifies premotor Parkinson's disease during a negative dopamine transporter scan. J Am Geriatr Soc 63 : 2428-2430, 2015.
PubMed
5) Tateno H, et al : Transdermal dopamine agonist ameliorates gastric emptying in Parkinson's disease. J Am Geriatr Soc 63 : 2416-2418, 2015.
PubMed
6) Sakakibara R, et al : Nizatidine ameliorates slow transit constipation in Parkinson's disease. J Am Geriatr Soc 63 : 399-401, 2015.
PubMed
7) 榊原隆次 (編著) : 神経因性膀胱ベッドサイドマニュアル, 中外医学社, 2014.
 
8) 榊原隆次, 館野冬樹 : 膀胱・性機能検査レビュー. 自律神経機能検査 (第5版) (日本自律神経学会編) p294-299, 文光堂, 2015.
 
9) Ogawa T, et al : Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy. Nat Rev Urol 14 : 79-89, 2017.
PubMed
10) Sakakibara R, et al : A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol Urodyn 35 : 551-563, 2016.
PubMed
11) パーキンソン病における下部尿路機能障害診療ガイドライン (日本排尿機能学会, パーキンソン病における下部尿路機能障害診療ガイドライン作成委員会編), 中外医学社, 2017.
 
P.280 掲載の参考文献
1) Ikemura M, et al : Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67 : 945-953, 2008.
PubMed
2) Miki Y, et al : Clinical availability of skin biopsy in the diagnosis of Parkinson's disease. Neurosci Lett 469 : 357-359, 2010.
PubMed
3) Donadio V, et al : Skin nerve α-synuclein deposits : a biomarker for idiopathic Parkinson disease. Neurology 82 : 1362-1369, 2014.
 
4) Hirayama M : Sweating dysfunctions in Parkinson's disease. J Neurol 253 (Suppl 7) : VII42-47, 2006.
 
5) Gowers WR : AManual of Diseases of the Nervous System, Vol 2, 2nd ed, Blakiston, Philadelphia, 1893.
 
6) Swinn L, et al : Sweating dysfunction in Parkinson's disease. Mov Disord 18 : 1459-1463, 2003.
PubMed
7) Zakrzewska-Pniewska B, Jamrozik Z : Are electrophysiological autonomic tests useful in the assessment of dysautonomia in Parkinson's disease? Parkinsonism Relat Disord 9 : 179-183, 2003.
PubMed
8) De Marinis M, et al : Sympathetic skin response and cardiovascular autonomic function tests in Parkinson's disease and multiple system atrophy with autonomic failure. Mov Disord 15 : 1215-1220, 2000.
PubMed
9) Choi BO, et al : Sympathetic skin response and cardiovascular autonomic function tests in Parkinson's disease. Yonsei Med J 39 : 439-445, 1998.
PubMed
10) 佐々木石雄, ほか : 進行性核上性麻痺における自律神経機能の検討-パーキンソン病および健常対照との比較. 臨床神経学 34 : 975-979, 1994.
 
11) Wang SJ, et al : Sympathetic skin response and R-R interval variation in Parkinson's disease. Mov Disord 8 : 151-157, 1993.
 
12) Kikkawa Y, et al : Cutaneous sympathetic function and cardiovascular function in patients with progressive supranuclear palsy and Parkinson's disease. Parkinsonism Relat Disord 10 : 101-106, 2003.
PubMed
13) Haapaniemi TH, et al : Suppressed sympathetic skin response in Parkinson disease. Clin Auton Res 10 : 337-342, 2000.
PubMed
14) Fusina S, et al : Sympathetic skin response asymmetry in early stage idiopathic Parkinson's disease. Clin Neurophysiol 110 : 358-366, 1999.
PubMed
15) Braune HJ, et al : Autonomic dysfunction in Parkinson's disease assessed by sympathetic skin response : a prospective clinical and neurophysiological trial on 50 patients. Acta Neurol Scand 95 : 293-297, 1997.
PubMed
16) Bordet R, et al : Sympathetic skin response and R-R interval variability in multiple system atrophy and idiopathic Parkinson's disease. Mov Disord 11 : 268-272, 1996.
 
17) Denislic M, Meh D : Sympathetic skin response in parkinsonian patients. Electromyogr Clin Neurophysiol 36 : 231-235, 1996.
PubMed
18) Hirashima F, et al : Sympathetic skin response in Parkinson's disease. Acta Neurol Scand 93 : 127-132, 1996.
PubMed
19) Jost WH, et al : [Sympathetic skin response in Parkinson syndrome]. Nervenarzt 66 : 777-780, 1995.
PubMed
20) Mano Y, et al : Sweat function in Parkinson's disease. J Neurol 241 : 573-576, 1994.
PubMed
21) Asahina M, et al : Sudomotor and cardiovascular dysfunction in patients with early untreated Parkinson's disease. J Parkinsons Dis 4 : 385-393, 2014.
PubMed
22) 吉岡雅之, ほか : パーキンソン病の重症度と発汗機能障害-エバポリメーターをもちいた検討. 臨床神経学 43 : 379-384, 2003.
 
23) Turkka JT, Myllyla VV : Sweating dysfunction in Parkinson's disease. Eur Neurol 26 : 1-7, 1987.
PubMed
24) Kihara M, et al : Assessment of sudomotor dysfunction in early Parkinson's disease. Eur Neurol 33 : 363-365, 1993.
PubMed
25) Sandroni P, et al : Autonomic involvement in extrapyramidal and cerebellar disorders, Clin Auton Res 1 : 147-155, 1991.
PubMed
26) 斎藤博, 小暮久也 : パーキンソン病における温熱発汗機能異常. 臨床神経学 29 : 734-740, 1989.
 
27) Lipp A, et al : Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol 66 : 742-750, 2009.
PubMed
28) Raudino F : Non motor off in Parkinson's disease. Acta Neurol Scand 104 : 312-315, 2001.
PubMed
29) 吉岡雅之, ほか : パーキンソン病の発汗機能障害と心臓交感神経機能障害の関連性について. 自律神経 41 : 61-67, 2004.
Medical*Online
30) Fischer M, et al : Skin function and skin disorders in Parkinson's disease. J Neural Transm (Vienna) 108 : 205-213, 2001.
PubMed
31) 藤田義行, ほか : パーキンソン病における温熱性発汗とMIBG心筋シンチグラフィーの障害進展の比較. 自律神経 46 : 241-247, 2009.
Medical*Online
32) 湊智美, ほか : パーキンソン病患者と家族の症状認識についての検討. 第9回パーキンソン病・運動障害疾患コングレスプログラム・抄録集, p105, 2015.
 
33) Goetz CG, et al : Autonomic dysfunction in Parkinson's disease. Neurology 36 : 73-75, 1986.
PubMed
34) Pursiainen V, et al : Sweating in Parkinsonian patients with wearing-off. Mov Disord 22 : 828-832, 2007.
PubMed
35) Sage JI, Mark MH : Drenching sweats as an off phenomenon in Parkinson's disease : treatment and relation to plasma levodopa profile. Ann Neurol 37 : 120-122, 1995.
PubMed
36) Witjas T, et al : Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 22 : 1729-1734, 2007.
PubMed
37) Appenzeller O, Goss JE : Autonomic deficits in Parkinson's syndrome. Arch Neurol 24 : 50-57, 1971.
PubMed
38) Wang N, et al : α-Synuclein in cutaneous autonomic nerves. Neurology 81 : 1604-1610, 2013.
 
P.288 掲載の参考文献
1) 米国睡眠学会 : AASMによる睡眠および随伴イベントの判定マニュアル-ルール, 用語, 技術仕様の詳細 VERSION 2.3. 日本睡眠学会 (翻訳), ライフサイエンス, 2017.
 
2) 日本睡眠学会 (編) : 改訂版臨床睡眠検査マニュアル, ライフサイエンス, 2015.
 
3) Carskadon MC, Dement WC : Normal Human Sleep. In : Principles and Practice of Sleep Medicine, 6th ed (ed by Kryger MH, et al), 15-24, Elsevier Philadelphia, 2017.
 
4) Ohayon MM, et al : Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals : developing normative sleep values across the human lifespan. Sleep 27 : 1255-1273, 2004.
PubMed
5) Ancoli-lsrael S, Shochat T : Insomnia in Older Adults. In : Principles and Practice of Sleep Medicine, 5th ed (ed by Kryger M, et al), p1544-1550, Philadelphia : Saunders, 2010.
 
6) Hori T, et al : Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard. Psychiatry Clin Neurosci 55 : 305-310, 2001.
PubMed
7) Littner MR, et al : Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 28 : 113-121, 2005.
PubMed
8) Thorpy MJ : The clinical use of the Multiple Sleep Latency Test. The Standards of Practice Committee of the American Sleep Disorders Association. Sleep 15 : 268-276, 1992.
PubMed
9) Doghramji K, et al : A normative study of the maintenance of wakefulness test (MWT). Electroencephalogr Clin Neurophysiol 103 : 554-562, 1997.
PubMed
10) Frauscher B, et al : Quantification of electromyographic activity during REM sleep in multiple muscles in REM sleep behavior disorder. Sleep 31 : 724-731, 2008.
PubMed
11) Postuma RB, et al : Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology 74 : 239-244, 2010.
PubMed
12) Shen Y, et al : Two polysomnographic features of REM sleep behavior disorder : Clinical variations insight for Parkinson's disease. Parkinsonism Relat Disord 44 : 66-72, 2017.
PubMed
13) Allen RP, et al : Restless legs syndrome/Willis-Ekbom disease diagnostic criteria : updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria-history, rationale, description, and significance. Sleep Med 15 : 860-873, 2014.
 
14) 鈴木圭輔, ほか : レストレスレッグス症候群・周期性四肢運動障害. 臨牀 と研究 92 : 1145-1151, 2015.
Medical*Online
15) American Academy of Sleep Medicine : Shift Work Disorder. In : International Classification of Sleep Disorders, 3rd ed, p215-219, American Academy of Sleep Medicine, Darien, 2014.
 
16) De Cock VC, et al : Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson's disease. Mov Disord 27 : 743-749, 2012.
PubMed
17) De Cock VC : Objective Measures of the Sleep-Wake Cycle in Parkinson's Disease. In : Disorders of Sleep and Circadian Rhythms in Parkinson's Disease (ed by Videnovic A, Hogl B), p51-60, Springer, Wien, 2015.
 
18) Klingelhoefer L, et al : Night-time sleep in Parkinson's disease-the potential use of Parkinson's KinetiGraph : a prospective comparative study. Eur J Neurol 23 : 1275-1288, 2016.
PubMed
19) Sringean J, et al : Time for a strategy in night-time dopaminergic therapy? An objective sensorbased analysis of nocturnal hypokinesia and sleeping Positions in Parkinson's disease. J Neurol Sci 373 : 244-248, 2017.
PubMed
P.295 掲載の参考文献
1) Hely MA, et al : The Sydney multicenter study of Parkinson's disease : the inevitability of dementia at 20 years. Mov Disord 23 : 837-844, 2008.
PubMed
2) Kempster PA, et al : Relationships between age and late progression of Parkinson's disease : a clinicopathological study. Brain 133 : 1755-1762, 2010.
PubMed
3) Svenningsson P, et al : Cognitive impairment in patients with Parkinson's disease : diagnosis, biomarkers, and treatment. Lancet Neurol 11 : 697-707, 2012.
PubMed
4) Emre M, et al : Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22 : 1689-1707 ; quiz 1837, 2007.
 
5) Litvan I, et al : Diagnostic criteria for mild cognitive impairment in Parkinson's disease : Movement Disorder Society Task Force guidelines. Mov Disord 27 : 349-356, 2012.
PubMed
6) Skorvanek M, et al : Global scales for cognitive screening in Parkinson's disease : Critique and recommendations. Mov Disord 33 : 208-218, 2018.
PubMed
7) Fujiwara Y, et al : Brief screening tool for mild cognitive impairment in older Japanese : validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int 10 : 225-232, 2010.
PubMed
8) Dubois B, et al : Diagnostic procedures for Parkinson's disease dementia : recomrnendations from the movement disorder society task force. Mov Disord 22 : 2314-2324, 2007.
PubMed
9) Abe Y, et al : Occipital hypoperfusion in Parkinson's disease without dementia : correlation to impaired cortical visual processing. J Neurol Neurosurg Psychiatry 74 : 419-422, 2003.
PubMed
10) Hosokai Y, et al : Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 24 : 854-862, 2009.
PubMed
11) McKeith IG, et al : Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 89 : 88-100, 2017.
PubMed
P.299 掲載の参考文献
1) Zucca FA, et al : Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog Neurobiol 155 : 96-119, 2017.
PubMed
2) Castellanos G, et al : Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. Mov Disord 30 : 945-952, 2015.
PubMed
3) Mahlknecht P, et al : Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. Mov Disord 32 : 619-623, 2017.
PubMed
4) Sung YH, et al : Differential involvement of nigral subregions in idiopathic parkinson's disease. Hum Brain Mapp 39 : 542-553, 2018.
PubMed
5) Ceravolo R, et al : Nigral anatomy and striatal denervation in genetic Parkinsonism : A family report. Mov Disord 30 : 1148-1149, 2015.
PubMed
6) Langley J, et al : Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited. Hum Brain Mapp 37 : 2547-2556, 2016.
PubMed
7) Akram H, et al : l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease. Mov Disord 32 : 874-883, 2017.
PubMed
8) Ten Harmsen BL, et al : Clinical correlates of cerebral white matter abnormalities in patients with Parkinson's disease. Parkinsonism Relat Disord 49 : 28-33, 2018.
PubMed
9) Meijer FJ, et al : Susceptibility-weighted imaging improves the diagnostic accuracy of 3T brain MRI in the work-up of parkinsonism. AJNR Am J Neuroradiol 36 : 454-460, 2015.
PubMed
10) Baj aj S, et al : Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy : A systematic review and meta-analysis. PLoS ONE 12 : e0189897, 2017.
 
11) Focke NK, et al : Differentiation of typical and atypical Parkinson syndromes by quantitative MR imaging. AJNR Am J Neuroradiol 32 : 2087-2092, 2011.
PubMed
12) Yu F, et al : Patterns of gray matter atrophy in atypical parkinsonism syndromes : a VBM meta-analysis. Brain Behav 5 : e0O329, 2015.
PubMed
13) Zanigni S, et al : Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease. Neuroimage Clin 11 : 736-742, 2016.
PubMed
14) Lee SH, et al : Brain regional iron contents in progressive supranuclear palsy. Parkinsonism Relat Disord 45 : 28-32, 2017.
PubMed
15) Sjostrom H, et al : Quantitative susceptibility mapping differentiates between parkinsonian disorders. Parkinsonism Relat Disord 44 : 51-57, 2017.
PubMed
16) Piattella MC, et al : Neuroimaging evidence of gray and white matter damage and clinical correlates in progressive supranuclear palsy. J Neurol 262 : 1850-1858, 2015.
PubMed
P.305 掲載の参考文献
1) Hakusui S, et al : A radiological analysis of heart sympathetic functions with meta- [123I] iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 49 : 81-84, 1994.
PubMed
2) Orimo S, et al : Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 109 : 583-588, 2005.
PubMed
3) Orimo S, et al : Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 17 : 24-30, 2007.
PubMed
4) Orimo S, et al : Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131 : 642-650, 2008.
PubMed
5) Postuma RB, et al : MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30 : 1591-1601, 2015,
PubMed
6) Nakajima K, et al : Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol 21 : 970-978, 2014.
PubMed
7) Nakajima K, : Normal values for nuclear cardlology : Japanese databases for myocardial perfusion, fatty acid and sympathetic imaging and left ventricular function. Ann Nucl Med 24 : 125-135, 2010.
PubMed
8) Manabe Y, et al : Systemic blood pressure profile correlates with cardiac 123I-MIBG uptake in patients with Parkinson's disease. J Neurol Sci 307 : 153-156, 2011.
PubMed
9) 織茂智之 : MIBG心筋シンチグラフィーとその異常. Clinical Neuroscience 35 : 621-623, 2017.
 
10) Frohlich I, et al : Myocardial MIBG scintigraphy : a useful clinical tool? : A retrospective study in 50 parkinsonian patients. Neurol Sci 31 : 403-406, 2010.
 
11) 織茂智之 : MIBG心筋シンチグラフィー. 内科 99 : 836-839, 2007.
 
12) Nagayama H, et al : Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 76 : 249-251, 2005.
PubMed
13) Treglia G, et al : MIBG scintigraphy in differential diagnosis of Parkinsonism : ameta-analysis. Clin Auton Res 22 : 43-55, 2012.
 
14) Yoshita M, et al : Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies : a multicenter study. PLoS ONE 10 : e0120540, 2015.
PubMed
15) Nagayama H, et al : Abnormal cardiac [ (123) I] -meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord 25 : 1744-1747, 2010.
PubMed
16) Nagayama H, et al : Low myocardial MIBG uptake in multiple system atrophy with incidental Lewy body pathology : an autopsy case report. Mov Disord 23 : 1055-1057, 2008.
PubMed
17) Berardelli A, et al : EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol 20 : 16-34, 2013.
PubMed
P.312 掲載の参考文献
1) Otsuka M, et al : Striatal blood flow, glucose metabolism and 18F-dopa uptake : difference in Parkinson's disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry 54 : 898-904, 1991.
PubMed
2) Eberling JL, et al : Cortical glucose metabolism in Parkinson's disease without dementia. Neurobiol Aging 15 : 329-335, 1994.
PubMed
3) 菊池昭夫, 武田篤 : 多系統萎縮症update多系統萎縮症のPET研究. 神経内科 73 : 346-350, 2010.
 
4) Kwon KY, et al : Comparison of brain MRI and 18F-FDG PET in the differential diagnog. is. of multiple system atrophy from Parkinson's disease. Mov Disord 22 : 2352-2358, 2007.
PubMed
5) Tang CC, et al : Differential diagnosis of parkinsonism : a metabolic imaging study using pattern analysis. Lancet Neurol 9 : 149-158, 2010.
PubMed
6) Nurmi E, et al : Rate of progression in Parkinson's disease : a 6- [18F] fluoro-L-dopa PET study. Mov Disord 16 : 608-615, 2001.
PubMed
7) Brooks DJ, et al : The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 113 (Pt 5) : 1539-1552, 1990.
 
8) Asari S, et al : Subregional 6- [18F] fluoro-L-m-tyrosine uptake in the striatum in Parkinson's disease. BMC Neurol 11 : 35, 2011.
 
9) Eberling JL, et al : Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70 : 1980-1983, 2008.
PubMed
10) Huang CY, et al : Chronic manganism : A long-term follow-up study with a new dopamine terminal biomarker of 18F-FP- (+) -DTBZ (18F-AV-133) brain PET scan. J Neurol Sci 353 : 102-106. 2015.
PubMed
11) Shinotoh H, et al : Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration : a positron emission tomography study. J Neurol Neurosurg Psychiatry 56 : 467-472, 1993.
PubMed
12) Cropley VL, et al : Pre-and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease : PET studies with [11C] NNC 112 and [18F] FDOPA. Psychiatry Res 163 : 171-182, 2008.
PubMed
13) Brooks DJ, et al : Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 31 : 184-192, 1992.
PubMed
14) Rinne JO, et al : PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord 8 : 134-138, 1993.
 
15) Antonini A, et al : Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 120 (Pt 12) : 2187-2195, 1997.
 
16) Mishina M, et al : Adenosine A (2A) receptors measured with [C] TMSX PET in the striata of Parkinson's disease patients. PLoS ONE 6 : e17338. 2011.
 
17) Ramlackhansingh AE et al : Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 76 : 1811-1816, 2011.
PubMed
18) 篠遠仁 : コリン神経伝達機能イメージング. Geriatric Medicine 44 : 1161-1171, 2006.
Medical*Online
19) 篠遠仁 : コリン神経系からみたアルツハイマー型痴・呆の画像診断. 老年精神医学雑誌 13 (増刊) : 11-18, 2002.
Medical*Online
20) Shinotoh H, et al : Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 46 : 62-69, 1999.
PubMed
21) Gilman S. et al : Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 74 : 1416-1423, 2010.
PubMed
22) Ouchi Y, et al : Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57 : 168-175, 2005.
PubMed
23) Gerhard A, et al : In vivo imaging of microglial activation with [11C] (R) -PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21 : 404-412, 2006.
PubMed
24) Edison P, et al : Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology 38 : 938-949, 2013.
PubMed
25) Iannaccone S, et al : In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat Disord 19 : 47-52, 2013.
 
26) Gerhard A, et al : [11C] (R) -PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 61 : 686-689, 2003.
PubMed
27) Gerhard A, et al : In vivo imaging of microglial activation with [11C] (R) -PK11195 PET in progressive supranuclear palsy. Mov Disord 21 : 89-93, 2006.
PubMed
28) Politis M, et al : Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol 3 : 96, 2012.
PubMed
29) Fan Z, et al : Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. Alzheimers Dement 11 : 608-621. e7, 2015.
 
30) Terada T, et al : Extrastriatal spreading of microglial activation in Parkinson's disease : a positron emission tomography study. Ann Nucl Med 30 : 579-587, 2016.
PubMed
31) Lorberboym M, et al : 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 45 : 1688-1693, 2004.
PubMed
32) O'Brien JT, et al : Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61 : 919-925, 2004.
PubMed
33) Benamer HT, et al : Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 15 : 692-698, 2000.
PubMed
34) Lavalaye J, et al : Effect of age and gender on dopamine transporter imaging with [123I] FP-CIT SPET in healthy volunteers. Eur J Nucl Med 27 : 867-869, 2000.
PubMed
35) Pirker W, et al : Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism : a longitudinal beta-CIT SPECT study. Mov Disord 17 : 45-53, 2002.
PubMed
36) Kagi G, et al : The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 81 : 5-12, 2010.
PubMed
37) Marek K, et al : [123I] beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57 : 2089-2094, 2001.
PubMed
38) Colloby SJ, et al : Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. Brain 135 : 2798-2808, 2012.
PubMed
39) Saari L et al : Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology 88 : 1461-1467, 2017.
 
40) Fearnley JM, Lees AJ : Ageing and Parkinson's disease : substantia nigra regional selectivity. Brain 114 : 2283-2301, 1991.
PubMed
41) Schwingenschuh P, et al : Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease : a clinical and electrophysiological study. Mov Disord 25 : 560-569, 2010.
PubMed
42) Batla A, et al : Patients with scans without evidence of dopaminergic deficit : a long-term follow-up study. Mov Disord 29 : 1820-1825, 2014.
PubMed
43) Marek K, et al : Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 82 : 1791-1797, 2014.
PubMed
44) Kikuchi A, et al : Hypoperfusion in the supplementary motor area, dorsolateral prefrontal cortex and insular cortex in Parkinson's disease. J Neurol Sci 193 : 29-36, 2001.
PubMed
45) Kim YJ, et al : Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 17 : 303-312, 2002.
PubMed
46) Ichise M. et al : SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopauntreated PD. Neurology 52 : 1206-1214, 1999.
 
47) 川端啓太, ほか : 123I-iomazenilを用いたParkinson病. 大脳皮質における中枢性ベンゾジアゼピン受容体の評価. 核医学 33 : 391-397, 1996.
Medical*Online
48) 川端啓太, 立花久大 : 123I-iomazenil (123I-IMZ) SPECTを用いるParkinson病大脳皮質Benzodiazepine受容体の評価. 日本臨牀 55 : 244-248, 1997.
Medical*Online
49) Kuhl DE, et al : In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 40 : 399-410, 1996.
PubMed
50) Beucke JC, et al : Midbrain serotonin transporters in de novo and L-DOPA-treated patients with early Parkinson's disease-a [123I] -ADAM SPECT study. Eur J Neurol 18 : 750-755, 2011.
 
P.319 掲載の参考文献
1) Hayashi T, Onoe H : Neuroimaging for optimization of stem cell therapy in Parkinson's disease. Expert Opin Biol Ther 13 : 1631-1638, 2013.
PubMed
2) Hayashi T, et al : Autologous mesenchymal stem cell-derived dopaminergic neurons function in parkinsonian macaques. J Clin Invest 123 : 272-284, 2013.
PubMed
3) Kikuchi T, et al : Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. Nature 548 : 592-596, 2017.
 
4) Morizane A, et al : MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat Commun 8 : 385, 2017.
PubMed
5) Hilker R, et al : Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans, Mov Disord 18 : 41-48, 2003.
 
6) Fukutomi H, et al : Neurite imaging reveals microstructural variations in human cerebral cortical gray matter. Neuroimage, 2018. [Epub ahead of print]
 
7) Greve DN, et al : Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage 92 : 225-236, 2014.
PubMed
8) Werner P, et al : Current status and future role of brain PET/MRI in clinical and research settings. Eur J Nucl Med Mol Imaging 42 : 512-526, 2015.
PubMed
9) Visser E, et al : Automated segmentation of the substantia nigra, subthalamic nucleus and red nucleus in 7T data at young and old age. Neuroimage 139 : 324-336, 2016.
 
10) Ohtsuka C, et al : Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord 20 : 755-760, 2014.
PubMed
11) Glasser MF, et al : The Human Connectome Project's neuroimaging approach. Nat Neurosci 19 : 1175-1187, 2016.
 
12) Glasser MF, et al : A multi-modal parcellation of human cerebral cortex. Nature 536 : 171-178, 2016.
PubMed
13) 林拓也 : 動物MRI解析-次世代イメージング技術の開発-. Annual Review神経 2018 (鈴木則宏, ほか編), p53-60, 中外医学社t 2018.
 
14) Donahue CJ, et al : Using Diffusion Tractography to Predict Cortical Connection Strength and Distance : A Quantitative Comparison with Tracers in the Monkey. J Neurosci 36 : 6758-6770, 2016.
PubMed
15) Yahata N, et al : A small number of abnormal brain connections predicts adult autism spectrum disorder. Nat Commun 7 : 11254, 2016.
PubMed
P.324 掲載の参考文献
1) Beach TG, et al : Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119 : 689-702, 2010.
PubMed
2) Ikemura M, et al : Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67 : 945-953, 2008,
PubMed
3) Ito S, et al : Alpha-synuclein immunohistochemistry of gastrointestinal and biliary surgical specimens for diagnosis of Lewy body disease. Int J Clin Exp Pathol 7 : 1714-1723, 2014.
PubMed
4) Qualman SJ, et al : Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology 87 : 848-856, 1984.
PubMed
5) Lebouvier T, et al : Pathological lesions in colonic biopsies during Parkinson's disease. Gut 57 : 1741-1743, 2008.
PubMed
6) Wakabayashi K, et al : Parkinson's disease : the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 76 : 217-221, 1988.
 
7) Schneider SA, et al : Can we use peripheral tissue biopsies to diagnose Parkinson's disease? A review of the literature. Eur J Neしirol 23 : 247-261, 2016.
 
8) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197-211, 2003.
PubMed
9) Stokholm MG, et al : Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol 79 : 940-949, 2016.
 
10) Donadio V, et al : Skin nerve α-synuclein deposits : a biomarker for idiopathic Parkinson disease. Neurology 82 : 1362-1369, 2014.
 
11) Miki Y, et al : Clinical availability of skin biopsy in the diagnosis of Parkinson's disease. Neurosci Lett 469 : 357-359, 2010.
PubMed
12) Doppler K, et al : Cutaneous neuropathy in Parkinson's disease : a window into brain pathology. Acta Neuropathol 128 : 99-109, 2014.
PubMed
13) Gibbons CH, et al : The diagnostic discrimination of cutaneous α-synuclein deposition in Parkinson disease. Neurology 87 : 505-512, 2016.
 
14) Ceravolo R, et al : Neuropathy and levodopa in Parkinson's disease : evldence from a multicenter study. Mov Disord 28 : 1391-1397, 2013.
PubMed
15) Sanchez-Ferro A, et al : In vivo gastric detection of α-synuclein inclusions in Parkinson's disease. Mov Disord 30 : 517-524, 2015.
 
P.329 掲載の参考文献
1) Postuma RB, et al : MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30 : 1591-1601, 2015.
PubMed
2) Postuma RB, Berg D : Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12 : 622-634, 2016.
PubMed
3) Tokuda T, et al : Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75 : 1766-1772, 2010.
 
4) Hong Z, et al : DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133 : 713-726, 2010.
PubMed
5) Mogi M, et al : Interleukin (IL) -1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 211 : 13-16, 1996.
PubMed
6) Shi M, et al : Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69 : 570-580, 2011.
PubMed
7) Havelund JF, et al : Biomarker Research in Parkinson's Disease Using Metabolite Profiling. Metabolites 7 : 2017. (pii : E42. doi : 10.3390/metabo7030042)
 
8) Malek N, et al : Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease-a systematic review. Acta Neurol Scand 130 : 59-72, 2014.
PubMed
9) Maita C, et al : Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett 431 : 86-89, 2008.
PubMed
10) Yamagishi Y, et al : Diagnosis of Parkinson's disease and the level of oxidized DJ-1 protein. Neurosci Res 128 : 58-62, 2018.
PubMed
11) Chen H. et al : Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 167 : 90-95, 2008.
PubMed
12) Rocha NP, et al : Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. Mov Disord 29 : 527-531, 2014.
PubMed
13) Chahine LM. et al : Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol 70 : 852-858, 2013.
PubMed
14) Cipriani S, et al : Urate : a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med 4 : 701-712, 2010.
PubMed
15) Fujimaki M, et al : Serum caffeine and metabolites are reliable biomarkers of early Parkinson's disease. Neurology 90 : e404-e411, 2018.
PubMed
16) Fernandez-Santiago R, et al : MicroRNA association with synucleinopathy conversion in rapid eye movement behavior disorder. Ann Neurol 77 : 895-901, 2015.
PubMed
P.336 掲載の参考文献
1) Steele JC, et al : Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10 : 333-359, 1964.
PubMed
2) Williams DR, et al : Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy : Richardson's syndrome and PSP-parkinsonism. Brain 128 : 1247-1258, 2005.
PubMed
3) Kanazawa M, et al : Cerebellar involvement in progressive supranuclear palsy : A clinicopathological study. Mov Disord 24 : 1312-1318, 2009.
PubMed
4) Takigawa H, et al : Prevalence of progressive supranuclear palsy in Yonago : change throughout a decade. Brain Behav 6 : e00557, 2016.
PubMed
5) Litvan I, et al : Environmental and occupational risk factors for progressive supranuclear palsy : Case-control study. Mov Disord 31 : 644-652, 2016.
PubMed
6) Litvan I, et al : Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : report of the NINDS-SPSP international workshop. Neurology 47 : 1-9, 1996.
PubMed
7) Respondek G, et al : The phenotypic spectrum of progressive supranuclear palsy : a retrospective multicenter study of 100 definite cases. Mov Disord 29 : 1758-1766, 2014.
PubMed
8) Yoshida M : Astrocytic inciusiong. in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 34 : 555-570, 2014.
PubMed
9) Williams DR, Lees AJ : Progressive supranuclear palsy : clinicopathological concepts and diagnostic challenges. Lancet Neurol 8 : 270-279, 2009.
PubMed
10) Owens E, et al : The clinical spectrum and natural history of pure akinesia with gait freezing. J Neurol 263 : 2419-2423, 2016.
PubMed
11) Boxer AL, et al : Advances in progressive supranuclear palsy : new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16 : 552-563, 2017.
PubMed
12) Hoglinger GU, et al : Clinical diagnosis of progressive supranuclear palsy : The movement disorder society criteria. Mov Disord 32 : 853-864, 2017.
PubMed
13) Whitwell JL, et al : Radiological biomarkers for diagnosis in PSP : Where are we and where do we need to be? Mov Disord 32 : 955-971, 2017.
PubMed
14) Quattrone A, et al : MR parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP-parkinsonism. Neurology 87 : 1266-1273, 2016.
PubMed
15) Schonhaut DR, et al : 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease : A multicenter study. Ann Neurol 82 : 622-634, 2017.
PubMed
16) 饗場郁子 : 進行性核上性麻痺と大脳皮質基底核症候群. 内科 118 : 223-228, 2016.
 
P.343 掲載の参考文献
1) Gibb WR, et al : Corticobasal degeneration. Brain 112 (Pt 5) : 1171-1192, 1989.
 
2) Constantinidis J, et al : Pick's disease. Histological and clinical correlations. Eur Neurol 11 : 208-217, 1974.
PubMed
3) Mesulam MM : Primary progressive aphasia. Ann Neurol 49 : 425-432, 2001.
PubMed
4) Kikuchi A, et al : In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology 87 : 2309-2316, 2016.
PubMed
P.349 掲載の参考文献
1) Graham JG, OPPenheimer DR : Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 32 : 28-34, 1969.
 
2) Quinn N : Multiple system atrophy-the nature of the beast. J Neurol Neurosurg Psychiatry. (Suppl) : 78-89, 1989.
PubMed
3) Papp MI, et al : Glial Cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neuro Sci 94 (1-3) : 79-100, 1989.
 
4) Gilman S, et al : Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71 : 670-676, 2008.
PubMed
5) Watanabe H, et al : Progression and prognosis in multiple system atrophy : an analysis of 230 Japanese patients. Brain 125 : 1070-1083, 2002.
PubMed
6) Wenning GK, et al : The natural history of multiple system atrophy : a prospective European cohort study. Lancet Neurol 12 : 264-274, 2013.
PubMed
7) Jellinger KA : Neuropathology of multiple system atrophy : new thoughts about pathogenesis. Mov Disord 29 : 1720-1741, 2014.
PubMed
8) Palma JA, et al : Diagnosis of multiple system atrophy. Auton Neurosci 211 : 15-25, 2018.
PubMed
9) Brooks DJ, et al : Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 24 : 949-964, 2009.
PubMed
10) Orimo S, et al : 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism : a systematic review and meta-analysis. Parkinsonism Relat Disord 18 : 494-500, 2012.
PubMed
11) Laurens B, et al : Fluid biomarkers in multiple system atrophy : A review of the MSA Biomarker Initiative. Neurobiol Dis 80 : 29-41, 2015.
PubMed
12) Zange L et al : Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Brain 138 : 2310-2321, 2015.
 
13) Lopez-Cuina M, et al : Present and future of disease-modifying therapies in multiple system atrophy. Auton Neurosci 211 : 31-38, 2018.
PubMed
14) Multiple-System Atrophy Research Collaboration : Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 369 : 233-244, 2013.
PubMed
P.354 掲載の参考文献
1) 服部信孝 : PDDとDLB. クリニシアン 638 : 418-422, 2015.
 
2) Kosaka K, et al : Diffuse type of Lewy body disease : progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree-a new disease? Clin Neuropathol 3 : 185-192, 1984.
PubMed
3) McKeith IG, et al : Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 89 : 88-100, 2017.
PubMed
4) 太田晃一 : PDの認知機能障害 レビー小体型認知症との鑑別は可能か. 認知症の最新医療 8 : 2-6, 2018.
 
5) Dubois B, et al : Diagnostic procedures for Parkinson's disease dementia : recommendations from the movement disorder society task force. Mov Disord 22 : 2314-2324, 2007.
PubMed
6) Emre M, et al : Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22 : 1689-1707 ; quiz 1837, 2007.
 
7) Litvan I, et al : Diagnostic criteria for mild cognitive impairment in Parkinson's disease : Movement Disorder Society Task Force guidelines. Mov Disord 27 : 349-356, 2012.
PubMed
8) Goldman JG, et al : The spectrum of cognitive impairment in Lewy body diseases. Mov Disord 29 : 608-621, 2014.
PubMed
9) Park E, et al : Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [ (18) F] FP-CIT PET/CT. Nucl Med Mol Imaging 48 : 106-113, 2014.
PubMed
10) Yoshita M, et al : Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies : a multicenter study. PLoS ONE 10 : e0120S40, 2015.
PubMed
11) Shimada H, et al : β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord 28 : 169-175, 2013.
 
12) Tokuda T, et al : Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 349 : 162-166, 2006.
PubMed
13) Hong Z, et al : DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133 : 713-726, 2010.
PubMed
14) Noguchi-Shinohara M, et al : CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res 1251 : 1-6, 2009.
 
15) Ono K : The Oligomer Hypothesis in α-Synucleinopathy. Neurochem Res 42 : 3362-3371, 2017.
 
16) Tokuda T, et al : Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75 : 1766-1772, 2010.
 
17) Siderowf A, et al : CSF amyloid β1-42 predicts cognitive decline in Parkinson disease. Neurology 75 : 1055-1061, 2010.
 
18) Yarnall AJ, et al : Characterizing mild cognitive impairment in incident Parkinson disease : the ICICLE-PD study. Neurology 82 : 308-316, 2014.
PubMed
19) Chen-Plotkin AS, et al : Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 69 : 655-663, 2011.
PubMed
P.360 掲載の参考文献
1) Chen KM : The chapter 1,2. In : The Mysterious Diseases of Guam. Micronesian Institute of Health and Aging Studies (ed by Chen KM), p29-57, University of Guam Mangilao, Guam, 2004.
 
2) Hirano A, et al : Parkinsonism-dementia complex, an endemic disease on the island of Guam. II. Pathological features. Brain 84 : 662-679, 1961.
PubMed
3) Kuzuhara S, et al : Familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan : clinical and neuropathological study and tau analysis. Ann Neurol 49 : 501-511, 2001.
PubMed
4) Gajdusek DC, Salazar AM : Amyotrophic lateral sclerosis and parkinsonian syndromes in high incidence among the Auyu and Jakai people of West New Guinea. Neurology 32 : 107-126, 1982.
PubMed
5) Okumiya K, et al : Amyotrophic lateral sclerosis and parkinsonism in Papua, Indonesia : 2001-2012 survey results. BMJ Open 4 : e004353, 2014.
PubMed
6) Kimura K, et al : Epidemiological and geomedical studies on ALS and allied diseases in Kii peninsula (Japan) : preliminary report. Proc Jpn Acad. 37 : 417-420, 1961.
 
7) Kuzuhara S, Kokubo Y : Amyotrophic lateral sclerosis-parkinsonism-dementia complex in the Kii peninsula of Japan (Muro disease) : a review on recent research and new concept. In : Amyotrophic Lateral Sclerosis and the Frontotemporal Dementias, 1st ed (ed by Strong MJ), p39-54, Oxford University Press, Oxford, 2012.
 
8) 小久保康昌, 葛原茂樹 : 紀伊半島多発地域の筋萎縮性側索硬化症とパーキンソン認知症複合の臨床神経学的および神経病理学的検討. 臨床神経 41 : 769-774, 2001.
 
9) Kokubo Y, Kuzuhara S : Neuroradiological study of patients with amyotrophic lateral sclerosis and parkinsonism-dementia complex on the Kii peninsula of Japan. Arch Neurol 60 : 1257-1261, 2003.
PubMed
10) Mimuro M, et al : Amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Hohara focus of the Kii Peninsula : A multiple proteinopathy? Neuropathology 38 : 98-107, 2018.
PubMed
11) Tomiyama H, et al : Mutation analyses in amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula, Japan. Mov Disord 23 : 2344-2348, 2008.
PubMed
12) 八瀬善郎 : 紀伊半島の筋萎縮性側索硬化症, 神経内科 2 : 17-24 : 1975.
 
13) Kihira T, et al : Lifestyle Changes and Oxidative Stress in a High-incidence Area of Amyotrophic Lateral Sclerosis in the Southwestern Kii Peninsula, Japan. Intern Med 56 : 1497-1506, 2017.
 
14) Kokubo Y, et al : β-N-methylamino-l-alanine analysis in the brains of patients with Kii ALS/PDC. Neurology 89 : 1091-1092, 2017.
 
15) Morimoto S, et al : Increased oxidative stress in patients with amyotrophic lateral sclerosis/parkinsonism-dementia complex in the Kii peninsula, Japan. Mov Disord 24 : 123-126, 2009.
PubMed
P.365 掲載の参考文献
1) Bradbury S, Eggleston C : Postural hypotension : a report of three cases. Am Heart J 1 : 73-86, 1925.
 
2) Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 46 : 1470, 1996.
PubMed
3) Kaufmann H, et al : Natural history of pure autonomic failure : A United States prospective cohort. Ann Neurol 81 : 287-297, 2017.
PubMed
4) Johnson RH, et al : Autonomic failure with orthostatic hypotension due to intermediolateral column degeneration. A report of two cases with autopsies. Q J Med 35 : 276-292, 1966.
PubMed
5) Isonaka R, et al : Pure autonomic failure without synucleinopathy. Clin Auton Res 27 : 97-101, 2017.
PubMed
6) Coon EA, Low PA : Pure autonomic failure without alpha-synuclein pathology : an evolving understanding of a heterogeneous disease. Clin Auton Res 27 : 67-68, 2017.
PubMed
7) Garland EM, et al : Pure autonomic failure. Handb Clin Neurol 117 : 243-257, 2013.
PubMed
8) Chung EJ, Kim SJ : (123) I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders : A Literature Review. J Mov Disord 8 : 55-66, 2015.
PubMed
9) Baschieri F, et al : Iodine-123-meta-iodobenzylguanidine Myocardial Scintigraphy in Isolated Autonomic Failure : Potential Red Flag for Future Multiple System Atrophy. Front Neurol 8 : 225, 2017.
PubMed
10) Goldstein DS, et al : Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 14 : 600-607, 2008.
PubMed
11) Garland EM, et al : A cross-sectional study contrasting olfactory function in autonomic disorders. Neurology 76 : 456-460, 2011.
PubMed
12) Donadio V, et al : Skin sympathetic fiber α-synuclein deposits : a potential biomarker for pure autonomic failure. Neurology 80 : 725-732, 2013.
 
13) Donadio V, et al : Autonomic innervation in multiple system atrophy and pure autonomic failure. J Neurol Neurosurg Psychiatry 81 : 1327-1335, 2010.
PubMed
14) Mabuchi N, et al : Progression and prognosis in pure autonomic failure (PAF) : comparison with multiple system atrophy. J Neurol Neurosurg Psychiatry 76 : 947-952, 2005.
PubMed
15) Goldstein DS, et al : Survival in synucleinopathies : A prospective cohort study. Neurology 85 : 1554-1561, 2015.
PubMed
P.370 掲載の参考文献
1) Freidman JH, et al : Drug-induced parkinsonism. In : Drug Induced Movement Disorders, 2nd ed (ed by Factor SA, et al), p103-139, Blackwell Futura, Massachusetts, 2005.
 
2) 森田洋 : 薬剤性パーキンソニズム. 日本臨床 67 (増刊 4 : パーキンソン病) : 264-268, 2009.
 
3) Drugs that cause movement disorders : The Canadian Movement Disorder Group. [http://www.cmdg.org/Movement_/drug/Drugsthatcausemovement/drugsthatcausemovement.htm]
 
4) 厚生労働省 : 重篤副作用疾患別対応マニュアル 薬剤性パーキンソニズム, 2006. [http://www.mhlw.go.jp/topics/2006/11/dl/tpll22-1cOl. pdf] (2018年1月閲覧)
 
5) Savica R, et al : Incidence and time trends of drug-induced parkinsonism : A 30-year population-based study. Mov Disord 32 : 227-234, 2017.
PubMed
6) Wilson JA, MacLennan WJ : Review : drug-induced parkinsonism in elderly patients. Age Ageing 18 : 208-210, 1989.
PubMed
7) Brigo F, et al : [123I] FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms : a meta-analysis. Eur J Neurol 21 : 1369-e90, 2014.
PubMed
8) Subramaniam RM. et al : ACR-ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders. Clin Nucl Med 42 : 847-852, 2017.
PubMed
9) Charness ME, et al : Frequent neurologic toxicity associated with amiodarone therapy. Neurology 34 : 669-671, 1984.
PubMed
P.374 掲載の参考文献
1) Critchley M : Arteriosclerotic parkinsonism. Brain 52 : 23-83, 1929,
 
2) Thompson PD, Marsden CD : Gait disorder of subcortical arteriosclerotic encephalopathy : Binswanger's disease. Mov Disord 2 : 1-8, 1987.
PubMed
3) FitzGerald PM, Jankovic J : Lower body parkinsonism : evidence for vascular etiology. Mov Disord 4 : 249-260, 1989.
PubMed
4) Winikates J, Jankovic J : Clinical correlates of vascular parkinsonism. Arch Neurol 56 : 98-102, 1999.
PubMed
5) Gupta D, Kuruvilla A : Vascular parkinsonism : what makes it different? Postgrad Med J 87 : 829-836, 2011.
PubMed
6) Korczyn AD : Vascular parkinsonism-characteristics, pathogenesis and treatment. Nat Rev Neurol 11 : 319-326, 2015.
PubMed
7) Sibon I, et al : Vascular parkinsonism. J Neurol 251 : 513-524, 2004.
PubMed
8) Glass PG, et al : The clinical features of pathologically confirmed vascular parkinsonism. J Neurol Neurosurg Psychiatry 83 : 1027-1029, 2012.
PubMed
9) Espay AJ, et al : Lower-body parkinsonism : reconsidering the threshold for external lumbar drainage. Nat Clin Pract Neurol 4 : 50-55, 2008.
PubMed
10) Yamanouchi H, Nagura H : Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopathologic study. Stroke 28 : 965-969, 1997.
PubMed
11) van der Holst HM, et al : Cerebral small vessel disease and incident parkinsonism : The RUN DMC study. Neurology 85 : 1569-1577, 2015.
PubMed
12) Hatate J, et al : Association between cerebral small vessel diseases and mild parkinsonian signs in the elderly with vascular risk factors. Parkinsonism Relat Disord 26 : 29-34, 2016.
PubMed
13) Deverdun J, et al : Diffusion tensor imaging differentiates vascular parkinsonism from parkinsonian syndromes of degenerative origin in elderly subjects. Eur J Radiol 83 : 2074-2079, 2014.
PubMed
14) Benitez-Rivero S, et al : Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease. J Neurol Neurosurg Psychiatry 84 : 122-129, 2013.
PubMed
15) Miguel-Puga A, et al : Therapeutic Interventions for Vascular Parkinsonism : A Systematic Review and Meta-analysis. Front Neurol 8 : 481, 2017.
PubMed
16) Zijlmans JC, et al : The L-dopa response in vascular parkinsonism. J Neurol Neurosurg Psychiatry 75 : 545-547, 2004.
 
P.380 掲載の参考文献
1) 井上尚英ほか : メチルアルコールによるパーキンソニズム. 日本災害医学会会誌 41 : 315-322, 1993.
 
2) Tanner CM, et al : Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 119 : 866-872, 2011.
PubMed
3) Inoue N : Occupational neurotoxicology due to heavy metals-especially manganese poisoning. Brain Nerve 59 : 581-589, 2007.
PubMed
4) Wilbur FP : Manganese poisoning. J Med Soc N J 29 : 48-50, 1932.
 
5) Mena I, et al : Chronic manganese poisoning. Clinical picture Ind manganese turnover. Neurology 17 : 128-136, 1967.
 
6) Rodier J : Manganese poisoning in Moroccan miners. Br J Ind Med 12 : 21-35, 1955.
PubMed
7) Guilarte TR : Manganese neurotoxicity : new perspectives from behavioral, neuroimaging, and neuropathological studies in humans and non-human primates. Front Aging Neurosci 5 : 23, 2013.
PubMed
8) 厚生労働省労働基準局労災補償部補償課 : マンガン又はその化合物 (合金を含む) による疾病の認定基準. [URL : http://www.joshrc.org/~open/kijun/std04-1-2. htm] (2018年5月閲覧)
 
9) Olanow CW : Manganese-induced parkinsonism and Parkinson's disease. Ann N Y Acad Sci 1012 : 209-223, 2004.
PubMed
10) Kato M : Carbon monoxide poisoning : clinical features of the victims of the explosion accident of Mitsui-Miike Mikawa coal mine 50 years ago. Brain Nerve 67 : 19-29, 2015.
 
11) 奥田志保, ほか : 遅発性低酸素白質脳症の2症例. 臨床神経学 52 : 672-676, 2012.
 
12) 志田堅四郎 : 急性一酸化炭素中毒症「間歇型」の病因論とその治療. 災害医学 18 : 391-396, 1975.
 
13) Kinoshita T, et al : Pallidoreticular damage in acute carbon monoxide poisoning : diffusion-weighted MR imaging findings. AJNR Am J Neuroradiol 26 : 1845-1848, 2005.
PubMed
14) Kamada K, et al : Cerebral metabolic changes in delayed carbon monoxide sequelae studied by proton MR spectroscopy. Neuroradiology 36 : 104-106, 1994.
PubMed
15) Wolf SJ, et al : Clinical policy : Critical issues in the management of adult patients presenting to the emergency department with acute carbon monoxide poisoning. Ann Emerg Med 51 : 138-152, 2008.
 
P.387 掲載の参考文献
1) Song CY, et al : Pseudohypoparathyroidism with basal ganglia calcification : A case report of rare cause of reversible parkinsonism. Medicine (Baltimore) 96 : e6312, 2017.
PubMed
2) 日本小児栄養消化器肝臓学会, ほか (編) : Wilson病診療ガイドライン 2015, 2015.
 
3) Czlonkowska A, et al : Wilson disease : neurologic features. Handb Clin Neurol 142 : 101-119, 2017.
PubMed
4) Hogarth P : Neurodegeneration with brain iron accumulation : diagnosis and management. J Mov Disord 8 : 1-13, 2015.
PubMed
5) Gregory A, Hayflick SJ : Geneticsof neurodegeneration with brain iron accumulation. Curr Neurol Neurosci Rep 11 : 254-261, 2011.
 
6) Kruer MC, Boddaert N : Neurodegeneration with brain iron accumulation : a diagnostic algorithm. Semin Pediatr Neurol 19 : 67-74, 2012.
 
7) 狩野修, ほか : 浸透圧性髄鞘崩壊症. 別冊 新領域別症候群シリーズ 神経症候群 (第2版) V, p847-850, 日本臨牀社, 2014.
 
8) de Souza A : Movement disorders and the osmotic demyelination syndrome. Parkinsonism Relat Disord 19 : 709-716, 2013.
 
9) Forster A, et al : Value of diffusion-weighted imaging in central pontine and extrapontine myelinolysis. Neuroradiology 55 : 49-56, 2013.
PubMed
10) Martin RJ : Central pontine and extrapontine myelinolysis : the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry 75 (Suppl 3) : iii22-28, 2004.
 
11) Wang HC, et al : Acute movement disorders with bilateral basal ganglia lesions in uremia. Mov Disord 13 : 952-957, 1998.
PubMed
12) Acar NP, et al : Diabetic uremic syndrome studied with cerebral MR spectroscopy and CT perfusion. Metab Brain Dis 28 : 711-715, 2013.
PubMed
13) Nzwalo H, et al : Reversible acute parkinsonism and bilateral Basal Ganglia lesions in a diabetic uremic patient. Case Rep Neurol 4 : 156-158, 2012.
 
P.394 掲載の参考文献
1) Evidente VG, Gwinn KA : Post-encephalitic parkinsonism J Neurol Neurosurg Psychiatry 64 : 5, 1988.
 
2) von Economo C : Die encephalitis lethargica, ihre Nachkrankheiten und ihre Behardlung, Berlin : Urban & Schwarzenberg ; 1929. 251 pp (published in English in l931 [Encephalitis lethargica : Its sequelae and treatment] translated by Newman, K. O. London : Oxford University Press ; 1931 : 200 pp).
 
3) Berger JR, Vilensky JA : Encephalitis lethargica (von Economo's encephalitis). Handb Clin Neurol 123 : 745-761, 2014.
PubMed
4) Taubenberger JK, et al : Initial genetic characterization of the 1918 "Spanish"i nfluenza virus. Science 275 : 1793-1796, 1997.
 
5) McCall S, et al : Influenza RNA not detected in archival brain tissues from acute encephalitis lethargica cases or in postencephalitic Parkinson cases. J Neuropathol Exp Neurol 60 : 696-704, 2001.
 
6) Bojinov S : Encephalitis with acute Parkinsonian syndrome and bilateral inflammatory necrosis of the substantia nigra. J Neurol Sci 12 : 383-415, 1971.
PubMed
7) Dimova PS, et al : Acute reversible parkinsonism in Epstein-Barr virus-related encephalitis lethargica-like illness. Mov Disord 21 : 564-566, 2006.
PubMed
8) Alarcon F, et al : Encephalitis lethargica due to Epstein-Barr virus infection. Mov Disord 26 : 2132-2134, 2011.
PubMed
9) Ghaemi M, et al : FDG- and Dopa-PET in postencephalitic parkinsonism. J Neural Transm (Vienna) 107 : 1289-1295, 2000.
PubMed
10) von Economo C : Encephalitis lethargica. Its sequelae and treatment. Translated by Newman KO, Oxford University Press, London, 1931.
 
11) Anderson LL, et al : Review : neuropathology of acute phase encephalitis lethargica : a review of cases from the epidemic period. Neuropathol Appl Neurobiol 35 : 462-472, 2009.
PubMed
12) Kiley M, Esiri MM : A contemporary case of encephalitis lethargica. Clin Neuropathol 20 : 2-7, 2001.
PubMed
13) Fearnley JM, Lees AJ : Ageing and Parkinson's disease : substantia nigra regional selectivity. Brain 114 (Pt 5) : 2283-2301, 1991.
 
14) Kish SJ, et al : Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318 : 876-880, 1988.
PubMed
15) Vilensky JA, et ai : A historical analysis of the relationship between encephalitis lethargica and postencephalitic parkinsonism : a complex rather than a direct relationship. Mov Disord 25 : 1116-1123, 2010.
 
16) Vilensky JA, et al : Does the historical literature on encephalitis lethargica support a simple (direct) relationship with postencephalitic Parkinsonism? Mov Disord 25 : ll24-1130, 2010.
 
17) Sacks O : Awakenings (日本タイトル : レナードの朝) HarperCollins Publishers, New York, 1973.
 
18) Dale RC, et al : Encephalitis lethargica syndrome : 20 new cases and evidence of basal ganglia autoimmunity. Brain 127 : 21-33. 2004.
PubMed
19) Dale RC, et al : Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 135 : 3453-3468, 2012.
PubMed
20) Brilot F, et al : Antibody binding to neuronal surface in Sydenham chorea, but not in PANDAS or Tourette syndrome. Neurology 76 : 1508-1513, 2011.
 
21) Dale RC, et al : N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 66 : 704-709, 2009.
PubMed
22) Pradhan S, et al : Parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis. Neurology 53 : 1781-1786, 1999.
PubMed
23) Ishii T, et al : Characteristic residual neuropathological features of Japanese B encephalitis. Acta Neuropathol 38 : 181-186, 1977.
PubMed
24) Ling H, et al : TDP-43 pathology is present in most post-encephalitic parkinsonism brains. Neuropathol Appl Neurobiol 40 : 654-657, 2014.
PubMed
25) Kim R, et al : Postencephalitic parkinsonism responsive to a dopamine agonist : A case report. Parkinsonism Relat Disord 21 : 667-668, 2015.
PubMed
26) Calne DB : Is idiopathic parkinsonism the consequence of an event or a process? Neurology 44 : 5-10, 1994.
 
P.399 掲載の参考文献
1) 近藤智善 : 脳腫瘍とParkinsonism. 日本臨牀 55 : 118-122, 1997.
Medical*Online
2) 安原隆雄 : 脳腫瘍とパーキンソニズム. 日本臨牀 67 (増刊号 : パーキンソン病) : 286-290, 2009.
 
3) 狩野修, ほか : 脳腫瘍によるパーキンソニズム. 別冊日本臨牀 新領域別症候群シリーズ 27 神経症候群 (第2版) II p155-158, 日本臨牀社, 2014.
 
4) Benincasa D, et al : Hemiparkinsonism due to frontal meningioma. Acta Neurol Belg 108 : 29-32, 2008.
PubMed
5) Frosini D, et al : Bilateral thalamic glioma presenting with parkinsonism. Mov Disord 24 : 2168-2169, 2009.
PubMed
6) Ghaemi K, et al : Hemiparkinsonism due to a pontomesencephalic cavernoma : improvement after resection. J Neurosurg Pediatr 4 : 143-146, 2009.
PubMed
7) Akhaddar A, et al : Chronic headache and hemiparkinsonisim due to a sylvian fissure dermoid cyst. Headache 50 : 479-480, 2010.
PubMed
8) Hortelano E, et al : Parkinsonism secondary to metastatic lesions within the central nervous system : a case report. J Med Case Rep 4 : 218, 2010.
PubMed
9) Tang V, et al : Primary intracranial hemangiopericytoma presenting as hemiparkinsonism. Can J Neurol Sci 38 : 349-351, 2011.
PubMed
10) Wachter T, et al : Slowly progressive Parkinson syndrome due to thalamic butterfly astrocytoma. Neurology 77 : 404-405, 2011.
PubMed
11) Choi KH, et al : Astrocytoma in the third ventricle and hypothalamus presenting with parkinsonism. J Korean Neurosurg Soc 51 : 144-146, 2012.
PubMed
12) Rocha H, et al : Reversible parkinsonism due to a large intracranial tumor. BMJ Case Rep 2012, 2012. (bcr2012007823. doi : 10.1136/bcr-2012-007823.)
 
13) Jang W, et al : Juvenile parkinsonism as an initial manifestation of gliomatosis cerebri. J Neurol 260 : 3161-3163, 2013.
PubMed
14) Pandit L, et al : Neoplastic Parkinsonism : An illustrative case report. Ann Indian Acad Neurol 16 : 437-439, 2013.
PubMed
15) Freeman JW, et al : Meningioma mimicking Parkinson's disease : a case report and analysis. S D Med 66 : 101-103, 2013.
 
16) Parvaresh M, et al : Parkinsonism : a rare manifestation of craniopharingioma. Electron Physician 7 : 1027-1031, 2015.
 
17) Choi MS, et al : Cortical tumor presenting with Parkinsonism. Iran J Neurol 14 : 219-221, 2015.
PubMed
18) Fong M, et al : Large intracranial meningioma masquerading as Parkinson's disease. J Neurol Neurosurg Psychiatry 87 : 1251, 2016.
PubMed
19) Kleib AS, et al : Hemiparkinsonism secondary to sphenoid wing meningioma. Neurochirurgie 62 : 281-283, 2016.
PubMed
20) Bajaj A, et al : Parkinson's disease and cancer risk : a systematic review and meta-analysis. Cancer Causes Control 21 : 697-707, 2010.
 
21) Catala-Lopez F, et al : Inverse and direct cancer comorbidity in people with central nervous system disorders : a meta-analysis of cancer incidence in 577,013 participants of 500bservational studies. Psychother Psychosom 83 : 89-105, 2014.
PubMed
22) Ye R, et al : The Relationship between Parkinson Disease and Brain Tumor : A Meta-Analysis. PLoS ONE 11 : e0164388, 2016. doi : 10.1371/journal.pone.0164388
 

V 治療

P.407 掲載の参考文献
1) 日本神経学会パーキンソン病治療ガイドライン作成小委員会 : パーキンソン病治療ガイドライン 2002. 臨床神経 42 : 428-494, 2002.
 
2) 日本神経学会 (監修), パーキンソン病治療ガイドライン作成委員会 (編) : パーキンソン病治療ガイドライン 2011, 医学書院, 2011.
 
3) 相原守夫 : 診療ガイドラインのためのGRADEシステム (第2版), 凸版メディア, 2015.
 
P.412 掲載の参考文献
1) Athauda D, Foltynie T : The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol 11 : 25-40, 2015.
PubMed
2) Antonini A, et al : A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 8 : 929-937, 2009.
PubMed
3) 日本神経学会パーキンソン病治療ガイドライン作成小委員会 : パーキンソン病治療ガイドライン 2002. 臨床神経 42 : 428-494, 2002.
 
4) 日本神経学会 (監), パーキンソン病治療ガイドライン作成委員会 (編) : パーキンソン病治療ガイドライン 2011, 医学書院, 2011.
 
5) 相原守夫 : 診療ガイドラインのためのGRADEシステム (第2版), 凸版メディア, 2015.
 
6) Fahn S, et al : Levodopa and the progression of Parkinson's disease. N Engl J Med 351 : 2498-2508, 2004.
PubMed
7) Clarke CE, et al : Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? Mov Disord 26 : 1187-1193, 2011.
PubMed
8) Olanow CW, et al : The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72 (21 Suppl 4) : S1-136, 2009.
 
9) Parkinson Study Group : A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 : 561-566, 2004.
 
10) Olanow CW, et al : A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361 : 1268-1278, 2009.
PubMed
11) Schapira AH, et al : Pramipexole in patients with early Parkinson's disease (PROUD) : a randomised delayed-start trial. Lancet Neurol 12 : 747-755, 2013.
 
12) PD Med Collaborative Group ; Gray R, et al : Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED) : a large, open-label, pragmatic randomised trial. Lancet 384 : 1196-1205, 2014.
 
13) Warren Olanow C, et al : Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 28 : 1064-1071, 2013.
PubMed
14) Watts RL, et al : Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord 25 : 858-866, 2010.
PubMed
15) Voon V, et al : Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease : an update. Lancet Neurol 16 : 238-250, 2017.
PubMed
16) 波田野琢 : パーキンソン病臨床の新展開パーキンソン病ガイドライン 2011以降の治療方針 : 薬物療法を中心に. 脳21 19 (特集 : パーキンソン病の基礎と臨牀の最先端) : 361-366, 2016.
 
P.416 掲載の参考文献
1) 日本神経学会 (監修), 「パーキンソン病治療ガイドライン」作成小委員会 (編) : 第II編パーキンソン病の治療ガイドライン 第22章各論パーキンソン病治療ガイドライン 2002, 医学書院, 2003.
 
2) Barone P, et al : The PRIAMO study : A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24 : 1641-1649, 2009.
PubMed
3) 日本神経学会 (監修), 「パーキンソン病治療ガイドライン」作成委員会 : 第2章 運動症状の薬物療法, パーキンソン病治療ガイドライン 2011, 医学書院, 2011.
 
4) Seppi K, et al : The Movement Disorder Society Evidence-Based Medicine Review Update : Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 26 (Suppl 3) : S42-80, 2011.
 
5) Keus SH, et al : Physical therapy in Parkinson's disease : evolution and future challenges. Mov Disord 24 : 1-14, 2009.
PubMed
P.421 掲載の参考文献
1) Xu Q, et al : Physical activities and future risk of Parkinson disease. Neurology 75 : 341-348, 2010.
PubMed
2) Yang F, et al : Physical activity and risk of Parkinson's disease in the Swedish National March Cohort. Brain 138 : 269-275, 2015.
PubMed
3) Toy WA, et al : Treadmill exercise reverses dendritic spine loss in direct and indirect striatal medium spiny neurons in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Neurobiol Dis 63 : 201-209, 2014.
PubMed
4) Frazzitta G, et al : Effectiveness of intensive inpatient rehabilitation treatment on disease progression in parkinsonian patients : a randomized controlled trial with 1-year follow-up. Neurorehabil Neural Repair 26 : 144-150, 2012.
PubMed
5) Frazzitta G, et al : Intensive rehabilitation increases BDNF serum levels in parkinsonian patients : a randomized study. Neurorehabil Neural Repair 28 : 163-168, 2014.
PubMed
6) Schenkman M, et al : Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease : A Phase 2 Randomized Clinical Trial. JAMA Neurol 75 : 219-226, 2018.
PubMed
7) Romo R, et al : Neuronal activity preceding self-initiated or externally timed arm movements in area 6 of monkey cortex. Exp Brain Res 67 : 656-662, 1987.
 
8) Mushiake H, et al : Neuronal activity in the primate premotor, supplementary, and precentral motor cortex during visually guided and internally determined sequential movements. J Neurophysiol 66 : 705-718, 1991.
PubMed
9) Wu T, et al : Effective connectivity of brain networks during self-initiated movement in Parkinson's disease. Neuroimage 55 : 204-215, 2011.
PubMed
10) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197-211, 2003.
PubMed
11) Frazzitta G, et al : Rehabilitation treatment of gait in patients with Parkinson's disease with freezing : a comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training. Mov Disord 24 : 1139-1143, 2009.
PubMed
12) Nieuwboer A, et al : The short-term effects of different cueing modalities on turn speed in people with Parkinson's disease. Neurorehabil Neural Repair 23 : 831-836, 2009.
PubMed
13) Spaulding SJ, et al : Cueing and gait improvement among People with Parkinson's disease : a meta-analysis. Arch Phys Med Rehabil 94 : 562-570, 2013.
PubMed
14) Mahler LA, et al : Evidence-based treatment of voice and speech disorders in Parkinson disease. Curr Opin Otolaryngol Head Neck Surg 23 : 209-215, 2015.
PubMed
15) Ebersbach G, et al : Comparing exercise in Parkinson's disease-the Berlin LSVTBIG study. Mov Disord 25 : 1902-1908, 2010.
PubMed
16) Sacco K, et al : Motor imagery of walking following training in locomotor attention. The effect of "the tango lesson". Neuroimage 32 : 1441-1449, 2006.
PubMed
17) Li F, et al : Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med 366 : 511-519, 2012.
PubMed
18) Song R, et al : The impact of Tai Chi and Qigong mind-body exercises on motor and non-motor function and quality of life in Parkinson's disease : A systematic review and meta-analysis. Parkinsonism Relat Disord 41 : 3-13, 2017.
PubMed
19) Farina N, et al : The effect of exercise interventions on cognitive outcome in Alzheimer's disease : a systematic review. Int Psychogeriatr 26 : 9-18, 2014.
PubMed
20) David FJ, et al : Exercise improves cognition in Parkinson's disease : The PRET-PD randomized, clinical trial. Mov Disord 30 : 1657-1663, 2015.
PubMed
21) Reynolds GO, et al : The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease. Mov Disord 31 : 23-38, 2016.
PubMed
P.427 掲載の参考文献
1) Snider J, et al : Non-exercise physical activity attenuates motor symptoms in Parkinson disease independent from nigrostriatal degeneration. Parkinsonism Relat Disord 21 : 1227-1231, 2015.
PubMed
2) Speelman AD, et al : How might physical activity benefit patients with Parkinson disease? Nat Rev Neurol 7 : 528-534, 2011.
PubMed
3) Petzinger GM, et al : Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease. Lancet Neurol 12 : 716-726, 2013.
PubMed
4) Yang F, et al : Physical activity and risk of Parkinson's disease in the Swedish National March Cohort. Brain 138 : 269-275, 2015.
PubMed
5) Oguh O, et al : Back to the basics : regular exercise matters in parkinson's disease : results from the National Parkinson Foundation QII registry study. Parkinsonism Relat Disord 20 : 1221-1225, 2014.
 
6) Reynolds GO, et al : The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease. Mov Disord 31 : 23-38, 2016.
PubMed
7) Tomlinson CL, et al : Physiotherapy for Parkinson's disease : a comparison of techniques. Cochrane Database Syst Rev 6 : CD002815, 2014.
PubMed
8) Ahlskog JE : Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology 77 : 288-294, 2011.
PubMed
9) Ebersbach G, et al : Comparing exercise in Parkinson's disease-the Berlin LSVTBIG study. Mov Disord 25 : 1902-1908, 2010.
PubMed
10) Negrini S, et al : Nintendo Wii Fit for balance rehabilitation in patients with Parkinson's disease : A comparative study. J Bodyw Mov Ther 21 : 117-123, 2017.
PubMed
11) Bombieri F, et al : Walking on four limbs : A systematic review of Nordic Walking in Parkinson disease. Parkinsonism Relat Disord 38 : 8-12, 2017.
PubMed
12) Aguiar LPC, et al : Therapeutic Dancing for Parkinson's Disease. Int J Gerontol 10 : 64-70, 2016.
 
13) Hashimoto H, et al : Effects of dance on motor functions, cognitive functions, and mental symptoms of Parkinson's disease : a quasi-randomized pilot trial. Complement Ther Med 23 : 210-219, 2015.
PubMed
14) Palfreman J : Chapter 4 ; Mind over matter. In : Brain Storms ; the race to unlock the mysteries of Parkinson's disease, p54-62, Scientific American, New York, 2015.
 
15) Frazzitta G, et al : Intensive rehabilitation treatment in early Parkinson's disease : a randomized pilot study with a 2-year follow-up. Neurorehabil Neural Repair 29 : 123-131, 2015.
PubMed
P.434 掲載の参考文献
1) 厚生労働統計協会 : 国民衛生の動向 難病対策 64 : 173-179, 2017/2018.
 
2) 厚生労働統計協会 : 国民の福祉と介護の動向 第3編障害者福祉 第4編介護と高齢者福祉等 64 : 116-191, 2017/2018.
 
3) Abbott RA, et al : Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr 46 : 879-884, 1992.
PubMed
4) 師尾郁, ほか : Parkinson病にみられる体重減少. 神経内科 41 : 65-67, 1994.
 
5) 山本敏之 : パーキンソン病医学・医療の最前線 第3部 : 治療上の問題点 5. 進行期パーキンソン病治療 摂食・嚥下・栄養障害の管理. Progress in Medicine 32 : 1241-1245, 2012.
 
6) Cereda E, et al : Low-protein and protein-redistribution diets for Parkinson's disease patients with motor fluctuations : a systematic review. Mov Disord 25 : 2021-2034, 2010.
PubMed
7) 高橋良輔, ほか : 教育, カウンセリング, 食事などの非薬物療法は運動症状改善に有効か. パーキンソン病治療ガイドライン 2011 (パーキンソン病治療ガイドライン作成委員会編), p143-145, 医学書院, 2011.
 
8) Lieberman AN, et al : Dysphagia in Parkinson's disease. Am J Gastroenterol 74 : 157-160, 1980.
PubMed
9) Ali GN, et al : Mechanisms of oral-pharyngeal dysphagia in patients with Parkinson's disease. Gastroenterology 110 : 383-392, 1996.
PubMed
10) Yamazaki Y, et al : Nutritional support by "conventional" percutaneous endoscopic gastrostomy feeding may not result in weight gain in Parkinson's disease. J Neurol 258 : 1561-1563, 2011.
 
11) 山本敏之 : 筋萎縮性側索硬化症, パーキンソン病に対する嚥下障害の評価と対策. 臨床神経 51 : 1072-1074, 2011.
 
12) Sheard JM, et al : Improved nutritional status is related to improved quality of life in Parkinson's disease. BMC Neurol 14 : 212, 2014.
PubMed
13) 野崎園子 : パーキンソン病の摂食・嚥下障害. IRYO 61 : 99-103, 2007.
Medical*Online
P.441 掲載の参考文献
1) Ovallath S, Deepa P : The history of parkinsonism : descriptions in ancient Indian medical literature. Mov Disord 28 : 566-568, 2013.
PubMed
2) Abbott A : Levodopa : the story so far. Nature 466 : S6-7, 2010.
PubMed
3) Carlsson A, et al : 3, 4-Dihydroxyphenytalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180 : 1200, 1957.
PubMed
4) Lees AJ, Tolosa E : Four pioneers of L-dopa treatment : Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord 30 : 19-36, 2015.
 
5) 佐野勇 : 錐体外路系の生化学. 神経研究の進歩 5 : 42-48, 1960.
 
6) Ehringer H, Hornykiewicz O : [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr 38 : 1236-1239, 1960.
PubMed
7) Birkmayer W, Hornykiewicz O : [The L-3, 4-dioxyphenylalanine (DOPA) -effect in Parkinson-akinesia]. Wien Klin Wochenschr 73 : 787-788. 1961.
 
8) Cotzias GC, et al : Aromatic amino acids and modification of parkinsonism. N Engl J Med. 276 (7) : 374-379. 1967.
PubMed
9) Yahr MD, et al : Treatment of parkins onism with levodopa. Arch Neurol 21 (4) : 343-354. 1969.
 
10) 柿本泰男, 佐野輝 : パーキンソン病患者の脳におけるドーパミンの減少の発見の歴史. 日本内科学会雑誌 83 : 533-538.
 
11) Bartholini G, et al : Increase of cerebral catecholamines caused by 3, 4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 215 : 852-853, 1967.
PubMed
12) Cotzias GC, Papavasiliou PS : Blocking the negative effects of pyridoxine on patients receiving levodopa. JAMA 215 : 1504-1505, 1971.
PubMed
13) 加瀬正夫 : 特発性パーキンソニズムに対するcarbidop L-dopa併用療法とL-Dopa単独療法の二重盲検法に対する比較検討. 医学のあゆみ 101 : 796-813, 1977.
 
14) 水野美邦, ほか : パーキンソン病に対するL-ドーパおよびBenserazide (Ro4-4602) の併用効果-二重盲検法によるL-ドーパ単独療法と併用療法の比較. 神経研究の進歩 21 : 807-834, 1977.
 
15) Kurlan R, et al : Duodenal delivery of levodopa for on-off fluctuations in parkinsonism : preliminary observations. Ann Neurol 20 : 262-265, 1986.
PubMed
16) Bredberg E, et al : Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol 45 : 117-122, 1993.
PubMed
17) Fahn S, et al : Levodopa and the progression of Parkinson's disease. N Engl J Med 351 : 2498-2508, 2004.
PubMed
18) Watts RL, et al : Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Dis ord 25 : 858-866, 2010.
PubMed
19) Tanaka Y, et al : Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the 13C-acetate breath test. J Neurol 258 : 421-426, 2011.
 
20) Doi H, et al : Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. J Neurol Sci 319 : 86-88, 2012.
PubMed
21) Arana A. et al : Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Proton Pump Inhibitors, or Metoclopramide : A Population-Based Nested Case-Control Study. Drug Saf 38 : 1187-119. 9, 2015.
PubMed
22) Tang LC, et al : L-3, 4-dihydroxyphenylalanine-induced hypersensitivity simulating features of denervation. Proc Natl Acad Sci USA 74 : 2126-2129, 19. 77.
 
23) Bibbiani F, et al : Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 192 : 73-78, 2005.
PubMed
24) Maratos EC, et al : Both short-and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp Neurol 179 : 90-102, 2003.
 
25) Hauser RA, et al : Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22 : 2409-2417, 2007.
PubMed
26) 加世田俊, ほか : Carbidopa製剤とBenserazide製剤の血中Levodopa濃度差の検討. 臨床薬理 31 : 327-328, 2000.
 
27) Stocchi E et al : Comparison of IPX066 with carbidopa-levodopa plus entacapone ill advanced PD patients. Parkinsonism Relat Disord 20 : 1335-1340, 2014,
 
28) 厚生労働省医薬・生活衛生局 (薬生発0929第4号平成29年9月29日) : 医薬品等適正広告基準の改正について. (http://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/0000112751.pdf) (2018年4月閲覧)
 
29) LeWitt PA. et al : A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. Mov Disord 31 : 1356-1365, 2016.
PubMed
P.447 掲載の参考文献
1) Calne DB, et al : Bromocriptine in Parkinsonism. Br Med J 4 : 442-444, 1974.
PubMed
2) Barone P, et al : Pergolide monotherapy in the treatment of early PD : a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 53 : 573-579, 1999.
 
3) Oertel WH, et al : Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study. Mov Disord 21 : 343-353, 2006.
 
4) Bracco F, et al : The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease : final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18 : 733-746, 2004.
 
5) Geminiani G, et al : Cabergoline in Parkinson's disease complicated by motor fluctuations. Mov Disord 11 : 495-500, 1996.
PubMed
6) Steiger MJ, et al : Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 243 : 68-72, 1996.
PubMed
7) Pritchett AM, et al : Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77 : 1280-1286, 2002.
PubMed
8) Tran T, et al : Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot-and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease : A Systematic Review of Observational Studies. CNS Drugs 29 : 985-998, 2015.
PubMed
9) Yamashiro K, et al : The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 23 : 935-941, 2008.
PubMed
10) Watanabe H, et al : B-type natriuretic peptide and cardiovalvulopathy in Parkinson disease with dopamine agonist. Neurology 72 : 621-626, 2009.
PubMed
11) 日本神経学会 (監修) : 第1編 第2章 ドパミンアゴニスト. パーキンソン病治療ガイドライン 2011 (パーキンソン病治療ガイドライン作成委員会編). 5-26. 医学書院, 2011.
 
12) Wood M, et al : Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol 172 : 1124-1135, 2015.
PubMed
13) Millan MJ, et al : Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303 : 791-804, 2002.
 
P.454 掲載の参考文献
1) 日本神経学会 (監修) : パーキンソン病診療ガイドライン 2017. (in submission ; パブリックコメント募集済. [https://www.kktcs.co.jp/jsnmypage/ProxyServlet/public/parkinson.html]
 
2) 中西孝雄ほか : B-HT 920 (塩酸タリペキソール) のパーキンソン病に対する臨床評価 メシル酸プロモクリプチンを対照とした第III相多施設二重盲検比較試験. 臨床評価 21 : 59-110, 1993.
 
3) Parkinson Study Group : Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 : 1653-1661, 2002.
 
4) Vu TQ, et al : Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm (Vienna) 107 : 159-176, 2000.
PubMed
5) Poewe W, et al : Extended-release pramipexole in early Parkinson disease : a 33-week randomized controlled trial. Neurology 77 : 759-766, 2011.
PubMed
6) Zhang Z, et al : The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease : a multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism Relat Disord 19 : 1022-1026, 2013.
 
7) Stocchi F, et al : Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease : a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 24 : 2883-2895, 2008.
PubMed
8) Mizuno Y, et al : Transdermal rotigotine in early stage Parkinson's disease : a randomized, double-blind, placebo-controlled trial. Mov Disord 28 : 1447-1450, 2013.
PubMed
9) Mizuno Y, et al : Rotigotine vs ropinirole in advanced stage Parkinson's disease : a double-blind study. Parkinsonism Relat Disord 20 : 1388-1393, 2014.
PubMed
10) Pahwa R, et al : Subcutaneous apomorphine in patients with advanced Parkinson's disease : a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 258 : 137-143, 2007.
 
11) Gunzler SA : A pomorphine in the treatment of Parkinson disease and other movement disorders. Expert Opin Pharmacother 10 : 1027-1038, 2009.
 
P.460 掲載の参考文献
1) Anderson MC, et al : Monoamine oxidase inhibitors and the cheese effect. Neurochem Res 18 : 1145-1149, 1993.
PubMed
2) Caccia C, et al : Safinamide : from molecular targets to a new anti-Parkinson drug. Neurology 67 : S18-23, 2006.
PubMed
3) Robakis D, Fahn S : Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease. CNS Drugs 29 : 433-441, 2015.
PubMed
4) Kandadai RM, et al : Safinamide for the treatment of Parkinson's disease. Expert Rev Clin Pharmacol 7 : 747-759, 2014.
PubMed
5) Parkinson Study Group : Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 : 176-183, 1993.
 
6) Shoulson I, et al : Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease : a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51 : 604-612, 2002.
PubMed
7) Olanow CW, et al : The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38 : 771-777, 1995.
PubMed
8) Parkinson Study Group : A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 : 561-566, 2004.
 
9) Rascol O, et al : A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study) : prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 10 : 415-423, 2011.
PubMed
10) Schapira AH, et al : Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations : A Randomized Clinical Trial. JAMA Neurol 74 : 216-224, 2017.
PubMed
11) Gregoire L, et al : Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord 19 : 508-514, 2013.
 
12) Borgohain R, et al : Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov Disord 29 : 1273-1280, 2014.
PubMed
13) Peretz C, et al : Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease : A Real-life Study. Clin Neuropharmacol 39 : 227-231, 2016.
PubMed
14) Cereda E, et al : Efficacy of rasagiline and selegiline in Parkinson's disease : a head-to-head 3-year retrospective case-control study. J Neurol 264 : 1254-1263, 2017.
PubMed
15) Caslake R, et al : Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease, Cochrane Database Syst Rev (4) : CD006661, 2009.
PubMed
16) Panisset M, et al : Serotonin toxicity association with concomitant antidepressants and rasagiline treatment : retrospective study (STACCATO). Pharmacotherapy 34 : 1250-1258, 2014.
PubMed
P.465 掲載の参考文献
1) Kanda T, et al : KF17837 : a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur J Pharmacol 256 : 263-268, 1994.
PubMed
2) Kanda T, et al : Combined use of the adenosine A (2A) antagonist KW-6002 with L-DOPA or with selective Dl or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162 : 321-327, 2000.
 
3) Mori A, et al : The story of istradefylline-the first approved A2A antagonist for the treatment of parkinson's disease. In The Adenosinergic System : A Non-Dopaminergic Target in Parkinson's Disease (ed by Morelli M, et al), p273-289, Springer International Publishing Switzerland, Cham, 2015.
 
4) Sako W, et al : The effect of istradefylline for Parkinson's disease : A meta-analysis. Sci Rep 7 : 18018, 2017.
PubMed
5) Yabe I, et al : The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease. Clin Neuropharmacol 40 : 261-263, 2017.
PubMed
6) Matsuura K, et al : Istradefylline is recommended for morning use : a report of 4 cases. Intern Med 54 : 09-511, 2015.
 
7) Vorovenci RJ, et al : The efficacy of oral adenosine A (2A) antagonist istradefylline for the treatment of moderate to severe Parkinson's disease. Expert Rev Neurother 15 : 1383-1390, 2015.
PubMed
8) Hodgson RA, et al : Preladenant, a selective A (2A) receptor antagonist, is active in primate models of movement disorders, Exp Neurol 225 : 384-390, 2010.
PubMed
9) Hauser RA, et al : Preladenant in patients with Parkinson's disease and motor fluctuations : a phase 2, double-blind, randomised trial. Lancet Neurol 10 : 221-229, 2011.
PubMed
10) Hauser RA, et al : Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa : a phase 2b, double-blind, randomised trial. Lancet Neurol 13 : 767-776, 2014.
PubMed
11) Rivera-Oliver M, et al : Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases : a review. Life Sci 101 : 1-9, 2014.
PubMed
12) Postuma RB, et al : Caffeine for treatment of Parkinson disease : a randomized controlled trial. Neurology 79 : 651-658, 2012.
PubMed
13) Postuma RB, et al : Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD) : A randomized trial. Neurology 89 : 1795-1803, 2017.
PubMed
14) Wills AM, et al : Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord 28 : 380-383, 2013.
PubMed
15) Bibbiani F, et al : A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 184 : 285-294, 2003.
PubMed
P.471 掲載の参考文献
1) Alves G, et al : Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 21 : ll23-1130, 2006.
 
2) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197-211, 2003.
PubMed
3) Cash R, et al : Parkinson's disease and dementia : norepinephrine and dopamine in locus ceruleus. Neurology 37 : 42-46, 1987.
PubMed
4) Chan-Palay V, et al : Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 287 : 373-392, 1989.
PubMed
5) Davidson DF, et al : Parkinson's disease : the effect of L-dopa therapy on urinary free catecholamines and metabolites. Ann Clin Biochem 44 : 364-368, 2007.
 
6) Dickson DW, et al : Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 115 : 437-444, 2008.
PubMed
7) Fukada K, et al : L-threo-3, 4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease. Med Hypotheses 80 : 209-212, 2013.
PubMed
8) Goldstein DS, et al : Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res 14 : 363-368, 2004.
PubMed
9) Goldstein DS, et al : Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. J Clin Pharmacol 51 : 66-74, 2011.
PubMed
10) Goldstein DS, et al : Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin Auton Res 17 : 118-121, 2007.
PubMed
11) Iwanaga K, et al : Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 52 : 1269-1271, 1999.
PubMed
12) Kalaitzakis ME, et al : Disturbed sleep in Parkinson's disease : anatomical and pathological correlates. Neuropathol Appl Neurobiol 39 : 644-653, 2013.
PubMed
13) Kaufmann H : L-dihydroxyphenylserine (Droxidopa) : a new therapy for neurogenic orthostatic hypotension : the US experience. Clin Auton Res 18 (Suppl 1) : 19-24, 2008.
 
14) Kaufmann H, et al : Droxidopa for neurogenic orthostatic hypotension : a randomized, placebocontrolled, phase 3 trial. Neurology 83 : 328-335, 2014.
PubMed
15) Kaufmann H, et al : Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 108 : 724-728, 2003.
PubMed
16) Marsh L, et al : Atomoxetine for the treatment of executive dysfunction in Parkinson's disease : a pilot open-label study. Mov Disord 24 : 277-282, 2009.
PubMed
17) Mathias CJ : L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension : the European experience. Clin Auton Res 18 (Suppl 1) : 25-29, 2008.
 
18) Miki Y, et al : Incidental Lewy body disease restricted to the heart and stellate ganglia. Mov Disord 24 : 2299-2301, 2009.
 
19) Narabayashi H, et al : Clinical effects of L-threo-3, 4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia. Adv Neurol 45 : 593-602, 1987.
PubMed
20) Orimo S, et al : Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 73 : 776-777, 2002.
PubMed
21) Palma JA, et al : Is cardiac function impaired in premotor Parkinson's disease? A retrospective cohort study. Mov Disord 28 : 591-596, 2013.
PubMed
22) Palma JA, et al : Autonomic disorders predicting Parkinson's disease. Parkinsonism Relat Disord 20 (Suppl 1) : S94-98, 2014.
 
23) Paulus W, et al : The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50 : 743-755, 1991.
PubMed
24) Remy P, et al : Depression in Parkinson's disease : loss of dopamine and noradrenaline innervation in the limbic system. Brain 128 : 1314-1322, 2005.
PubMed
25) Robbins TW : From arousal to cognition : the integrative position of the prefrontal cortex. Prog Brain Res 126 : 469-483, 2000.
PubMed
26) Rommelfanger KS, et al : Norepinephrine : The redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74 : 177-190, 2007.
PubMed
27) Shibao C, et al : Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension 50 : 47-53, 2007.
PubMed
28) Tohgi H, et al : The effects of L-threo-3, 4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J Neural Transm Park Dis Dement Sect 5 : 27-34, 1993.
PubMed
29) Tohgi H, et al : Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease : relationship to clinical symptoms and subsequent therapeutic outcomes. J Neural Transm Park Dis Dement Sect 5 : 17-26, 1993.
PubMed
30) Weintraub D, et al : Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 75 : 448-455, 2010,
PubMed
P.476 掲載の参考文献
1) 「てんかん治療ガイドライン」作成委員会 (編) : てんかん治療ガイドライン 2010, 医学書院, 2010.
 
2) Murata M, et al : Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res 41 : 397-399, 2001.
PubMed
3) Murata M, et al : Zonisamide improves motor function in Parkinson disease : a randomized, double-blind study. Neurology 68 : 45-50, 2007.
PubMed
4) Murata M, et al : Randomized placebo-controlled trial of zonisamide in patients with Parkinson's isease. Neurol Clin Neurosci 4 : 10-15, 2016.
 
5) Murata M, et al : Zonisamide improves wearing-off in Parkinson's disease : A randomized, double-blind study. Mov Disord 30 : 1343-1350, 2015.
PubMed
6) Murata M : Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des 10 : 687-693, 2004.
PubMed
7) 「パーキンソン病治療ガイドライン」作成委員会 (編) : パーキンソン病治療ガイドライン 2011, 医学書院, 2011.
 
8) Miwa H, Kondo T : T-type calcium channel as a new therapeutic target for tremor. Cerebellum 10 : 563-569, 2011.
PubMed
9) Yamamura S, et al : Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology 57 : 322-331, 2009.
PubMed
10) Maeda T, et al : Zonisamide in the early stage of Parkinson's disease. Neurol Clin Neurosci 3 : 127-130, 2015.
 
11) Ikeda K, et al : Preliminary study of zonisamide monotherapy in de novo patients with early Parkinson's disease. Neurol Clin Neurosci 3 : 163-166, 2015.
 
12) Nakanishi I, et al : [Effect of zonisamide on resting tremor resistant to antiparkinsonian medication]. No To Shinkei 55 : 685-689, 2003.
PubMed
13) Bermejo PE, et al : Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 257 : 1682-1685, 2010.
PubMed
14) Murata M, et al : Adjunct zonisamide to levodopa for DLB parkinsonism : A randomized, double-blind phase 2 study. Neurology 90 : e664-e672. 2018.
PubMed
15) Kinrys G, et al : Adjunctive zonisamide for treatment refractory anxiety. Int J Clin Pract 61 : 1050-1053, 2007.
PubMed
P.481 掲載の参考文献
1) Schwab RS, et al : Artane in the treatment of Parkinson's disease ; a report of its effectiveness alone and in combination with benadryl and parpanit. N Engl J Med 241 : 483-485, 1949.
PubMed
2) Roberts J, et al : The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. Br J Clin Pharmacol 41 : 331-337, 1996.
PubMed
3) Contin M, et al : Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease. Effect on levodopa bioavailability. Clin Neuropharmacol 14 : 148-155, 1991.
PubMed
4) Giugni JC, et al : Anticholinergic agents in the management of Parkinson's disease. In : Parkinson's Disease : Current and Future Therapeutics and Clinical Trials (ed by Galvez-Jimenez N, et al), p5-12, Cambridge University Press, Cambridge, 2016.
 
5) 中木敏夫 (訳) : 運動制御. 分子神経薬理学-臨床神経科学の基礎- (樋口宗史, 前山一隆監訳), p272-292, 西村書店, 2004.
 
6) Ding J, et al : RGS-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat Neruosci 9 : 832-842, 2006.
PubMed
7) Pakhotin P, et al : Cholinergic interneurons control the excitatory input to the striaturn. J Neurosci 27 : 391-400, 2007.
 
8) Benarroch EE : Effects of acetylcholine in the striatum. Recent insights and therapeutic implications. Neurology 79 : 274-281, 2012.
PubMed
9) Griffiths PD, et al : Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease. J Neurol Sci 100 : 131-136, 1990.
PubMed
10) Quik M, et al : Nicotine and Parkinson's disease : implications for therapy. Mov Disord 23 : 1641-1652, 2008.
PubMed
11) Itti E, et al : Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease : an observational study. Nucl Med Commun 30 : 513-518, 2009.
PubMed
12) Lang AE : Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists : controversies and new approaches. Can J Neurol Sci 11 : 210-220, 1984.
PubMed
13) Katzenschlager R, et al : Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev (2) CD003735, 2003.
PubMed
14) Koller WC : Pharmacologic treatment of parkinsonian tremor. Arch Neurol 43 : 126-127, 1986.
PubMed
15) Machado D, et al : Treatment of Parkinson's disease with anticholinergic medication. In : Parkinson's disease, 2nd ed (ed by Pfeiffer RF, et al), p811-818, CRC Press, Boca Raton, 2013.
 
16) Baba Y, et al : Anti-cholinergics for axial symptoms in Parkinson's disease after subthalamic stimulation. Clin Neurol Neurosurg 114 : 1308-1311, 2012.
PubMed
17) Thomsen TR, et al : Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 22 : 2268-2273, 2007.
PubMed
18) Arbouw ME, et al : Glycopyrrolate for sialorrhea in Parkinson disease : a randomized, double-blind, crossover trial. Neurology 74 : 1203-1207, 2010.
PubMed
19) Lloret SP, et al : A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. J Neurol Sci 310 : 248-250, 2011.
PubMed
20) Bennett N, et al : Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 171 : 749-751, 2004.
PubMed
21) Tune LE : Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 62 (Suppl 21) : 11-14, 2001.
 
22) Ehrt U, et al : Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease : acohort study. J Neurol Neurosurg Psychiatry 81 : 160-165, 2010.
 
23) Bohnen NI, et al : Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease : an in vive positron emission tomographic study. Arch Neurol 60 : 1745-1748, 2003.
 
P.486 掲載の参考文献
1) Bonifacio MJ, et al : Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev 13 : 352-379, 2007.
PubMed
2) Olanow CW, Obeso JA : Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease : implications for the early use of COMT inhibitors. Neurology 55 (11 Supple 4) : S72-S77, 2000.
 
3) Sotnikova TD. et al : The dopamine metabolite 3-methoxytyramine is a neuromodulator. PLoS ONE 5 : e13452, 2010.
PubMed
4) Rajput AH, et al : Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. Parkinsonism Relat Disord 10 : 221-226, 2004.
PubMed
5) Murphy KC, et al : High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56 : 940-945, 1999.
PubMed
6) Gothelf D, et al : Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome. Biol Psychiatry 75 : 406-413, 2014.
PubMed
7) OMIM #116790.
 
8) Hoda F, et al : No association between Parkinson's disease and low-activity alleles of catechol Omethyltransferase. Biochem Biophys Res Commun 228 : 780-784, 1996.
PubMed
9) Corvol JC, et al : The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease : a randomized crossover clinical trial. Ann Neurol 69 : 111-118, 2011.
PubMed
10) Learmonth DA, et al : Synthesis of 1- (3, 4-dihydroxy-5-nitrophenyl) -2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. J Med Chem 45 : 685-695, 2002.
PubMed
11) Learmonth DA, et al : Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 47 : 6207-6217, 2004.
PubMed
12) Baldacci F, et al : Occurrence of Takotsubo syndrome in a patient with Parkinson's disease after entacapone add-on. Parkinsonism Relat Disord 20 : 1313-1314, 2014.
 
13) Li J, et al : Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation : A Systematic Meta-Analysis. Eur Neurol 78 : 143-153, 2017.
PubMed
14) Haasio K, et al : Effects of entacapone and tolcapone on mitochondrial rnembrane potential. Eur J Pharmacol 453 : 21-26, 2002.
PubMed
15) Di Giovanni S, et al : Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem 285 : 14941-14954, 2010.
PubMed
16) Rocha JF, et al : Opicapone : a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 76 : 763-775, 2013.
 
17) Paulini R, et al : Bisubstrate inhibitors of catechol O-methyltransferase (COMT) : the crucial role of the ribose structural unit for inhibitor binding affinity. Chem Med Chem 1 : 340-357, 2006.
PubMed
18) Apud JA, et al : Treatment of cognitive deficits associated with schizophrenia : potential role of catechol-O-methyltransferase inhibitors. CNS Drugs 21 : 535-557, 2007.
PubMed
P.493 掲載の参考文献
1) Birkmayer W, et al : Weitere experimentelle Untersuchungen uber den Catecholamin-stoffwechsel bei extrapyramidalen Erkrankungen. Arch Psychiat Z ges Neurol 210 : 29-35, 1967.
 
2) Cotzias GC : Levodopa in the treatment of Parkinsonism. JAMA 218 : 1903-1908, 1971.
PubMed
3) Marsden CD, et al : A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet 2 : 1459-1462, 1973.
PubMed
4) Murata M, et al : Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson's disease patients. NPJ Parkinsons Dis 2 : 16020, 2016.
PubMed
5) Shoulson I, et al : Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease : a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51 : 604-612, 2002.
PubMed
6) Mizuno Y, et al : Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients. Mov Disord 22 : 75-80, 2007.
PubMed
7) Katzenschlager R, et al : Fourteen-year final report of the randomized PDRG-UK, trial comparing three initial treatments in PD. Neurology 71 : 474-480, 2008.
PubMed
8) Rascol O, et al : Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 21 : 1844-1850, 2006.
 
9) Arai A, et al : Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats. Brain Res 972 : 229-234, 2003.
PubMed
10) Sawada H, et al : Amantadine for dyskinesias in Parkinson's disease : a randomized controlled trial. PLoS ONE 5 : e15298, 2010.
PubMed
11) Pahwa R, et al : ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study) : A Randomized Clinical Trial. JAMA Neurol 74 : 941-949, 2017.
PubMed
12) Kim JM, et al : Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease : an open-label study. BMC Neurol 15 : 17, 2015.
PubMed
13) Hauser RA, et al : Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease. Mov Disord 29 : 1028-1034, 2014.
PubMed
14) Giladi N, et al : Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease : A Post Hoc Analysis. J Parkinsons Dis 6 : 401-411, 2016.
PubMed
15) Olanow CW, et al : A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. Mov Disord 32 : 783-789, 2017.
PubMed
P.500 掲載の参考文献
1) Poewe W, Antonini A : Novel formulations and modes of delivery of levodopa. Mov Disord 30 : 114-120, 2015.
PubMed
2) Ellis JM, Fell MJ : Current approaches to the treatment of Parkinson's Disease. Bioorg Med Chem Lett 27 : 4247-4255, 2017.
 
3) Magrinelli F, et al : Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinsons Dis 2016 : 9832839, 2016.
PubMed
4) Meidahl AC, et al : Adaptive Deep Brain Stimulation for Movement Disorders : The Long Road to Clinical Therapy. Mov Disord 32 : 810-819, 2017.
 
5) Tsuboi T, et al : Distinct phenotypes of speech and voice disorders in Parkinson's disease after subthalamic nucleus deep brain stimulation. J Neurol Neurosurg Psychiatry 86 : 856-864, 2015.
PubMed
6) Mak MK, et al : Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat Rev Neurol 13 : 689-703, 2017.
PubMed
7) Schneider RB, Biglan KM : The promise of telemedicine for chronic neurological disorders : the example of Parkinson's disease. Lancet Neurol 16 : 541-551, 2017.
PubMed
8) Olanow CW, et al : Clinical approaches to the development of a neuroprotective therapy for PD. Exp Neurol 298 : 246-251, 2017.
 
9) Wong YC, Krainc D : α-synuclein toxicity in neurodegeneration : mechanism and therapeutic strategies. Nat Med 23 : 1-13, 2017.
 
10) Valdes P, Schneider BL : Gene Therapy : A Promising Approach for Neuroprotection in Parkinson's Disease? Front Neuroanat 10 : 123, 2016.
PubMed
11) Dhivya V, Balachandar V : Cell replacement therapy is the remedial solution for treating Parkinson's disease. Stem Cell Investig 4 : 59, 2017.
PubMed
12) Kikuchi T, et al : Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. Nature 548 : 592-596, 2017.
 
13) Vaiserman AM, et al : Gut microbiota : A player in aging and a target for anti-aging intervention. Ageing Res Rev 35 : 36-45, 2017.
 
14) Gao F, et al : Mitophagy in Parkinson's Disease : Pathogenic and Therapeutic Implications. Front Neurol 8 : 527, 2017.
PubMed
15) Jiang P, Dickson DW : Parkinson's disease : experimental models and reality. Acta Neuropathol 135 : 13-32, 2018.
PubMed
P.508 掲載の参考文献
1) Silberstein P, et al : Patterning of globus pallidus local field potentials differs between Parkinson's disease and dystonia. Brain 126 : 2597-2608, 2003.
PubMed
2) Deep-Brain Stimulation for Parkinson's Disease Study Group ; Obeso JA, et al : Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 345 : 956-963, 2001.
PubMed
3) Charles PD, et al : Predictors of effective bilateral subthalamic nucleus stirnulation for PD. Neurology 59 : 932-934, 2002.
PubMed
4) Russmann H, et al : Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 63 : 1952-1954, 2004.
PubMed
5) Follett KA, et al : Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 362 : 2077-2091, 2010.
PubMed
6) Odekerken VJ, et al : Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study) : a randomised controlled trial. Lancet Neurol 12 : 37-44, 2013.
PubMed
7) Kempster PA, et al : Relationships between age and late progression of Parkinson's disease : a clinico-pathological study. Brain 133 : 1755-1762, 2010.
PubMed
8) Kempster PA, et al : Patterns of levodopa response in Parkinson's disease : a clinico-pathological study. Brain 130 : 2123-2128, 2007.
PubMed
9) Schuepbach WM, et al : Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 368 : 610-622, 2013.
PubMed
10) Witt K, et al : Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease : a randomised, multicentre study. Lancet Neurol 7 : 605-614, 2008.
PubMed
11) Fasano A, et al : Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 133 : 2664-2676, 2010.
PubMed
12) Floden D, et al : Predicting quality of life outcomes after subthalamic nucleus deep brain stimulation. Neurology 83 : 1627-1633, 2014.
PubMed
13) Lewis CJ, et al : Parkinson's disease patients with subthalamic stimulation and carers judge quality of life differently. Parkinsonism Relat Disord 20 : 514-519, 2014.
PubMed
14) Baba T, et al : Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease : a 3 year longitudinal study. Brain 135 : 161-169, 2012.
PubMed
15) Krack P, et al : Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349 : 1925-1934, 2003,
PubMed
16) Merola A, et al : Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease : a different long-term outcome? J Neurol Neurosurg Psychiatry 85 : 552-559, 2014.
PubMed
17) Castrioto A, et al : Ten-year outcome of subthalamic stimulation in Parkinson disease : a blinded evaluation. Arch Neurol 68 : 1550-1556, 2011.
PubMed
18) Lilleeng B, et al : Progression and survival in Parkinson's disease with subthalamic nucleus stirnulation. Acta Neurol Scand 130 : 292-298, 2014.
PubMed
19) Ngoga D, et al : Deep brain stimulation improves survival in severe Parkinson's disease. J Neurol Neurosurg Psychiatry 85 : 17-22, 2014.
PubMed
20) Weaver FM, et al : Randomized trial of deep brain stimulation for Parkinson disease : thirty-six-month outcomes. Neurology 79 : 55-65, 2012.
PubMed
21) Odekerken VJ, et al : GPi vs STN deep brain stimulation for Parkinson disease : Three-year follow-up. Neurology 86 : 755-761, 2016.
PubMed
22) Sako W, et al : Which target is best for patients with Parkinson's disease? Ameta-analysis of pallidal and subthalamic stimulation. J Neurol Neurosurg Psychiatry 85 : 982-986, 2014.
 
23) Liu Y, et al : Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease. J Neurosurg 121 : 709-718, 2014.
PubMed
24) Xie CL, et al : Effects of neurostimulation for advanced Parkinson' s disease patients on motor symptoms : A multiple-treatments meta-analysas of randomized controlled trials. Sci Rep 6 : 25285, 2016.
PubMed
25) Sako W, et al : On-period unified Parkinson's disease rating scale before surgery correlates with differences in outcomes between pallidal and subthalamic stimulation : ameta-analysis. Neurol Sci 37 : 135-137, 2016.
 
26) Bonenfant J, et al : Pallidal stimulation in Parkinson's patients with contraindications to subthalamic target : A 3 years follow-up. Parkinsonism Relat Disord 34 : 20-25, 2017.
 
27) Little S, et al : Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol 74 : 449-457, 2013.
PubMed
P.514 掲載の参考文献
1) Kitagawa M, et al : Two-year follow-up of chronic stimulation of the posterior subthalamic white matter for tremor-dominant Parkinson's disease. Neurosurgery 56 : 281-289, 2005.
PubMed
2) Plaha P, et al : Stimulation of the caudal zona incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. Brain 129 : 1732-1747, 2006.
PubMed
3) Katayama Y, et al : Direct effect of subthalamic nucleus stimulation on levodopa-induced peak-dose dyskinesia in patients with Parkinson's disease. Stereotact Funct Neurosurg 84 : 176-179, 2006.
PubMed
4) 深谷親, ほか : パーキンソン病に対する視床下核DBS. 機能的脳神経外科手術の基本-コツと注意点- (新井一編), p12-23, メジカルビュー社, 2011.
 
5) 深谷親, ほか : 定位・機能神経外科手術とモニタリング. 脳神経外科手術のコンパス-術中機能・画像情報モニタリングマニュアル- (森田明夫編), p158, メジカルビュー社, 2016.
 
6) 深谷親, 山本隆充 : 合併症のシステマティック・レビュー 適切なInformed Consentのために定位・機能的脳神経外科手術. Neurological Surgery 42 : 751-768, 2014.
 
P.521 掲載の参考文献
1) Rossi PJ, et al : Proceedings of the Third Annual Deep Brain Stimulation Think Tank : A Review of Emerging Issues and Technologies. Front Neurosci lO : 119, 2016. (doi : 10.3389/fnins. 2016. 00119)
 
2) Ashkan K, et al : Insights into the mechanisms of deep brain stimulation. Nat Rev Neurol 13 : 548-554, 2017.
PubMed
3) Tsuboi T, et al : Distinct phenotypes of speech and voice disorders in Parkinson's disease after subthalamic nucleus deep brain stimulation. J Neurol Neurosurg Psychiatry 86 : 856-864, 2015.
PubMed
4) Montgomery J, EB Jr : Deep Brain Stimulation Programming : Mechanisms, Principles and Practice, 2nd, ed, Oxford University Press, Oxford, 2016.
 
5) Baizabal-Carvallo JF, Alonso-Juarez M : Low-frequency deep brain stimulation for movement disorders. Parkinsonism Relat Disord 31 : 14-22, 2016.
PubMed
6) di Biase L, Fasano A : Low-frequency deep brain stimulation for Parkinson's disease : Great expectation or false hope? Mov Disord 31 : 962-967, 2016.
 
7) Steigerwald F, et al : Directional deep brain stimulation of the subthalamic nucleus : A pilot study using a novel neurostimulation device. Mov Disord 31 : 1240-1243, 2016.
PubMed
8) Reich MM, et al : Short pulse width widens the therapeutic window of subthalamic neurostimulation. Ann Clin Transl Neurol 2 : 427-432, 2015.
PubMed
9) Odekerken VJ, et al : Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study) : a randomised controlled trial. Lancet Neurol 12 : 37-44, 2013.
PubMed
10) Williams NR, et al : STN vs. GPi Deep Brain Stimulation : Translating the Rematch into Clinical Practice. Mov Disord Clin Pract 1 : 24-35, 2014.
PubMed
11) Vora AK, et al : Rebound symptoms following battery depletion in the NIH OCD DBS cohort : clinical and reimbursement issues. Brain Stimul 5 : 599-604, 2012.
PubMed
12) Neuneier J, et al : Malignant deep brain stimulation-withdrawal syndrome in a patient with Parkinson's disease. Mov Disord 28 : 1640-1641, 2013.
 
P.527 掲載の参考文献
1) Borovac JA : Side effects of a dopamine agonist therapy for Parkinson's disease : a mini-review of clinical pharmacology. Yale J Biol and Med 89 : 37-47, 2016.
PubMed
2) 大山彦光, 服部信孝 : Device-aided therapy. Medical Practice 35 : 457-462, 2018.
Medical*Online
3) Wirdefeldtl K, Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease : A Systematic Review. CNS Drugs 30 : 381-404, 2016.
 
4) Nyholm D, et al : Optimizing levodopa pharmacokinetics : intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 26 : 156-163, 2003.
PubMed
5) Nyholm D, et al : Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64 : 216-223, 2005.
PubMed
6) Olanow CW, et al : Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease : a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13 : 141-149, 2014.
PubMed
7) Murata M, et al : Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson's disease patients. NPJ Parkinsons Dis 2 : 16020, 2016.
PubMed
8) Nyholma D, et al : Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol 19 : 1079-1085, 2012.
 
9) Chang FCE, et al : Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. J Clin Neurosci 25 : 41-45, 2016.
 
10) Merola A, et al : Advanced therapies in Parkinson's disease : Long-term retrospective study. Parkinsonism Relat Disord 29 : 104-108, 2016.
PubMed
P.533 掲載の参考文献
1) 長谷川一子 : パーキンソン病の基礎と臨床の最先端. パーキンソン病新薬紹介 Dudopa. 脳21 19 : 408-410, 2016.
 
2) 日本消化器内視鏡学会 (監修) : 消化器内視鏡ハンドブック (日本消化器内視鏡学会卒後教育委員会編), p288-295, 日本メディカルセンター, 2012.
 
3) 合田文則 : 胃ろう [PEG] 管理のすべて (合田文則編), p36-41, 医歯薬出版, 2010.
 
4) 高橋美香子 : 内視鏡的胃瘻造設術のコツとトラブル対策. 日本消化器内視鏡学会雑誌 56 : 2198-2210, 2014.
 
5) 中谷吉宏, ほか : PEG手技のトラブルシューティング. 日本消化器内視鏡学会雑誌 53 : 1650-1663, 2011,
 
P.539 掲載の参考文献
1) Rossi S, et al : Safety, ethical considerations, and application guidelines for theuse of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 120 : 2008-2039, 2009.
 
2) Ben-Shachar D, et al : Transcranial magnetic stimulation induces alterations in brain monoamines. J Neural Transm (Vienna) 104 : 191-197, 1997.
PubMed
3) Keck ME, et al : Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system. Neuropharmacology 43 : 101-109, 2002.
PubMed
4) Strafella AP, et al : Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain 126 : 2609-2615, 2003.
PubMed
5) Ohnishi T, et al : Endogenous dopamine release induced by repetitive transcranial magnetic stimulation over the primary motor cortex : an [11C] raclopride positron emission tomography study in anesthetized macaque monkeys. Biol Psychiatry 55 : 484-489, 2004.
PubMed
6) Koch G : Do studies on cortical plasticity provide a rationale for using non invasive brain stimulation as a treatment for Parkinson's disease patients? Front in Neurol 4 : 180, 2013.
PubMed
7) Yang X, et al : The effect of repetitive transcranial magnetic stimulation on a model rat of Parkinson's disease. Neuroreport 21 : 268-272, 2010.
 
8) Fregni F, Wichmann T : Non-invasive brain stimulation for Parkinson's disease : a systematic review and meta-analysis of the literature. J Neurol Neurosurg Psychiatry 76 : 1614-1623, 2005.
 
9) Elahi B, Chen R : Effect of transcranial magnetic stimulation on Parkinson motor function-systematic review of controlled clinical trials. Mov Disord 24 : 357-363, 2009.
PubMed
10) Alexander GE, et al : Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9 : 357-381, 1986.
PubMed
11) DeLong MR, et al : Circuits and circuit disorders of the basal ganglia. Arch Neurol 64 : 20-24, 2007.
PubMed
12) Hamada M, et al : High-frequency rTMS over the supplementary motor area for treatment of Parkinson's disease. Mov Disord 23 : 1524-1531, 2008.
PubMed
13) Hamada M, et al : High-frequency rTMS over the supplementary motor area improves bradykinesia in Parkinson's disease : subanalysis of double-blind sham-controlled study. J Neurol Sci 287 : 143-146, 2009.
PubMed
14) Shirota Y, et al : Supplementary motor area stimulation for Parkinson disease : a randomized controlled study. Neurology 80 : 1400-1405, 2013.
PubMed
P.543 掲載の参考文献
1) Pittenger MF, et al : Multilineage potential of adult human mesenchymal stem cells. Science 284 : 143-147, 1999.
PubMed
2) Olanow CW, et al : Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 19 : 102-109, 1996.
 
3) Freed CR, et al : Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 : 710-719, 2001.
PubMed
4) Olanow CW, et al : A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 : 403-414, 2003.
PubMed
5) Singh M, et al : Synergistic Effect of BDNF and FGF2 in Efficient Generation of Functional Dopaminergic Neurons from human Mesenchymal Stem Cells. Sci Rep 7 : 10378, 2017.
PubMed
6) Fu YS, et al : Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro : potential therapeutic application for Parkinsonism. Stem Cells 24 : 115-124, 2006.
PubMed
7) Li Y, et al : Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett 316 : 67-70, 2001.
 
8) Kuroda Y, et al : Bone marrow mesenchymal cells : how do they contribute to tissue repair and are they really stem cells? Arch Immunol Ther Exp (Warsz) 59 : 369-378, 2011.
PubMed
9) Dezawa M, et al : Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 113 : 1701-1710, 2004.
PubMed
10) Hayashi T, et al : Autologous mesenchymal stem cell-derived dopaminergic neurons function in parkinsonian macaques. J Clin Invest 123 : 272-284, 2013.
PubMed
11) Venkataramana NK, et al : Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Transl Res 155 : 62-70, 2010.
PubMed
12) Blandini F, et al : Transplantationof undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant 19 : 203-217, 2010.
 
13) Kim YJ, et al : Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action. Glia 57 : 13-23, 2009.
PubMed
14) Choi HS, et al : Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson's disease. Neurobiol Aging 36 : 2885-2892, 2015.
PubMed
15) Glavaski-Joksimovic A, Bohn MC : Mesenchymal stem cells and neuroregeneration in Parkinson's disease. Exp Neurol 247 : 25-38, 2013.
PubMed
P.548 掲載の参考文献
1) Freed CR, et al : Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 : 710-719, 2001.
PubMed
2) Olanow CW, et al : A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 : 403-414, 2003.
PubMed
3) Piccini P, et al : Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128 : 2977-2986, 2005.
PubMed
4) Barker RA, Widner H : Immune problems in central nervous system cell therapy. NeuroRx 1 : 472-481, 2004.
PubMed
5) Hagell P, Brundin P : Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol 60 : 741-752, 2001.
PubMed
6) Hardman CD, et al : Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans : volume and neuronal number for the output, internal relay, and striatal modulating nuclei. J Comp Neurol 445 : 238-255, 2002.
PubMed
7) Kefalopoulou Z, et al : Long-term clinical outcome of fetal cell transplantation for Parkinson disease : two case reports. JAMA Neurol 71 : 83-87, 2014.
PubMed
8) Li W, et al : Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci USA 113 : 6544-6549, 2016.
PubMed
9) Politis M, et al : Graft-induced dyskinesias in Parkinson's disease : High striatal serotonin/dopamine transporter ratio. Mov Disord 26 : 1997-2003, 2011.
PubMed
10) Barker RA, et al : Cell-based therapies for Parkinson disease-past insights and future potential. Nat Rev Neurol 11 : 492-503, 2015.
PubMed
11) Morizane A, et al : Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports 1 : 283-292, 2013.
PubMed
12) Morizane A, et al : MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat Commun 8 : 385, 2017.
PubMed
13) Doi D, et al : Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports 2 : 337-350, 2014.
PubMed
14) Kikuchi T, et al : Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. Nature 548 : 592-596, 2017.
 
15) Barker RA, et al : Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease : Dawn of a New Era. Cell Stem Cell 21 : 569-573, 2017.
PubMed
P.554 掲載の参考文献
1) Dunbar CE, et al : Gene therapy comes of age. Science 359 : 2018.
PubMed
2) 村松慎一 : パーキンソン病の遺伝子治療. 日本臨牀 75 : 146-150, 2017.
Medical*Online
3) Hastie E, Samulski RJ : Adeno-associated virus at 50 : agolden anniversary of discovery, research, and gene therapy success-a personal perspective. Hum Gene Ther 26 : 257-265, 2015.
 
4) Sehara Y, et al : Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's Disease. Hum Gene Ther Clin Dev 28 : 74-79, 2017.
 
5) The Journal of Gene Medicine, Clinical Trials Database. [http://www.wiley.com/legacy/wileychi/genmed/clinical/ (accessed Jan 25, 2018)]
 
6) Palfi S, et al : Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease : a dose escalation, open-label, phase 1/2 trial. Lancet 383 : 1138-1146. 2014.
PubMed
7) Nagatsu T, Sawada M : Biochemistry of postmortem brains in Parkinson's disease : historical overview and future prospects. J Neural Transm Suppl 72 : 113-120, 2007.
PubMed
8) Christine CW, et al : Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73 : 1662-1669, 2009.
PubMed
9) Muramatsu S, et al : A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 18 : 1731-1735, 2010.
PubMed
10) Hwu WL, et al : Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med 4 : 134ra61, 2012.
PubMed
11) Chien YH, et al : Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency : an open-label, phase l/2 trial. Lancet Child Adolesc Health 1 : 265-273, 2017.
PubMed
12) Muramatsu S, et al : Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13 : 345-354, 2002.
 
13) Marks WJ, et al : Gene delivery of AAV2-neurturin for Parkinson's disease : a double-blind, randomised, controlled trial. Lancet Neurol 9 : 1164-1172, 2010.
PubMed
14) LeWitt PA, et al : AAV2-GAD gene therapy for advanced Parkinson's disease : a double-blind, shamsurgery controlled, randomised trial. Lancet Neurol 10 : 309-319, 2011.
PubMed
15) Iida A, et al : Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice. Biomed Res Int 2013 : 974819, 2013.
PubMed
P.559 掲載の参考文献
1) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197-211, 2003.
PubMed
2) Polymeropoulos MH, et al : Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 : 2045-2047, 1997.
PubMed
3) Singleton AB, et al : alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 : 841, 2003,
PubMed
4) Fire A, et al : Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 : 806-811, 1998.
PubMed
5) Sapru MK, et al : Silencing of human alpha-synuclein in vitro and in rat brain using lentiviralmediated RNAi. Exp Neurol 198 : 382-390, 2006.
PubMed
6) Gorbatyuk OS, et al : In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther 18 : 1450-1457, 2010.
PubMed
7) Zharikov AD, et al : shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. J Clin Invest 125 : 2721-2735, 2015.
 
8) Fountaine TM, et al : The effect of alpha-synuclein knockdown on MPP+toxicity in models of human neurons. Eur J Neurosci 28 : 2459-2473, 2008.
PubMed
9) Yahara A, et al : Amido-bridged nucleic acids (AmNAs) : synthesis, duplex stability, nuclease resistance, and in vitro antisense potency. Chembiochem 13 : 2513-2516, 2012.
PubMed
10) Mendell JR, et al : Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74 : 637-647, 2013.
 
11) Finkel RS, et al : Treatment of infantile-onset spinal muscular atrophy with nusinersen : a phase 2, open-label, dose-escalation study. Lancet 388 : 3017-3026, 2016.
PubMed
12) Hache M, et al : Intrathecal Injections in Children With Spinal Muscular Atrophy : Nusinersen Clinical Trial Experience. J Child Neurol 31 : 899-906, 2016.
PubMed
P.563 掲載の参考文献
1) Keus SH, et al : Physical therapy in Parkinson's disease : evolution and future challenges. Mov Disord 24 : 1-14, 2009.
PubMed
2) Jain SS, Kirshblum SC : Parkinson's disease and other movement disorders. In : Rehabilitation Medicine : Principles and Practice, 3rd ed (ed by Delisa JA, et al, p1035-1056, Lippincott, Philadelphia, 1998.
 
3) Keus SH, et al : Evidence-based analysis of physical therapy in Parkinson's disease with recommendations for practice and research. Mov Disord 22 : 451-460 ; quiz 600, 2007.
PubMed
4) Tomlinson CL, et al : Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev (9) : CD002817.
 
5) Bloem BR, et al : Nonpharmacological treatments for patients with Parkinson's disease. Mov Disord 30 : 1504-1520, 2015.
PubMed
6) Frazzitta G, et al : Intensive rehabilitation increases BDNF serum levels in parkinsonian patients : a randomized study. Neurorehabil Neural Repair 28 : 163-168, 2014.
PubMed
7) Petzinger GM, et al : Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease. Lancet Neurol 12 : 716-726, 2013.
PubMed
8) Shulman LM, et al : Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. JAMA Neurol 70 : 183-190, 2013.
PubMed
9) Frazzitta G, et al : Intensive rehabilitation treatment in early Parkinson's disease : a randomized pilot study with a 2-year follow-up. Neurorehabil Neural Repair 29 : 123-131, 2015.
PubMed
10) Corcos DM, et al : Atwo-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord 28 : 1230-1240, 2013.
 
11) Sturkenboom IH, et al : The impact of occupational therapy in Parkinson's disease : a randomized controlled feasibility study. Clin Rehabil 27 : 99-112, 2013.
PubMed
12) Foster ER, et al : Systematic review of the effectiveness of occupational therapy-related interventions for people with Parkinson's disease. Am J Occup Ther 68 : 39-49, 2014.
PubMed
13) Russell JA, et al : Targeted exercise therapy for voice and swallow in persons with Parkinson's disease. Brain Res 1341 : 3-11, 2010.
PubMed
14) Fox C, et al : LSVT LOUD and LSVT BIG : Behavioral Treatment Programs for Speech and Body Movement in Parkinson Disease. Parkinsons Dis 2012 : 391946, 2012.
PubMed
P.569 掲載の参考文献
1) Thaut MH, et al : Rhythmic auditory stimulation in gait training for Parkinson's disease patients. Mov Disord 11 : 193-200, 1996.
PubMed
2) 林維菊, ほか : パーキンソン病の歩行障害に対する音リズム刺激の効果の検討. 運動障害 8 : 1-6, 1998.
Medical*Online
3) 林明人 : パーキンソン病. 医学的音楽療法-基礎と臨床-, p128-140, 北大路書房, 2014.
 
4) Satoh M, Kuzuhara S : Training in mental singing while walking improves gait disturbance in Parkinson's disease patients. Eur Neurol 60 : 237-243, 2008.
PubMed
5) 大塚祐一 : パーキンソン病患者に対する音楽療法の効果-歌唱が肺機能に与える影響-. 音楽療法研究 5 : 45-50, 2000.
 
6) Haneishi E : Effects of a music therapy voice protocol on speech intelligibility, vocal acoustic measures, and mood of individuals with Parkinson's disease. J Music Ther 38 : 273-290, 2001.
PubMed
7) Pacchetti C, et al : Active music therapy in Parkinson's disease : an integrative method for motor and emotional rehabilitation. Psychosom Med 62 : 386-393, 2000.
PubMed
8) 服部優子, 服部達哉 : パーキンソン病に対する音楽療法-UPDRS, QOL, 呼吸機能に及ぼす長期効果の検討-. 臨床神経学 46 : 1014, 2006.
 
9) 服部優子 : 訪問音楽療法-神経難病患者に対する実践-. 日本在宅医学会雑誌 13 : 81-87, 2012.
 
10) 服部優子 : 音楽療法. レジデントのためのパーキンソン病ハンドブック (山本光利編), p166-175, 中外医学社, 2014.
 
11) 羽石英里 : 歌唱が呼吸・発声・構音機能に与える影響. パーキンソン病のための歌による発声リハビリテーション, p58-70, 春秋社, 2012.
 
12) Zhang S, et al : Can music-based movement therapy improve motor dysfunction in patients with Parkinson's disease? Systematic review and meta-analysis. Neurol Sci 38 : 1629-1636, 2017.
PubMed
13) Sihvonen AJ, et al : Music-based interventions in neurological rehabilitation. Lancet Neurol 16 : 648-660, 2017.
PubMed
P.575 掲載の参考文献
1) 神経変性疾患領域における基盤的調査研究班 : パーキンソン病, 診断・治療指針 (医療従事者向け), 2017. [http://www.nanbyou.or.jp/entry/314] (2018年3月16日アクセス)
 
2) Fahn S, et al : Levodopa and the progression of Parkinson's disease. N Engl J Med 351 : 2498-2508, 2004.
PubMed
3) Ebersbach G, et al : Comparing exercise in Parkinson's disease-the Berlin LSVTBIG study. Mov Disord 25 : 1902-1908, 2010.
PubMed
4) Li F, et al : Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med 366 : 511-519, 2012.
PubMed
5) Zafar M, et al : Adapted Tango improves aspects of participation in older adults versus individuals with Parkinson's disease. Disabil Rehabil 39 : 2294-2301, 2017.
PubMed
6) Mehrholz J, et al : Treadmill training for patients with Parkinson's disease. Cochrane Database Syst Rev (9) : CD007830, 2015.
 
7) Picelli A, et al : Robot-assisted gait training versus equal intensity treadmill training in patients with mild to moderate Parkinson's disease : a randomized controlled trial. Parkinsonism Relat Disord 19 : 605-610, 2013.
 
8) サイバーダイン : HAL医療用下肢タイプ添付文書. 2016. [https://www.cyberdyne.jp/products/pdf/HT010910A-U01_R1.pdf] (2018年3月16日アクセス)
 

VI 治療上の問題点と対策

P.584 掲載の参考文献
1) Ahlskog JE, Muenter MD : Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 : 448-458, 2001.
PubMed
2) Stacy M, Hauser R : Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease. J Neural Transm (Vienna) 114 : 211-217, 2007.
PubMed
3) Witjas T, et al : Nonmotor fluctuations in Parkinson's disease : frequent and disabling. Neurology 59 : 408-413, 2002.
PubMed
4) Seki M, et al : Clinical features and varieties of non-motor fluctuations in Parkinson's disease : a Japanese multicenter study. Parkinsonism Relat Disord 19 : 104-108, 2013.
 
5) Warren Olanow C, et al : Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 28 : 1064-1071, 2013.
PubMed
6) Parkinson Study Group : Pramipexole vs levodopa as initial treatment for Parkinson disease : A randomized controlled trial. Parkinson Study Group. JAMA 284 : 1931-1938, 2000.
 
7) Rascol O, et al : A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342 : 1484-1491, 2000.
PubMed
8) PD Med Collaborative Group ; Gray R, et al : Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED) : a large, open-label, pragmatic randomised trial. Lancet 384 : 1196-1205, 2014.
 
9) Murata M : Pharmacokinetics of L-dopa. J Neurol 253 (Suppl 3) : iii47-iii52, 2006.
 
10) Odin P, et al : Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease : Consensus from an international survey and discussion program. Parkinsonism Relat Disord 21 : 1133-1144, 2015.
PubMed
11) Schuepbach WM, et al : Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 368 : 610-622, 2013.
PubMed
12) Evans MA, et al : Gastric emptying rate in the elderly : implications for drug therapy. J Am Geriatr Soc 29 : 201-205, 1981.
PubMed
13) Pierantozzi M, et al : Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 66 : 1824-1829, 2006.
PubMed
14) 近藤智善, ほか : FPF1100 (塩酸セレギリン) のパーキンソン病患者に対する臨床的有用性 プラセボを対照とした二重盲検群間比較試験. 医学のあゆみ 177 : 157-231, 1996.
 
15) Politis M, et al : Parkinson's disease symptoms : the patient's perspective. Mov Disord 25 : 1646-1651, 2010.
PubMed
P.590 掲載の参考文献
1) Fahn S : The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 23 (Suppl 3) : S497-508, 2008.
 
2) Rascol O, et al : New treatments for levodopa-induced motor complications. Mov Disord 30 : 1451-1460, 2015.
PubMed
3) Ahlskog JE, Muenter MD : Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 : 448-458, 2001.
PubMed
4) Del Sorbo F, Albanese A : Levodopa-induced dyskinesias and their management. J Neurol 255 (Suppl 4) : 32-41, 2008.
 
5) Olanow CW, et al : Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 28 : 1064-1071, 2013.
 
6) Sato K, et al : Prognosis of Parkinson's disease : time to stage III, IV, V, and to motor fluctuations. Mov Disord 21 : 1384-1395, 2006.
 
7) Fox SH, Lang AE : Levodopa-related motor complications-phenomenology. Mov Disord 23 (Suppl 3) : S509-514, 2008.
 
8) Olanow CW, et al : Continuous dopamine-receptor treatment of Parkinson's disease : scientific rationale and clinical implications. Lancet Neurol 5 : 677-687, 2006.
PubMed
9) Tomiyama M : [Symptoms and Pathophysiology of Dyskinesias]. Brain Nerve 69 : 1409-1416, 2017.
PubMed
10) Cheshire PA, Williams DR : Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. J Clin Neurosci 19 : 343-348, 2012.
 
11) 田代淳, 菊地誠志 : CDSとCDDの概念と今後の展望. 特集 : パーキンソン病治療の最新動向. Pharma Medica 30 (suppl 4) : 8-11, 2012.
 
12) NICE guideline : Parkinson's disease in adults, 2017. [https://www.nice.org.uk/guidance/ng71/chapter/Recommendations] (2018年2月閲覧)
 
13) PD Med Collaborative Group ; Gray R, et al : Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED) : a large, open-label, pragmatic randomised trial. Lancet 384 : 1196-1205, 2014.
 
14) 「パーキンソン病治療ガイドライン」作成委員会 (編), 日本神経学会 (監修) : CQ2-5 ジスキネジアの治療はどうするか. 第2章 運動症状の薬物治療. 第II編 クリニカル・クエスチョン. パーキンソン病治療ガイドライン 2011, 医学書院, 2011.
 
15) Antonini A, et al : Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. Mov Disord 31 : 530-537, 2016.
PubMed
16) Odin P, et al : Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease : Consensus from an international survey and discussion program. Parkinsonism Relat Disord 21 : 1133-1144, 2015.
PubMed
P.596 掲載の参考文献
1) Meyer JS, Barron DW : Apraxia of gait : a clinico-physiological study. Brain 83 : 261-284, 1960.
 
2) Nonnekes J, et al : Freezing of gait : a practical approach to management. Lancet Neurol 14 : 768-778, 2015.
 
3) Giladi N, et al : Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Mov Disord 24 : 655-661, 2009.
PubMed
4) Nieuwboer A, et al : Reliability of the new freezing of gait questionnaire : agreement between patients with Parkinson's disease and their carers. Gait Posture 30 : 459-463, 2009.
PubMed
5) 柳澤信夫 : 日本におけるParkinson病運動障害治療研究の歴史と展望. 神経治療学 32 : 22-34, 2015.
Medical*Online
6) Plotnik M, et al : Is freezing of gait in Parkinson's disease related to asymmetric motor function? Ann Neurol 57 : 656-663, 2005.
PubMed
7) 水野真由子, ほか : パーキンソン病患者におけるステップ運動の運動学的解析. 臨床神経学 50 : 74-80, 2010.
 
8) 「パーキンソン病治療ガイドライン」作成委員会 (編) : すくみ足の治療をどうするか? パーキンソン病治療ガイドライン 2011, p114-117, 医学書院, 2011.
 
9) Giladi N, et al : Freezing of gait in PD : prospective assessment in the DATATOP cohort. Neurology 56 : 1712-1721, 2001.
PubMed
10) Fukada K, et al : L-threo-3, 4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease. Med Hypotheses 80 : 209-212, 2013.
PubMed
11) Chung KA, et al : Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 75 : 1263-1269, 2010.
PubMed
12) Moreau C, et al : Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation : a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 11 : 589-596, 2012.
PubMed
13) Devos D, et al : Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 24 : 993-1000, 2009.
PubMed
14) Gurevich T, et al : The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease : a double blind placebo-controlled pilot study. Mov Disord 22 : 880-883, 2007.
PubMed
15) Vercruysse S, et al : Effects of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease : a prospective controlled study. J Neurol Neurosurg Psychiatry 85 : 871-877, 2014.
PubMed
16) Wang JW, et al : Deep Brain Stimulation of Pedunculopontine Nucleus for Postural Instability and Gait Disorder After Parkinson Disease : A Meta-Analysis of Individual Patient Data. World Neurosurg 102 : 72-78, 2017.
PubMed
17) 山永裕明, 野尻晋一 : 住宅生活支援事例 (1) 早期経過例. パーキンソン病の理解とリハビリテーション, p92-95, 三輪書店, 2010.
 
18) Barthel C, et al : The laser shoes : A new ambulatory device to alleviate freezing of gait in Parkinson disease. Neurology 90 : e164-e171, 2018.
PubMed
P.601 掲載の参考文献
1) van de Warrenburg BP, et al : The phenomenon of disproportionate antecollis in Parkinson's disease and multiple system atrophy. Mov Disord 22 : 2325-2331, 2007.
PubMed
2) Kashihara K, et al : Dropped head syndrome in Parkinson's disease. Mov Disord 21 : 1213-1216, 2006.
PubMed
3) Azher SN, Jankovic J : Camptocormia : pathogenesis, classification, and response to therapy. Neurology 65 : 355-359, 2005.
PubMed
4) Bonanni L, et al : Botulinus toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord 22 : 2097-2103, 2007.
 
5) Proctor F, et al : Judgment of visual and postural vertical by parkinsonian patients. Neurology 14 : 287-293, 1964.
PubMed
6) Abe K, et al : Camptocormia in Parkinson's disease. Parkinsons Dis 2010 ; published by online june 30. DOI : 10.4061/2010/26764
 
7) Ungerstedt U, et al : Direct chemical stimulation of dopaminergic mechanisms in the neostriatum of the rat. Brain Res 14 : 461-471, 1969.
PubMed
8) Herrera-Marschitz M, et al : Scoliosis in rats with experimentally-induced hemiparkinsonism : dependence upon striatal dopamine denervation. J Neurol Neurosurg Psychiatry 53 : 39-43, 1990.
PubMed
9) van de Warrenburg BP, et al : Pisa syndrome after unilateral pallidotomy in Parkinson's disease : an unrecognised, delayed adverse event? J Neurol Neurosurg Psychiatry 78 : 329-330, 2007.
PubMed
10) Bonnevill F, et al : Camptocormia and parkinson's disease : MR imaging. Euro Radiol 18 : 1710-1719, 2008.
 
11) Duvoisin RC, Marsden CD : Note on the scoliosis of Parkinsonism. J Neurol Neurosurg Psychiatry 38 : 787-793, 1975.
PubMed
12) Broussolle E, et al : Contribution of Jules Froment to the study of parkinsonian rigidity. Mov Disord 22 : 909-914, 2007.
 
13) Burleigh A, et al : Levodopa reduces muscle tone and lower extremity tremor in Parkinson's disease. Can J Neurol Sci 22 : 280-285, 1995.
PubMed
14) Vanacore N, et al : Pisa syndrome in a cohort of Alzheimer's disease patients. Acta Neurol Scand 111 : 199-201, 2005.
 
P.606 掲載の参考文献
1) Tse L, et al : Neuroleptic Malignant Syndrome : A Review from a Clinically Oriented Perspective. Curr Neuropharmacol 13 : 395-406, 2015.
PubMed
2) Rossi AE, Disksen RT : Sarcoplasmic reticulum : the dynamic calcium governor of muscle. Muscle Nerve 33 : 715-731, 2006.
 
3) Stotz M, et al : Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication. Br J Anaesth 93 : 868-871, 2004.
PubMed
4) Gelenberg AJ, et al : A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J psychiatry 145 : 517-518, 1988.
 
5) Levenson JL : Neuroleptic malignant syndrome. Am J psychiatry 142 : 1137-1145, 1985.
PubMed
6) Pope HG, et al : Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 143 : 1227-1233, 1986.
 
7) Caroff SN, Mann SC : Neuroleptic malignant syndrome. Psychopharmacol Bull 24 : 25-29, 1988.
PubMed
8) Gurrera RJ, et al : An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 72 : 1222-1228, 2011.
PubMed
9) Sakkas P, et al : Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 27 : 381-384, 1991.
PubMed
10) Reulbach U, et al : Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 11 : R4, 2007.
PubMed
P.612 掲載の参考文献
1) Aarsland D, et al : Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 67 : 492-496, 1999.
PubMed
2) Aarsland D, et al : Neuropsychiatric symptoms in patients with Parkinson's disease and dementia : frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 78 : 36-42, 2007.
PubMed
3) Barone P, et al : The PRIAMO study : A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24 : 1641-1649, 2009.
PubMed
4) Global Parkinson's Disease Survey (GPDS) Steering Committee : Factors impacting on quality of life in Parkinson's disease : results from an international survey. Mov Disord 17 : 60-67, 2002.
 
5) Diederich NJ, et al : Hallucinations in Parkinson disease. Nat Rev Neurol 5 : 331-342, 2009.
PubMed
6) Kempster PA, et al : Relationships between age and late progression of Parkinson's disease : a clinico-pathological study. Brain 133 : 1755-1762, 2010.
PubMed
7) Lenka A, et al : Predictors of onset of psychosis in patients with Parkinson's disease : Who gets it early? Parkinsonism Relat Disord 44 : 91-94, 2017.
PubMed
8) パーキンソン病治療ガイドライン作成委員会 (編) : 幻覚・妄想の治療はどうするか. パーキンソン病治療ガイドライン 2011, p163-166, 医学書院, 2011.
 
9) Seppi K, et al : The Movement Disorder Society Evidence-Based Medicine Review Update : Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 26 (Suppl 3) : S42-80, 2011.
 
10) Antonini A, et al : The PRIAMO study : background, methods and recruitment. Neurol Sci 29 : 61-65, 2008.
PubMed
11) Barone P, et al : Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease : a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9 : 573-580, 2010.
PubMed
12) Troeung L, et al : A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease. PLoS ONE 8 : e79510, 2013.
PubMed
13) Wu PL, et al : Effectiveness of physical activity on patients with depression and Parkinson's disease : A systematic review. PLoS ONE 12 : e0181515, 2017.
PubMed
14) Graff-Radford J, et al : Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain 135 : 2470-2477, 2012.
PubMed
15) Rolinski M, et al : Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev (3) : CD006504, 2012.
PubMed
P.619 掲載の参考文献
1) Barone P, et al : The PRIAMO study : A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24 : 1641-1649, 2009.
PubMed
2) Maeda T, et al : Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson's disease patients from 35 medical centers. Parkinsonism Relat Disord 38 : 54-60, 2017.
PubMed
3) Prakash KM, et al : The impact of non-motor symptoms on the quality of life of Parkinson's disease patients : a longitudinal study. Eur J Neurol 23 : 854-860, 2016.
PubMed
4) Suzuki K, et al : Parkinson's disease and sleep/wake disturbances. Curr Neurol Neurosci Rep 15 : 8, 2015.
PubMed
5) Yong MH, et al : Case control polysomnographic studies of sleep disorders in Parkinson's disease. PLoS One 6 : e22511, 2011.
PubMed
6) Rodrigues TM, et al : Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease : Systematic review and meta-analysis. Parkinsonism Relat Disord 27 : 25-34, 2016.
PubMed
7) Tholfsen LK, et al : Changes in insomnia subtypes in early Parkinson disease. Neurology 88 : 352-358, 2017.
PubMed
8) Simuni T, et al : Correlates of excessive daytime sleepiness in de novo Parkinson's disease : A case control study. Mov Disord 30 : 1371-1381, 2015.
PubMed
9) Amara AW, et al : Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. J Neurol Neurosurg Psychiatry 88 : 653-662, 2017.
PubMed
10) Cochen De Cock V, et al : Daytime sleepiness in Parkinson's disease : a reappraisal. PLoS ONE 9 : elO7278, 2014.
PubMed
11) Chahine LM, et al : A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. Sleep Med Rev 35 : 33-50, 2017.
PubMed
12) Nomura T, et al : Characteristics of obstructive sleep apnea in patients with Parkinson's disease. J Neurol Sci 327 : 22-24, 2013.
PubMed
13) Zhou J, et al : Excessive Daytime Sleepiness Predicts Neurodegeneration in Idiopathic REM Sleep Behavior Disorder. Sleep 40, 2017. (doi : 10.1093/sleep/zsx041)
 
14) Postuma RB, et al : Insomnia and somnolence in idiopathic RBD : a prospective cohort study. NPJ Parkinsons Dis 3 : 9, 2017.
PubMed
15) Nomura T, et al : Clinical significance of REM sleep behavior disorder in Parkinson's disease. Sleep Med 14 : 131-135, 2013.
PubMed
P.624 掲載の参考文献
1) Antonini A, et al : Impulsivity and compulsivity in drug-naive patients with Parkinson's disease. Mov Disord 26 : 464-468, 2011.
PubMed
2) Voon V, et al : Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67 : 1254-1257, 2006.
PubMed
3) Seeman P : Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69 : 183-189, 2015.
PubMed
4) Gallagher DA, et al : Pathological gambling in Parkinson's disease : risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 22 : 1757-1763, 2007.
PubMed
5) Tanaka K, et al : Impulsive compulsive behaviors in Japanese Parkinson's disease patients and utility of the Japanese version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease. J Neurol Sci 331 : 76-80, 2013.
PubMed
6) Antonini A, et al : ICARUS study : prevalence and clinical features of impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry 88 : 317-324, 2017.
PubMed
7) Zhang Y, et al : Clinical characteristics of impulse control and related disorders in Chinese Parkinson's disease patients. BMC Neurol 17 : 98, 2017.
PubMed
8) Sarathchandran P, et al : Impulse control disorders and related behaviors in Indian patients with Parkinson's disease. Mov Disord 28 : 1901-1902, 2013.
PubMed
9) Grall-Bronnec M, et al : Dopamine Agonists and Impulse Control Disorders : A Complex Association. Drug Saf 41 : 19-75, 2018.
 
10) Kim YE, et al : Genetic susceptibility of impulse control and related behavior in Parkinson's disease. J Parkinsons Dis 4 : 261-272, 2014.
PubMed
11) Phu AL, et al : Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients. J Clin Neurosci 21 : 63-66, 2014.
PubMed
12) Poletti M, et al : Alexithymia is associated with impulsivity in newly-diagnosed, drug-naive patients with Parkinson's disease : an affective risk factor for the development of impulse-control disorders? J Neuropsychiatry Clin Neurosci 24 : E36-37, 2012.
PubMed
13) Ricciardi L, et al : Impulsive compulsive behaviours in Parkinson's disease : patients' versus caregivers' perceptions. J Neurol 263 : 1019-1021, 2016.
PubMed
14) Weintraub D, et al : Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 24 : 1461-1467, 2009.
PubMed
15) Wu K, et al : Problematic Internet use in Parkinson's disease. Parkinsonism Relat Disord 20 : 482-487, 2014.
PubMed
16) Rabinak CA, et al : Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 67 : 58-63, 2010.
PubMed
17) Rizos A, et al : A European multicentre survey of impulse controi behaviours in Parkinson's disease patients treated with short-and long-acting dopamine agonists. Eur J Neurol 23 : 1255-1261, 2016.
 
18) Mamikonyan E, et al : Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 23 : 75-80, 2008.
PubMed
19) Lyons KE, et al : Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol 33 : 5-10, 2010.
PubMed
20) Thomas A, et al : Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68 : 400-404, 2010.
PubMed
21) Weintraub D, et al : Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68 : 963-968, 2010.
PubMed
22) Walsh RA, Lang AE : Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. Mov Disord 27 : 326, 2012.
PubMed
23) Kasemsuk C, et al : Management of impulse control disorders with deep brain stimulation : A double-edged sword. J Neurol Sci 374 : 63-68, 2017.
 
24) Rossi PJ, et al : Measures of impulsivity in Parkinson's disease decrease after DBS in the setting of stable dopamine therapy. Parkinsonism Relat Disord 44 : 13-17, 2017.
PubMed
25) Todorova A, et al : Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease : Clinical Experience After 3 Years' Follow-up. Clin Neuropharmacol 38 : 132-134, 2015.
PubMed
26) Zhang S, et al : Management of impulse control disorders in Parkinson's disease. Int Psychogeriatr 28 : 1597-1614, 2016.
PubMed
27) Kehagia AA, et al : Targeting impulsivity in Parkinson's disease using atomoxetine. Brain 137 (Pt 7) : 1986-1997, 2014.
 
28) Bermejo PE : Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 14 : 448-449, 2008.
PubMed
29) Hicks CW, et al : Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease. Parkinsonism Relat Disord 17 : 379-381, 2011.
PubMed
30) Bermejo PE, et al : Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 257 : 1682-1685, 2010.
PubMed
31) Ivanco LS, Bohnen NI : Effects of donepezil on compulsive hypersexual behavior in Parkinson disease : a single case study. Am J Ther 12 : 467-468, 2005.
PubMed
32) Okai D, et al : Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 80 : 792-799, 2013.
PubMed
P.631 掲載の参考文献
1) Zhang LM, Zhang XP : Investigation of Urination Disorder in Parkinson's disease. Chin Med J 128 : 2906-2912, 2015.
PubMed
2) Kavia RB, et al : Functional imaging and the central control of the bladder. J Comp Neurol 493 : 27-32, 2005.
PubMed
3) de Groat WC : Integrative control of the lower urinary tract : Preclinical perspective. Br J Pharmacol 147 (Suppl 2) : S25-40, 2006.
 
4) Sakakibara R, et al : SPECT imaging of the dopamine transporter with [ (123) I] -beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J Neurol Sci 187 : 55-59, 2001.
PubMed
5) Winge K, Fowler CJ : Bladder dysfunction in Parkinsonism : mechanisms, prevalence, symptoms, and management. Mov Disord 21 : 737-745, 2006.
PubMed
6) Sakakibara R, et al : Bladder function of patients with Parkinson's disease. Int J Urol 21 : 638-646, 2014.
PubMed
7) Sakakibara R, et al : A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol Urodyn 35 : 551-563, 2016.
PubMed
8) Kuno S, et al : Effects of pergolide on nocturia in Parkinson's disease : three female cases selected from over 400 patients. Parkinsonism Relat Disord 10 : 181-187, 2004.
PubMed
9) 日本排尿機能学会過活動膀胱診療ガイドライン作成委員会 (編) : 過活動膀胱診療ガイドライン [第2版], リッチヒルメディカル, 2015.
 
10) Verbaan D, et al : Patient-reported autonomic symptoms in Parkinson disease. Neurology 69 : 333-341, 2007.
PubMed
11) Braak H, et al : Idiopathic Parkinson's disease : possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) 110 : 517-536, 2003.
PubMed
12) Abbott RD, et al : Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57 : 456-462, 2001.
PubMed
13) 日本消化器病学会関連研究会慢性便秘の診断・治療研究会 (編) : 慢性便秘症診療ガイドライン 2017, 南江堂, 2017.
 
14) Rossi M, et al : Management of constipation in Parkinson's disease. Expert Opin Pharmacother 16 : 547-557, 2015.
PubMed
15) Ondo WG, et al : Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 78 : 1650-1654, 2012.
PubMed
P.649 掲載の参考文献
1) Masters WH, Johnson VE : Human Sexual Response, First published in 1966, Ishi Press International, New York, 2009.
 
2) Ottesen B, et al : Penile erection : possible role for vasoactive intestinal polypeptide as a neurotransmitter. Br Med J (Clin Res Ed) 288 : 9-11, 1984.
PubMed
3) Andersson KE, Wagner G : Physiology of penile erection. Physiol Rev 75 : 191-236, 1995.
PubMed
4) Giuliano FA, et al : Neural control of penile erection. Urol Clin North Am 22 : 747-766, 1995.
PubMed
5) Carson CC, Lue TF : Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 96 : 257-280, 2005.
PubMed
6) McKenna KE, et al : A model for the study of sexual function in anesthetized male and female rats Am J Physiol 261 (5 pt 2) : R1276-1285, 1991.
 
7) Del Tredici K, Braak H : Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol 124 : 643-664, 2012.
PubMed
8) Giuliano FA, et al : Neural control of penile erection. Urol Clin North Am 22 : 747-766, 1995.
PubMed
9) Courtois F, et al : The control of male sexual responses. Curr Pharm Des 19 : 4341-4356, 2013.
 
10) Buijs RM, et al : The dopaminergic innervation of the supraoptic and paraventricular nucleus. A light and electron microscopical study. Brain Res 323 : 65-72, 1984.
PubMed
11) Lindvall O, et al : Selective histochemical demonstration of dopamine terminal systems in rat di- and telencephalon : new evidence for dopaminergic innervation of hypothalamic neurosecretory nuclei. Brain Res 306 : 19-30, 1984.
 
12) Carmichael MS, et al : Plasma oxytocin increases in the human sexual response. J Clin Endocrinol Metab 64 : 27-31, 1987.
PubMed
13) Carmichael MS, et al : Relationships among cardiovascular, muscular, and oxytocin responses during human sexual activity. Arch Sex Behav 23 : 59-79, 1994.
PubMed
14) Soulariac A, Soulariac ML : [Action of amphetamine, adrenalin and atropine on the sexual behavior of male rats]. J Physiol (Paris) 49 : 381-385, 1957.
PubMed
15) Bowers MB, et al : Sexual behavior during L-dopa treatment for Parkinsonism. Am J Psychiatry 127 : 1691-1693, 1971.
 
16) Uitti RJ, et al : Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12 : 375-383, 1989.
PubMed
17) Komisaruk BR, Diakow C : Lordosis reflex intensity in rats in relation to the estrous cycle, ovariectomy, estrogen administration and mating behavior. Endocrinology 93 : 548-557, 1973.
 
18) Marshall JF, et al : Sensory neglect produced by lateral hypothalamic damage. Science 174 : 523-525, 1971.
PubMed
19) Weder B, et al : Disturbed functional brain interactions underlying deficient tactile object discrimination in Parkinson's disease. Hum Brain Mapp 11 : 131-145, 2000.
PubMed
20) Pleim ET, et al : Correlation of dopamine release in the nucleus accumbens with masculine sexual behavior in rats. Brain Res 524 : 160-163, 1990.
PubMed
21) Pfaus JG, Phillips AG : Role of dopamine in anticipatory and consummatory aspects of sexual behavior in the male rat. Behav Neurosci 105 : 727-743, 1991.
PubMed
22) Melis MR, et al : Apomorphine-and oxytocin-induced penile erection and yawning in intact and castrated male rats : effect of sexual steroids. Neuroendocrinology 59 : 349-354, 1994.
PubMed
23) Dominguez JM, Hull EM : Dopamine, the medial preoptic area, and male sexual behavior. Physiol Behav 86 : 356-368, 2005.
PubMed
24) Holstege G, et al : Brain activation during human male ejaculation. J Neurosci 23 : 9185-9193, 2003.
PubMed
25) Kornisaruk BR, et al : Brain activation during vaginocervical self-stimulation and orgasm in women with complete spinal cord injury : fMRI evidence of mediation by the vagus nerves. Brain Res 1024 : 77-88, 2004.
 
26) Bellomo G, et al : Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's disease. J Neurol 238 : 19-22, 1991.
 
27) Hull EM, et al : Dopamine and serotonin : influences on male sexual behavior. Physiol Behav 83 : 291-307, 2004.
PubMed
28) Reece M, et al : Sexual behaviors, relationships, and perceived health among adult men in the United States : results from a national probability sample. J Sex Med 7 (Suppl 5) : 291-304, 2010.
 
29) Herbenick D, et al : Sexual behaviors, relationships, and perceived heaith status among adult women in the United States : results from a national probability sample. J Sex Med 7 (Suppl 5) : 277-290, 2010.
 
30) Bancroft JH : Sex and aging. N Engl J Med 357 : 820-822, 2007.
PubMed
31) Lindau ST, et al : A study of sexuality and health among older adults in the United States. N Engl J Med 357 : 762-774, 2007.
PubMed
32) Bronner G, et al : Sexual dysfunction in Parkinson's disease. J Sex Marital Ther 30 : 95-105, 2004.
PubMed
33) Brown RG, et al : Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry 53 : 480-486, 1990.
 
34) Pfeiffer RF : Gastrointestinal, urological, and sexual dysfunction in Parkinson's disease. Mov Disord (25 Suppl 1) : S94-97, 2010.
 
35) Jacobs H. et al : Sexuality in young patients with Parkinson's disease : apopulation based comparison with healthy controls. J Neurol Neurosurg Psychiatry 69 : 550-552, 2000.
 
36) Sakakibara R, et al : Genitourinary dysfunction in Parkinson's disease. Mov Disord 25 : 2-12, 2010.
PubMed
37) Bronner G : Sexual problems in Parkinson's disease : the multidimensional nature of the problem and of the intervention. J Neurol Sci 310 : 139-143, 2011.
PubMed
38) Hand A, et al : Sexual and relationship dysfunction in people with Parkinson's disease. Parkinsonism Relat Disord 16 : 172-176, 2010.
PubMed
39) Moore O, et al : Quality of sexual life in Parkinson's disease. Parkinsonism Relat Disord 8 : 243-246, 2002.
PubMed
40) Koller WC, et al : Sexual dysfunction in Parkinson's disease. Clin Neuropharmacol 13 : 461-463, 1990.
PubMed
41) Lipe H, et al : Sexual function in married men with Parkinson's disease compared to married men with arthritis. Neurology 40 : 1347-1349, 1990.
PubMed
42) Witjas T, et al : Nonmotor fluctuations in Parkinson's disease : frequent and disabling. Neurology 59 : 408-413, 2002.
PubMed
43) Kotkovii P, Weiss P : Psychiatric factors related to sexual functioning in patients with Parkinson's disease. Clin Neurol Neurosurg 115 : 419-424, 2013.
 
44) Kummer A, et al : Loss of libido in Parkinson's disease. J Sex Med 6 : 1024-1031, 2009.
PubMed
45) Wermuth L, Stenager E : Sexual aspects of Parkinson's disease. Semin Neurol 12 : 125-127, 1992.
PubMed
46) Singer C, et al : Autonomic dysfunction in men with Parkinson's disease. Eur Neurol 32 : 134-140, 1992.
PubMed
47) Porst H, et al : The Premature Ejaculation Prevalence and Attitudes (PEPA) survey : prevalence, comorbidities, and professional help-seeking. Eur Urol 51 : 816-823 ; discussion 824, 2007.
PubMed
48) Gao X, et al : Erectile function and risk of Parkinson's disease. Am J Epidemiol 166 : 1446-1450, 2007.
PubMed
49) Okun MS, et al : Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency : a common unrecognized comorbidity. Arch Neurol 59 : 807-811, 2002.
PubMed
50) Ready RE, et al : Testosterone deficiency and apathy in Parkinson's disease : a pilot study. J Neurol Neurosurg Psychiatry 75 : 1323-1326, 2004.
PubMed
51) Lewis RW, et al : Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med 7 : 1598-1607, 2010.
PubMed
52) Basson R : Sexuality and parkinson's disease. Parkinsonism Relat Disord 2 : 177-185, 1996.
PubMed
53) Rubin SM : Parkinson's disease in women. Dis Mon 53 : 206-213, 2007.
PubMed
54) Posen J, et al : Young women with PD : a group work experience. Soc Work Health Care 32 : 77-91, 2000.
PubMed
55) Schartau E, et al : Parkinson's disease : the effects on womanhood. Nurs Stand 17 : 33-39, 2003.
PubMed
56) Yahr MD, Duvoisin RC : Drug therapy of parkinsonism. N Engl J Med 287 : 20-24, 1972.
PubMed
57) Kanovsky P, et al : Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson's disease. J Neurol 249 : 112-114, 2002.
PubMed
58) Pohanka M, et al : Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease : the results of an open, prospective, 6-month follow-up. Eur J Neurol 11 : 483-488, 2004.
PubMed
59) O'Sullivan JD, Hughes AJ : Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 13 : 536-539, 1998.
PubMed
60) Segraves RT : Sexual dysfunction associated with antidepressant therapy. Urol Clin North Am 34 : 575-579, vii, 2007.
PubMed
61) Serretti A, Chiesa A : Sexual side effects of pharmacological treatment of psychiatric diseases. Clin Pharmacol Ther 89 : 142-147, 2011.
PubMed
62) 日本性機能学会, 日本泌尿器科学会 (編) : ED診療ガイドライン (第3版), リッチヒルメディカル, 2018.
 
63) Bronner G, Vodu§ek DB : Management of sexual dysfunction in Parkinson's disease. Ther Adv Neurol Disord 4 : 375-383, 2011.
 
64) Munhoz RP, et al : Increased frequency and range of sexual behavior in a patient with Parkinson's disease after use of pramipexole : a case report. J Sex Med 6 : 1177-1180, 2009.
 
65) Horita H, et al : Effects of levodopa on nocturnal penile tumescence : apreliminary study. J Androl 19 : 619-624, 1998.
 
66) Okun MS, et al : Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. Arch Neurol 59 : 1750-1753, 2002.
PubMed
P.656 掲載の参考文献
1) 中馬孝容, 小林庸子 : 滋賀県の理学療法士を対象としたパーキンソン病の理学療法に関するアンケート調査, 厚生労働科学研究費補助金 難治性疾患克服研究事業 希少性難治性疾患患者に関する医療の向上及び患者支援のあり方に関する研究 平成24年度 総括・分担研究報告書 平成25年3月, p134-136, 2013.
 
2) Akbar U, et al : Incidence and mortality trends of aspiration pneumonia in Parkinson's disease in the United States, 1979-2010. Parkinsonism Relat Disord 21 : 1082-1086, 2015.
PubMed
3) Simons JA, et al : Development and validation of a new screening questionnaire for dysphagia in early stages of Parkinson's disease. Parkinsonism Relat Disord 20 : 992-998, 2014.
PubMed
4) 日指志乃布, ほか : パーキンソン病における嚥下障害. 臨床神経学 56 : 550-554, 2016.
 
5) Moteiro L, et al : Swallowing impairment and pulmonary dysfunction in Parkinson's disease : the silent threats. J Neurol Sci 339 : 149-152, 2014.
 
6) Oh ES, et al : Autonomic and cognitive functions in Parkinson's disease (PD). Arch Gerontol, Geriatr 52 : 84-88, 2011.
PubMed
7) Hunter PC, et al : Response of parkinsonian swallowing dysfunction to dopaminergic stimulation. J Neurol Neurosurg Psychiatry 63 : 579-583, 1997.
PubMed
8) Ali GN, et al : Mechanisms of oral-pharyngeal dysphagia in patients with Parkinson's disease. Gastroenterology 110 : 383-392, 1996.
PubMed
9) 野崎園子 : パーキンソン病の摂食嚥下障害. Monthly Book Medical Rehabilitation (196) : 57-62, 2016.
Medical*Online
10) パーキンソン病治療ガイドライン 2011 (監修 : 日本神経学会, 編集 : 「パーキンソン病治療ガイドライン」作成委員会), 医学書院, 2011.
 
11) Nagaya M, et al : Videofluorographic observations on swallowing in patients with dysphagia due to neurodegenerative diseases. Nagoya J Med Sci 67 : 17-23, 2004.
PubMed
12) Troche MS, et al : Aspiration and swallowing in Parkinson disease and rehabilitation with EMST : a randomized trial. Neurology 75 : 1912-1919, 2010.
 
13) El Sharkawi A, et al : Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT) : a pilot study. J Neurol Neurosurg Psychiatry 72 : 31-36, 2002.
 
14) Miles A, et al : Effect of Lee Silverman Voice Treatment (LSVT LOUD(R)) on swallowing and cough in Parkinson's disease : A pilot study. J Neurol Sci 383 : 180-187, 2017.
 
15) 中馬孝容 : パーキンソン病のVisual View パーキンソン病のリハビリテーション. Frontiers in Parkinson Disease 5 : 22-26, 2012.
 
P.660 掲載の参考文献
1) パーキンソン病治療ガイドライン作成委員会 (編) : 第4章 非運動症状の治療 起立性低血圧の治療はどうするか, パーキンソン病治療ガイドライン 2011 (日本神経学会監修), p175-177, 医学書院, 2011.
 
2) Velseboer DC, et al : Prevalence of orthostatic hypotension in Parkinson's disease : a systematic review and meta-analysis. Parkinsonism Relat Disord 17 : 724-729, 2011.
PubMed
3) Espay AJ, et al : Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies : prioritisation of treatment targets. Lancet Neurol 15 : 954-966, 2016.
PubMed
4) Oh YS, et al : Association between nocturnal/supine hypertension and restless legs syndrome in patients with Parkinson's disease. J Neurol Sci 344 : 186-189, 2014.
PubMed
5) Freeman R, et al : Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21 : 69-72, 2011.
PubMed
6) Palma JA, et al : Orthostatic hypotension in Parkinson disease : how much you fall or how low you go? Mov Disord 30 : 639-645, 2015.
PubMed
7) Anang JB, et al : Predictors of dementia in Parkinson disease : a prospective cohort study. Neurology 83 : 1253-1260, 2014.
PubMed
8) Tanaka R, et al : Association between abnormal nocturnal blood pressure profile and dementia in Parkinson's disease. Parkinsonism Relat Disord 46 : 24-29, 2018.
PubMed
9) Centi J, et al : Effects of orthostatic hypotension on cognition in Parkinson disease. Neurology 88 : 17-24, 2017.
PubMed
10) Udow SJ, et al : 'Under pressure' : is there a link between orthostatic hypotension and cognitive impairment in α-synucleinopathies? J Neurol Neurosurg Psychiatry 87 : 1311-1321, 2016.
 
11) Goldstein DS, et al : Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension : independence from levodopa treatment. Hypertension 46 : 1333-1339, 2005.
PubMed
12) Gill SS, et al : Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors : a population-based cohort study. Arch Intern Med 169 : 867-873, 2009.
PubMed
13) Hauser RA, et al : Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord 30 : 646-654, 2015.
PubMed
14) 太田光一 : 非運動症状への対応起立性低血圧, Clinical Neuroscience 29 : 536-538, 2011.
 
15) 栗崎玲一 : 進化するパーキンソン病治療 Unmet needsとしての非運動症状とその対策 自律神経症状. Progress in Medicine 34 : 241-245, 2014.
Medical*Online
P.665 掲載の参考文献
1) Postuma RB, Berg D : Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12 : 622-634, 2016.
PubMed
2) Schapira AHV, et al : Non-motor features of Parkinson disease. Nat Rev Neurosci 18 : 435-450, 2017.
PubMed
3) Doty RL : Olfaction in Parkinson's disease and related disorders. Neurobiol Dis 46 : 527-552, 2012.
PubMed
4) Postuma RB, et al : MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30 : 1591-1601, 2015.
PubMed
5) Baba T, et al : Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease : a 3 year longitudinal study. Brain 135 : 161-169, 2012.
PubMed
6) Schrag A, et al : Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease : a cohort study. Lancet Neurol 16 : 66-75, 2017.
PubMed
7) Ansari KA, Johnson A : Olfactory function in patients with Parkinson's disease. J Chronic Dis 28 : 493-497, 1975.
PubMed
8) Iijima M, et al : Smell identification in Japanese Parkinson's disease patients : using the odor stick identification test for Japanese subjects. Intern Med 47 : 1887-1892, 2008.
PubMed
9) Iijima M, et al : Cardiac sympathetic degeneration correlates with olfactory function in Parkinson's disease. Mov Disord 25 : 1143-1149, 2010.
PubMed
10) Oka H, et al : Olfactory dysfunction and cardiovascular dysautonomia in Parkinson's disease. J Neurol 257 : 969-976, 2010.
PubMed
11) Suzuki M, et al : The odor stick identification test for Japanese differentiates Parkinson's disease from multiple system atrophy and progressive supra nuclear palsy. BMC Neurol 11 : 157, 2011.
PubMed
12) Izawa MO, et al : Combination of transcranial sonography, olfactory testing, and MIBG myocardial scintigraphy as a diagnostic indicator for Parkinson's disease. Eur J Neurol 19 : 411-416, 2012.
 
13) 飯嶋睦 : 神経変性疾患と嗅覚. 味嗅覚の科学 (斉藤幸子, 小早川達編), p168-174, 朝倉書店, 2018.
 
14) Watanabe Y, et al : A Card-type Odor Identification Test for Japanese Patients with Parkinson's Disease and Related Disorders. Intern Med 56 : 2871-2878, 2017.
PubMed
15) Iijima M, et al : Differences in Odor Identification among Clinical Subtypes of Parkinson's disease. Eur J Neurol 18 : 425-429, 2011.
PubMed
16) Ross GW, et al : Pre-motor features of Parkinson's disease : the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord 18 (Suppl 1) : S199-202, 2012.
 
17) Ross GW, et al : Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 63 : 167-173, 2008.
PubMed
18) Lerche S, et al : Risk factors and prodromal markers and the development of Parkinson's disease. J Neurol 261 : 180-187, 2014.
PubMed
19) Iijima M, et al : Odor identification function differs between vascular parkinsonism and akinetic-type Parkinson's disease. J Alzheimers Dis Parkinsonism 6 : 1-4, 2016.
 
20) Sengoku R, et al : Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J Neuropathol Exp Neurol 67 : 1072-1083, 2008.
PubMed
21) Saito Y, et al : Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders. Mov Disord 31 : 135-138, 2016.
PubMed
22) Sengoku R, et al : Olfactory function combined with morphology distinguishes Parkinson's disease. Parkinsonism Relat Disord 21 : 771-777, 2015.
PubMed
23) Yoneyama N, et al : Severe hyposmia and aberrant functional connectivity in cognitively normal Parkinson's disease. PLoS ONE 13 : e0190072, 2018.
PubMed
24) Haehner A, et al : Effects of rasagiline on olfactory function in patients with Parkinson's disease. Mov Disord 28 : 2023-2027, 2013.
PubMed
25) Chiu WH, et al : Selegiline normalizes, while L-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease. Neuropharmacology 79 : 212-221, 2014.
 
26) Petit GH, et al : Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease. PLoS ONE 8 : e60691, 2013.
 
27) Rosenfeldt AB, et al : Aerobic exercise preserves olfaction function in individuals with Parkinson's disease. Parkinsons Dis 2016 : 9725089, 2016.
PubMed
28) Fabbri M, et al : Subthalamic deep brain stimulation effects on odor identification in Parkinson's disease. Eur J Neurol 22 : 207-210, 2015.
PubMed
P.670 掲載の参考文献
1) Pritchett AM, et al : Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77 : 1280-1286, 2002.
PubMed
2) Flaherty KR, Bates JR : Mitral regurgitation caused by chronic ergotamine use. Am Heart J 131 : 603-606, 1996.
PubMed
3) Connolly HM, et al : Valvular heart disease associated with fen fluramine-phentermine. N Engl J Med 337 : 581-588, 1997.
 
4) Xu J, et al : Serotonin mechanisms in heart valve disease II : the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol 161 : 2209-2218, 2002.
PubMed
5) Kvernmo T, et al : A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28 : 1065-1078, 2006.
PubMed
6) Van Camp G, et al : Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363 : 1179-1183, 2004.
PubMed
7) 日本神経学会 : ドパミンアゴニスト使用上の注意, 2007年5月22日.
 
8) Yamamoto M, et al : Dopamine agonists and cardiac valvulopathy in Parkinson disease : a case-control study. Neurology 67 : 1225-1229, 2006.
PubMed
9) Rasmussen VG, et al : The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists. Mov Disord 26 : 801-806, 2011.
PubMed
10) Zenettini R, et al : Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc Ther 29 : 404-410, 2011.
 
11) Tan LC, et al : Bromocriptine use and the risk of valvular heart disease. Mov Disord 24 : 344-349, 2009.
PubMed
12) Tran T, et al : Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot-and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease : A Systematic Review of Observational Studies. CNS Drugs 29 : 985-998, 2015.
PubMed
13) 日本神経学会 (監修), パーキンソン病治療ガイドライン作成委員会 (編) : 抗パーキンソン病薬の副作用とその対策について-心臓弁膜症. パーキンソン病治療ガイドライン, p91-93, 医学書院, 2011.
 
14) Cosyns B, et al : Drug-induced valvular heart disease, Heart 99 : 7-12, 2013.
PubMed
15) Belmonte Y, et al : Pleuropulmonary Toxicity of Another Anti-Parkinson's Drug : Cabergoline. Open Respir Med J 3 : 90-93, 2009.
PubMed
P.675 掲載の参考文献
1) Kalia LV, Lang AE : Parkinson's disease. Lancet 386 : 896-912, 2015.
PubMed
2) Ravn AH, et al : Skin disorders in Parkinson's disease : potential biomarkers and risk factors. Clin Cosmet Investig Dermatol 10 : 87-92, 2017.
PubMed
3) Beitz JM : Skin and wound issues in patients with Parkinson's disease : an overview of common disorders. Ostomy Wound Manage 59 : 26-36, 2013.
PubMed
4) Arsic Arsenijevic VS, et al : A laboratory-based study on patients with Parkinson's disease and seborrheic dermatitis : the presence and density of Malassezia yeasts, their different species and enzymes production. BMC Dermatol 14 : 5, 2014.
 
5) Chen ST, et al : Update on the Epidemiology of Melanoma. Curr Dermatol Rep 2 : 24-34, 2013.
PubMed
6) Shalaby SY, Louis ED : Increased Odds of Melanoma : Parkinson' s Disease, Essential Tremor, Dystonia versus Controls. Neuroepidemiology 46 : 128-136, 2016.
PubMed
7) Huang P, et al : The association between Parkinson's disease and melanoma : a systematic review and meta-analysis. Transl Neurodegener 4 : 21, 2015.
PubMed
8) Constantinescu R, et al : Malignant melanoma in early-treated Parkinson's disease : the NET-PD trial. Mov Disord 29 : 263-265, 2014.
PubMed
9) Pan T, et al : The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS ONE 7 : e45183, 2012.
PubMed
10) Srivanitchapoom P, et al : Drooling in Parkinson's disease : a review. Parkinsonism Relat Disord 20 : 1109-1118, 2014.
PubMed
11) Langan SM, et al : The relationship between neurological disease and bullous pemphigoid : a population-based case-control study. J Invest Dermatol 131 : 631-636, 2011.
PubMed
12) Lai YC, et al : Bullous pemphigoid and its association with neurological diseases : asystematic review and meta-analysis. J Eur Acad Dermatol Venereol 30 : 2007-2015, 2016.
 
13) 日本褥瘡学会教育委員会ガイドライン改訂委員会 : 褥瘡予防・管理ガイドライン (第4版). 日本褥瘡学会 17 : 487-557, 2015.
 
14) Ikemura M, et al : Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67 : 945-953, 2008.
PubMed
15) Wang N, et al : α-Synuclein in cutaneous autonomic nerves. Neurology 81 : 1604-1610, 2013,
 

VII QOL

P.681 掲載の参考文献
1) 津山直一 : 標準リハビリテーション医学, p173-205, 医学書院, 2000.
 
2) 野川茂, ほか : パーキンソン病症状の新しい包括的自記式質問票 (MASAC-PD31) の開発・評価. 臨床神経学 51 : 321-329, 2011.
 
3) 高橋裕秀 : パーキンソン病患者自己評価スケール. 日本臨牀 75 : 156-160, 2017.
Medical*Online
4) 河本純子, ほか : 日本人におけるParkinson's disease Questionnaire-39 (PDQ-39) の信頼性評価. 臨床神経学 43 : 71-76, 2003.
 
P.689 掲載の参考文献
1) 木下栄作 : 地域医療構想について. 平成27年都道府県等栄養施策担当者会議 資料4. 厚生労働省.
 
2) 日本在宅医学会テキスト編集委員会編 : 在宅医学, メディカルレビュー社, 2011.
 
3) 佐藤猛, ほか : パーキンソン病・パーキンソン症候群の在宅ケア-合併症・認知症の対応, 看護ケア, 中央法規出版, 2016.
 
4) 宮下公美子 : 多職種連携から統合へ向かう地域包括ケア, MCメディカ出版, 2017.
 
5) 在宅ケアを支える診療所・市民全国ネットワーク編 : 在宅医療実践マニュアル (第2版), 医歯薬出版, 2006.
 
P.708 掲載の参考文献
1) 竹島多賀夫 : パーキンソン病の疫学研究. 医学のあゆみ 225 : 361-364, 2008.
Medical*Online
2) 中島健二, ほか : 鳥取県米子市のパーキンソン病の疫学 (第二報). 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 神経変性疾患に関する調査研究班 平成18年度報告書, p124-126, 2007.
 
3) Nakashima K, et al : Prognosis of Parkinson's disease in Japan. Tottori University Parkinson's Disease Epidemiology (TUPDE) Study Group. Eur Neurol 38 (Suppl 2) : 60-63, 1997.
 
4) Nagayama H, et al : Initial symptoms of Parkinson's disease with elderly onset. Gerontology 46 : 129-132, 2000.
PubMed
5) 秋下雅弘 : 高齢者における安全な薬物療法のポイント. 日本医事新報 4381 : 57-61, 2008.
Medical*Online
6) 村田美穂 : パーキンソン病における併用療法のあり方と注意点. Geriatric Medicine 46 : 365-369, 2008.
Medical*Online
7) Marras C, et al : Predicting motor decline and disability in Parkinson disease : a systematic review. Arch Neurol 59 : 1724-1728, 2002.
PubMed
8) 日本神経学会 (監修), パーキンソン病治療ガイドライン作成委員会 (編) : CQ1-8 未治療のパーキンソン病の薬物治療は何で開始すべきか. パーキンソン病治療ガイドライン 2011, p73-78, 医学書院, 2011.
 
9) Russmann H, et al : Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 63 : 1952-1954, 2004.
PubMed
10) 梅村淳ほか : 75歳以上のパーキンソン病に対する視床下核刺激療法の適応についての再考. 機能的脳神経外科 47 : 80-81, 2008.
 
11) 伊藤和則 : 治療戦略と在宅医療. 難病と在宅ケア 19 : 45-48, 2013.
Medical*Online
12) 鈴木隆雄 : 転倒外来の実際. 臨床医 28 : 1830-1833, 2002.
 

書評

最近チェックした商品履歴

Loading...